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Abstract

Shanshan Deng
VERU-111 as an Oral Tubulin Inhibitor Suppressing
Triple-Negative Breast Cancer and Evaluation of Novel Tubulin
Inhibitors for Cancer Therapy
Triple-negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular
subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet,
treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.
We previously reported a series of novel 2-aryl-4-benzoyl-imidazoles and derivatives that target the colchicine-binding site with potent cytotoxicity, improved aqueous
solubility and lack of multidrug resistance. VERU-111 is the most potent 2-aryl-4-benzoylimidazole analog with favorable pharmacokinetic properties and acceptable oral bioavailability, we hypothesized that VERU-111 could inhibit the TNBC tumor growth preclinically. To test this hypothesis, we firstly determined the efficacy of VERU-111 in vitro.
VERU-111 showed potent antiproliferative activity against several taxane-sensitive and
taxane-resistant TNBC cell lines tested, inducing apoptosis and cell-cycle arrest in a concentration-dependent manner. In vivo evaluation of VERU-111 using two metastatic taxanesensitive TNBC models showed that orally administered VERU-111 inhibited TNBC tumor
growth in a dose-dependent manner with antitumor potency similar to paclitaxel and repressed visceral metastasis either originating from the mammary fat pad (orthotopic), or in
an experimental metastasis model. However, relative to paclitaxel, VERU-111 significantly
inhibited the tumor growth in an orthotopic MDA-MB-231/TxR model and reduced lung
metastases originating from the mammary fat pad. In addition to the MDA-MB-231/TxR
model, we also tested the efficacy of VERU-111 in a multidrug-resistant PDX model, HCI10. VERU-111 significantly inhibited HCI-10 primary tumor growth and suppressed the
growth of lymph node metastases present prior to therapy and suppressed lung, liver and
kidney metastases at the endpoint. In contrast, paclitaxel had no efficacy to repress tumor
growth or metastasis in this model, and in fact, stimulated liver metastasis. Taken together, our data demonstrate that VERU-111 is a new generation of oral tubulin inhibitor

iv
that potently inhibits the growth of taxane-sensitive and taxane-resistant TNBC. Therefore,
VERU-111 therapy is a promising strategy for the treatment of metastatic TNBC patients,
including those patients who progress on taxanes.
We recently reported the crystal structure of tubulin in complex with a colchicinebinding site inhibitor (CBSI), VERU-111, having a 2-aryl-4-benzoyl-imidazole structure.
Based on this and additional crystal structures, to discover the CBSIs with better efficacy
and good solubility, here we report the structure-activity relationship study of a novel series of pyridine analogues of VERU-111. Among all the analogues generated, compound
4v was the most potent one (average IC50 ~1.8 nM) against a panel of cancer cell lines. We
then determined the crystal structures of another potent CBSI ABI-274 and 4v in complex
with tubulin and confirmed their direct binding at the colchicine site. 4v inhibited tubulin polymerization, strongly suppressed A375 melanoma tumor growth, induced tumor
necrosis, disrupted tumor angiogenesis, and led to tumor cell apoptosis in vivo. Due to the
strong cytotoxicity of 4v, we then determined the efficacy of 4v in TNBC. 4v was shown to
induce the inhibition of colony formation, G2/M phase arrest and apoptosis of TNBC cells
significantly and it could remarkably inhibit the TNBC tumor growth. Collectively, these
studies suggest that 4v represents a promising new generation of tubulin inhibitors.
Metabolic stability studies showed that 4v had a short half-life time possibly due to
the reduction of the carbonyl linker and demethylation in the trimethoxy phenyl group,
to further improve the metabolic stability of 4v analogues, a novel series of analogues
structurally modified at metabolically labile sites were designed and synthesized based on
lead compound 4v. Two analogues, 40a and 60c, preserved the potency while improving
the metabolic stability by 3-5 folds compared to the parent lead compound (48 and 30 vs 10
min in human microsomes). We determined the high-resolution X-ray crystal structures of
40a and 60c in complex with tubulin and confirmed their direct binding at the colchicine
site. 60c maintained its mode of action by inhibiting tubulin polymerization. 60c was
effective against P-gp mediated multiple drug resistance and taxane resistance, and it was
able to inhibit the colony formation of taxane-resistant cancer cells, arrest cells in the G2/M
phase, and induce cell apoptosis. Finally, 60c exhibited a strong inhibitory effect on tumor
growth and metastasis in a taxane-resistant A375/TxR xenograft model without obvious
toxicity in vivo.
Apart from the pyridine analogues of VERU-111, we also reported the design, synthesis and antitumor efficacies of new dihydroquinoxalinone pyridopyrimidine analogs
that target the colchicine-binding site. Eight analogues, 5j, 5k, 5l, 5m, 5n, 5r, 5t and
5v, showed significant improvement in metabolic stability and demonstrated strong anticancer potency in a panel of human cancer cell lines, including melanoma and breast
cancer. Among them, 5m, 5t and 5v showed the strongest antiproliferative activity with
sub-nanomolar IC50 range. They also shared trademark characteristics with other potent
antimitotic agents such as inhibiting colony formation, inducing G2/M phase cell cycle arrest and promoting apoptosis. We also reported high-resolution crystal structures for four

v
representative compounds, 5j, 5k, 5l and 5m, providing direct confirmation for their binding to the colchicine site in tubulin as well as understanding their molecular interactions
to tubulin proteins. In vivo, 5m (4 mg/kg), 5t (5 mg/kg) and 5v (4 mg/kg) significantly
inhibited tumor growth as well as melanoma spontaneous metastasis into lung and liver
against a highly paclitaxel-resistant A375/TxR xenograft model. Overall, all these novel
analogues are promising new generation of tubulin inhibitors that could be used for cancer
therapy.
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Chapter 1
Introduction

According to the World Health Organization (WHO), cancer is the second leading cause of
death in the world, resulting in approximately 9.6 million deaths globally in 2018. Among
all cancers, breast cancer (BC) accounts for around 2.09 million cases and 0.62 million
deaths, making it a second leading cause of cancer-related death in women worldwide.
BC is classified into four major biological subtypes according to hormone and human
epidermal growth factor 2 (HER2) receptor expression, which are luminal A (hormone
receptors (HR)-positive/HER2-negative); luminal B (HR-positive/HER2-positive); HER2overexpressing (HER2-positive); and triple negative (estrogen receptor (ER)-negative/progesterone receptor (PR)-negative/HER2-negative) (Tong et al., 2018). These four different
subtypes have different treatment response, diverse disease progression, specific pathways with the preferred sites of metastasis and distinct clinical outcomes (Tong et al.,
2018; Al-Mahmood et al., 2018; Kennecke et al., 2010). The common treatment options
for breast cancer include surgery, chemotherapy, radiation therapy, hormonal therapy and
immunotherapy.
Triple negative breast cancer (TNBC), a subtype of breast cancer with low expression of PR, ER and HER2, accounts for nearly 15-20% of all diagnosed breast cancers (Yeh
et al., 2017). TNBC can be subdivided into 6 different subgroups, which are basal-like (BL1
and BL2), immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen
receptors and unstable subtype (Lehmann et al., 2011; S. Y. Hwang, Park, and Kwon, 2019).
TNBC is highly aggressive and associated with early recurrence, a tendency to spread to
the lung, liver and central nervous system, and poor survival rates (Dent et al., 2007; Bae
et al., 2013). The prognosis of TNBC patients is relatively poor, and they cannot benefit
from endocrine therapy or treatment targeting HER2 because of the lack of relevant targets. Therefore, this type of breast cancer needs special treatments (Al-Mahmood et al.,
2018; Liedtke et al., 2008).
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Current Treatment Strategies for TNBC

Although TNBC is aggressive and lacks targets, a large number of clinical and preclinical
studies have now been carried out and continued to provide treatment options. Chemotherapy is often the only viable option for early-stage and advanced TNBC to reduce and prevent the tumor recurrence and metastasis. However, apart from surgery and radiotherapy,
recent clinical trials have shown that the targeted therapy and nanotechnology play a pivotal role in the treatment of this deadly disease in the neoadjuvant setting.

1.1.1

Chemotherapy

Since early-stage TNBC is highly sensitive to cytotoxic chemotherapy, and chemotherapy
is one of the standard treatments for TNBC in the adjuvant, neoadjuvant and metastatic
settings, so here we listed some frequently used regimens for the treatment of TNBC
(Figure 1.1).

Figure 1.1: Structures of representative chemotherapeutic drugs.

Anthracyclines
Anthracyclines are one of the most important anticancer drugs that are extracted from
Streptomyces bacterium for all breast cancer subtypes including TNBC (Belknap et al.,
2020; Cai et al., 2019). These agents could bind to DNA, exerting antitumor effects by
causing DNA damage and interfering with the synthesis of DNA, RNA and protein (K. C.
Nitiss and J. L. Nitiss, 2014). Doxorubicin, a well-known anthracycline anticancer drug, is
mainly used for combination chemotherapy in the treatment of patients with malignant tumors, especially TNBC (Krausz et al., 2018). A previous retrospective study using 96 TNBC
patients with 2 prospective neoadjuvant settings was conducted based on anthracyclines
(Le Tourneau, 2007). One group of patients received the standard 5-fluorouracil, epirubicin
and cyclophosphamide, another group of patients received a higher dose of 5-fluorouracil,
doxorubicin and cyclophosphamide. The overall pathological complete response (pCR)
rate of patients was 29%, but the pCR rate was significantly different between two treatment groups. The pCR rate of 5-fluorouracil/doxorubicin/cyclophosphamide treatment
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group was 47%, while the 5-fluorouracil/doxorubicin/cyclophosphamide treatment group
was 13%. This study emphasizes the significance of anthracyclines in TNBC therapy (Le
Tourneau, 2007). A common first-line treatment for TNBC is the combination of anthracycline and taxane, and capecitabine is always used when the TNBC disease progresses
(Cardoso et al., 2018).
Taxanes
Taxanes are widely used in many types of cancers including TNBC. These anticancer
agents induce cell apoptosis or permanent mitotic arrest by inhibiting the spindle microtubule dynamics (Abal, Andreu, and Barasoain, 2003). Many studies are working to
determine the best taxanes that should be used in each clinical setting. According to the
lack of hypersensitivity, the ability to inject higher doses in a short period of time and the
improved response rate (RR), nab-paclitaxel was selected as one of the best taxanes in the
neoadjuvant setting (W. J. Gradishar et al., 2005). Taxanes can be used alone or in combination with other chemotherapy drugs for the treatment of TNBC. For example, anthracycline plus taxane chemotherapy can improve the disease-free survival better than anthracyclines or taxanes alone (Sledge et al., 2003; Swain et al., 2010). Usually, the taxanes, such
as paclitaxel, are used for the first-line treatment of neoadjuvant, adjuvant or metastatic
TNBC patients who are resistant to anthracycline treatments with a higher complete RR,
but acquired resistance to taxanes is commonly observed after repeated exposure to TNBC
patients, which lowers the overall survival (OS) rate and limits the use of paclitaxel-based
chemotherapy (Liedtke et al., 2008; Schiff, Fant, and Horwitz, 1979; Mustacchi and De
Laurentiis, 2015; Bachegowda, Makower, and Sparano, 2014).
Platinum-based alkylating regimens
Platinum reagents are cytotoxic compounds that can cause DNA strand breaks and thus
lead to cell apoptosis (Siddik, 2003). Platinum-based systemic treatment in TNBC demonstrate that platinum-based chemotherapy can increase the pCR rate in TNBC patients, and
it is a practical option for neoadjuvant therapy patients (Pandy et al., 2019; Chan et al.,
2010). Cisplatin is an infrequently used chemotherapeutic agent in breast cancer treatment.
As a DNA damaging agent, cisplatin may be an effective treatment for hereditary breast
cancer type 1 susceptibility protein (BRCA1) mutant breast cancers (Silver et al., 2010).
In a phase 3 clinical trial (TNT trial), Patients with metastatic TNBC were divided into
two groups: one group receiving carboplatin, one group receiving docetaxel (Tutt et al.,
2015). The progression-free survival (PFS) and OS rates were similar between two groups.
However, the PFS in carboplatin treatment group increased significantly in patients with
BRCA1 mutation, with 6.8 months as compared to 3.1 months in patients taking docetaxel.
Additionally, the RR of patients receiving carboplatin was 68.0%, which was significantly
higher than that in patients receiving docetaxel (Tutt et al., 2015). In the treatment of breast
cancer, the combination uses of carboplatin and docetaxel (or paclitaxel) showed a higher
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efficacy than carboplatin or taxane alone, and it had a better effect in the treatment of breast
cancer that has metastasized to brain (Pentheroudakis et al., 2006; X. Chen et al., 2010).
The chemotherapy regimen for TNBC patients depends on several factors, such as
tumor size, lymph node involvement, tumor grade, metastasis and the presence of medical
complications, so there is no preferred chemotherapy regimen choice for TNBC patients
(O’Reilly et al., 2015). Most often, combinations of 2 or 3 of these chemotherapeutic drugs
are used.

1.1.2

Targeted therapy

There are several promising therapeutic targets for TNBC in the preclinical investigations
or clinical evaluations, such as Poly ADP-ribose polymerase (PARP), epidermal growth
factor receptor (EGFR), Ki-67, cell cycle regulating proteins, vascular endothelial growth
factor (VEGF), etc (S. Y. Hwang, Park, and Kwon, 2019; Silva et al., 2020). Below are some
examples of available targeted therapy for TNBC (Figure 1.2).

Figure 1.2: Structures of representative targeted drugs.

PARP inhibitors
One of the phenotypes of TNBC is BRCA1 or breast cancer type 2 susceptibility protein
(BRCA2) mutations. BRCA1/2 mutations are found in approximately 10%-15% of patients
with TNBC, and US Food and Drug Administration (FDA) recently approved PARP inhibitors for the treatment of TNBC patients with BRCA1/2 germline mutations (McCann
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and Hurvitz, 2018; Guney Eskiler et al., 2019). PARP inhibitors target the DNA repair process of PARP and BRCA1/2, and produce synthetic lethality by causing abnormal function of homologous recombination, thus causing chromosomal instability and cell death
(Sonnenblick et al., 2015; Javle and Curtin, 2011). Therefore, in BRCA1/2-mutated TNBC,
PARP inhibitors, such as olaparib and talazoparib, can increase the RR and PFS rate of
patients compared with standard chemotherapy (Pantelidou et al., 2019). A phase 3 clinical trial of olaparib monotherapy was carried out and compared to the standard singleagent chemotherapeutics by Robson group in HER2-negative breast cancer patients with
BRCA mutation, who had not taken more than 2 previous chemotherapeutics (Robson et
al., 2017). The trial results showed that the RR of patients receiving olaparib was 59.9%
versus that of 28.8% in patients receiving chemotherapeutics (capecitabine, eribulin, or
vinorelbine), and the median PFS was 7.2 months in olaparib treatment group as compared to 4.2 months in standard therapy group. In addition, olaparib was less toxic than
the chemotherapeutics with 36.6% of adverse events (AEs) observed in olaparib treatment
and 50.5% of AEs observed in standard chemotherapy treatment (Robson et al., 2017). In
2018, olaparib was approved by the FDA for the treatment of HER2-negative metastatic
breast cancer patients with germline mutations in BRCA1/2 and relapse after previously
received chemotherapy (Caulfield, Davis, and Byers, 2019).
Another classic PARP inhibitor, BMN 673 (also termed talazoparib), was shown to
have better antiproliferative and antitumor activity than other PARP inhibitors in vitro and
in vivo (Y. Shen et al., 2013; Andrei et al., 2015; Murai et al., 2014). In preclinical studies
and clinical trials, BMN 673 has been shown promising results in breast cancer patients
with advanced germline BRCA1/2 mutations (McCann and Hurvitz, 2018; Bono et al.,
2017). A similar randomized phase 3 clinical trial of BMN 673 was performed on patients
with advanced breast cancer with germline BRCA1/2 mutations (Litton et al., 2018). The
medium PFS was 8.6 months in patients taking BMN 673 as compared to that of 5.6 months
taking the standard single-agent chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine) based on the physician’s choice. And the RR was 62.6% in BMN 673 treatment
group, which was much higher than 27.2% in standard chemotherapy group despite the
fact that BMN 673 showed severer AEs than standard treatment (55% of grade 3/4 hematologic toxicities versus 38%) (Litton et al., 2018). However, the dose of BMN 673 was 1
mg once per day, which was much less than that of olaparib (300 mg twice per day), still
demonstrating that BMN 673 was more potent than olaparib. BMN 673 was approved by
the FDA in 2018 for the treatment of patients with HER2-negative breast cancer containing
BRCA1/2 mutations (Faraoni and Graziani, 2018).
Immune checkpoint inhibitors
One subtype of TNBC is immunomodulatory TNBC that is associated with tumor-infiltrating lymphocytes and high expression of programmed cell death ligand 1 (PD-L1) (S. Adams
et al., 2014; Mittendorf et al., 2014; Schalper et al., 2014). PD-L1 is an immune checkpoint protein, which is mainly overexpressed on tumor cells and tumor infiltrating cells,
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and can downregulate the antitumor function of T cells by binding to PD-1 and CD80
(Cimino-Mathews et al., 2016; Buisseret et al., 2017). Thus, immunotherapy is an attractive
therapeutic strategy for this kind of TNBC through blocking the interaction between PD-1
and CD80, which subsequently can restore the antitumor function of T cells (Butte et al.,
2007). Atezolizumab, a humanized monoclonal antibody immune checkpoint inhibitor,
targets PD-L1 and inhibits the binding of PD-L1 to its receptor PD-1 or CD80 (Heimes
and Schmidt, 2019; Kagihara, Andress, and Diamond, 2020). In 2018, a phase 3 clinical trial of atezolizumab in combination with nab-paclitaxel was carried out on patients
with previously untreated metastatic TNBC in comparison with the standard chemotherapy (nab-paclitaxel) (Schmid et al., 2018). The median PFS in all the patients enrolled and
administered atezolizumab plus nab-paclitaxel was longer than that administered with
nab-paclitaxel (7.2 months versus 5.5 months), while in TNBC patients with PD-L1 overexpression, the median PFS in atezolizumab plus nab-paclitaxel treatment group was much
longer as compared to nab-paclitaxel treatment group (7.5 months versus 5.0 months)
(Schmid et al., 2018). In addition, the median OS of patients receiving atezolizumab in
combination with nab-paclitaxel was higher as compared to those receiving nab-paclitaxel
(21.3 months versus 17.6 months). Similarly, the median OS was prolonged in PD-L1positive patients receiving atezolizumab plus nab-paclitaxel (Schmid et al., 2018). In 2019,
the FDA accelerated the approval of atezolizumab in combination with nab-paclitaxel for
patients with unresectable or metastatic TNBC. But the tumors of these patients are required to have the high expression of PD-L1, that is, PD-L1 expression needs to exceed 1%
in the tumor area (Kagihara, Andress, and Diamond, 2020).
In another phase 3 KEYNOTE-355 clinical trial, pembrolizumab, another anti-PD-1
monoclonal antibody, was studied in combination with nab-paclitaxel in treating patients
with previously untreated metastatic TNBC (Cortes et al., 2020). Current results showed
that pembrolizumab plus nab-paclitaxel treatment remarkably increased the median PFS
of TNBC patients as compared to the nab-paclitaxel treatment alone (17.5 months versus
15.5 months), and the combination was well tolerated without the appearance of new AEs.
Immunotherapy has shown great potential in many other disease sites, including TNBC.
Therefore, the results of the above-mentioned clinical trials are highly promising.
Antibody-drug conjugate 1
ADCs represent a unique approach to treat breast cancer. ADCs are tripartite drugs, and
each ADC integrates a highly tumor-specific monoclonal antibody (mAb) with a potent
small molecule drug via an appropriate linker (Figure 1.3) (Shanshan Deng, Zongtao Lin,
and Wei Li, 2017). Early generations of ADCs have limited efficacy due to low numbers of
small molecule drugs integrated in the ADCs, immunogenicity associated with the use of
mAbs derived from murine sources, or insufficient selectivity of mAbs in ADCs to tumors
1 Reprinted

from the final submission with permission from Bentham Science Publishers. Shanshan Deng,
Zongtao Lin, and Wei Li. Recent advances in antibody-drug conjugates for breast cancer treatment. Current
Medicinal Chemistry. 2017; 24 (23) : 2505-2527. https://doi.org/10.2174/0929867324666170530092350.
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versus normal cells (Tolcher et al., 1999; Lambert, 2005; Teicher and Chari, 2011; Hughes,
2010). With the recent development of more potent cytotoxic drugs, humanized mAbs,
and more specific targets and antibodies, ADC therapeutics have been revitalized for cancer therapy. Currently, two ADCs are approved by the FDA for treating cancer: brentuximab vedotin (SGN-35, approved in 2011) for refractory CD30 overexpressed Hodgkin
lymphoma and anaplastic large-cell lymphomas (Katz, Janik, and Younes, 2011; Foyil and
Bartlett, 2011), and trastuzumab emtansine (T-DM1, approved in 2013) for patients with
human epidermal growth factor receptor 2 (HER2)-positive breast cancer (LoRusso et al.,
2011; Amiri-Kordestani et al., 2014). Following these successes, a number of novel ADCs
have been developed, and their anticancer efficacies are currently being evaluated preclinically or clinically.

Figure 1.3: Schematic illustration of key components of an ADC. ADC is
a tripartite drug consisting of a highly tumor-specific mAb, a potent small
molecule drug, and an appropriate linker between mAb and drug.
Trop-2 (trophoblast cell surface antigen 2), was originally found on normal and malignant trophoblast cells. It was subsequently reported to be highly expressed in various human malignant carcinomas and plays an important role in tumor progression and
poor prognosis (Varughese et al., 2011; Zeng et al., 2016; Trerotola et al., 2013). IMMU132, also known as sacituzumab govitecan, is an SN-38-conjugated ADC targeting Trop-2
by delivering SN-38, an active metabolite of irinotecan, inhibiting DNA topoisomerase
I of tumor cells. IMMU-132 is composed of a humanized anti-Trop-2 mAb (hRS7) and
SN-38 through a linker containing a PAB moiety, a lysine peptide, a short PEG moiety, a
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triazole spacer, and a maleimidomethyl cyclohexane-1-carboxylate (MCC) group to couple to hRS7 (Cardillo, Govindan, Sharkey, Trisal, and Goldenberg, 2011; Govindan et al.,
2009; Goldenberg et al., 2015). The reported drug-antibody ratio of IMMU-132 is about
8, and its antibody-dependent cellular cytotoxicity activity is much lower than that of
hRS7. In addition to the internalization and lysosomal degradation, IMMU-132 also undergoes upregulation of early pro-apoptosis signaling events. These events upregulate
pJNK1/2 and p21WAF1/Cip1 ; cleaved-caspases 3, 7, and 9; and finally cause cleavage of
poly-ADP-ribose polymerase and the breaking of double-stranded DNA (Cardillo, Govindan, Sharkey, Trisal, Arrojo, et al., 2015). A phase 1/2 clinical trial of IMMU-132 was
carried out in 108 TNBC patients in 2019. The overall RR of patients receiving IMMU-132
was 33.3%, the clinical benefit rate of patients was 45.4%, the median PFS of patients was
5.5 months and the median OS of patients was 13 months (Bardia et al., 2019). In 2020,
the FDA approved the use of Trodelvy, the product name of IMMU-132, for the treatment
of adult TNBC patients with tumors metastasizing to other parts of the body. Before taking Trodelvy, patients must have received at least two therapeutic treatments, including
capecitabine, cisplatin, the combination of paclitaxel and carboplatin and etc. (Syed, 2020;
Starodub et al., 2015).
Nanotechnology-based therapy
Nanotechnology-based therapy has shown great potential in improving the anti-TNBC
activity of chemotherapy drugs with reduced systematic toxicity. There are several factors
that are very important for nanomedicines targeting the target receptors on cancer cells,
e.g., nanoparticle surface charge, encapsulation capacity, drug loading efficiency, metabolic
stability in circulation, and sustained and controlled release of cytotoxic drugs (Thakur
and Kutty, 2019). In the past few decades, several nanomedicines have been developed
for cancer therapy and some of them got FDA approval for treating patients with cancer,
such as liposomal doxorubicin (Doxil, approved in 1995) and nab-paclitaxel (Abraxane,
approved in 2005) (Barenholz, 2012; Green et al., 2006). Doxil is the first FDA-approved
nanomedicine, which is commonly used for the treatment of Kaposi’s sarcoma, refractory
breast cancer and ovarian cancer (Barenholz, 2012).
Paclitaxel and docetaxel are taxanes that are used in the clinical treatment of cancer. Both of these drugs have solubility problems due to their hydrophobicity. Therefore,
in the process of dissolving paclitaxel, Cremophor-EL is required, and in the process of
dissolving docetaxel, Tween-80 is required. These two solvents can cause severe hypersensitivity reactions or other side effects when used in patients (Haley and Frenkel, 2008).
Abraxane, an albumin-bound paclitaxel (also called nab-paclitaxel), is a nanoparticle formulation that was designed for overcoming the solvent problem of paclitaxel. The FDA
approved nab-paclitaxel for the treatment of metastatic breast cancer that failed combination chemotherapy or recurred within 6 months after adjuvant chemotherapy. In a phase
3 clinical trial, efficacy of nab-paclitaxel was compared with the standard chemotherapy
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paclitaxel in patients with metastatic breast cancer (W. J. Gradishar et al., 2005). The trial results showed that the RRs were higher in patients receiving nab-paclitaxel, which was 33%
versus 19% in patients receiving paclitaxel. And nab-paclitaxel was able to prolong the
time of tumor progression as compared to paclitaxel (23 weeks versus 16.9 weeks). More
importantly, the incidence rate of major AE, neutropenia, was only 9% in nab-paclitaxeltreated patients, while there was 22% of paclitaxel-treated patients experienced neutropenia. Although neuropathy commonly appeared in patients receiving nab-paclitaxel, these
symptoms could be easily managed (W. J. Gradishar et al., 2005).
Other targeted therapy under investigation
In TNBC, EGFR is frequently overexpressed and only specific to TNBC as compared to
other subtypes of breast cancers, and the overexpression of EGFR usually promotes the
tumor progression and increases drug resistance to conventional therapies (Nakai, Hung,
and Yamaguchi, 2016; Al-Mahmood et al., 2018). Huge efforts have been made to investigate if anti-EGFR monoclonal antibodies, such as cetuximab, could have effects on TNBC
(Nakai, Hung, and Yamaguchi, 2016). A phase 2 clinical trial was performed, and results showed that RR was 6% in cetuximab-treated patients and 16% in cetuximab plus
carboplatin-treated patients, which was not as potent as expected in the preclinical studies
(Carey et al., 2012). In view of these results, cetuximab is not recommended to be used in
the treatment of EGFR-overexpressing TNBC. Another potential targeted therapy is using
anti-angiogenic agents targeting VEGF, which is a principal angiogenic factor that is highly
expressed in TNBC and related with short recurrence-free survival and OS of patients (Linderholm et al., 2009; Ribatti et al., 2016). The use of a combination of anti-angiogenic
agent bevacizumab with chemotherapeutic was tested in treating TNBC patients (Bell et
al., 2017). However, due to no significant OS benefit observed in the combination therapy
group as compared to the mono chemotherapy group, bevacizumab treatment was not
accepted for TNBC treatment.
Due to the heterogeneity of TNBC, many TNBC patients would have different RRs
to traditional or new targeted therapies, so differences in time of survival usually appear
among TNBC patients, and the standard chemotherapy is still the mainstay of treatment
(Silva et al., 2020).

1.2

Role of Microtubules in Cancer Therapy

Microtubules are the key elements of polymerized α- and β-tubulin heterodimers arranged
in a head-to-tail manner, in which the α-subunit in one dimer is binding with the β-subunit
in the next dimer. The non-covalent binding of these subunits forms the protofilament. The
protofilaments are assembled longitudinally into a cylindrical structure, usually there are
13 pieces, constituting a 22 nm microtubules (Jordan and Wilson, 2004; Kaul, Risinger, and
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Mooberry, 2019). The microtubules undergo two stages of alternation, growth and shrinkage, a behavior called dynamic instability (Lawrence and Zanic, 2019). The continuous alterations of slow polymerization and fast depolymerization dynamics make microtubules
play a fundamental and essential role in many cellular processes including cell division,
cell structure maintenance, intracellular transport and movement regulation (Bollinger et
al., 2020; Janke and Magiera, 2020).
Microtubule-targeting agents (MTAs) affect microtubule dynamics by binding to
the microtubules through different mechanisms. In the intercellular phase, MTAs have a
great influence on the microtubules that are involved in intracellular transport of proteins,
vesicles and organelles, and interphase cytoskeleton. In mitosis, the structure required to
separate duplicated chromosomes, that is, the mitotic spindle composed of the cytoskeleton of rearranged microtubules, is also greatly affected by MTAs. The destruction of microtubule dynamics causes the cell cycle to stagnate in the G2/M phase, leading to mitotic
arrest (Komlodi-Pasztor et al., 2011; Terada and Hirokawa, 2000; Foley and Kapoor, 2013).
In view of the important role of microtubules in cell growth, microtubules have become
attractive targets for the development of anticancer drugs.
According to the mechanisms of action, MTAs are usually divided into two categories: microtubule-stabilizing agents and microtubule-destabilizing agents. For example,
taxanes, epothilone, and laulimalide are microtubule-stabilizing agents that can promote
and stabilize the microtubules and increase the density of microtubules. While microtubuledestabilizing agents do the opposite, such as vinblastine, colchicine and maytansine, they
prevent the polymerization of tubulin and promote depolymerization, and thus decrease
the density of microtubules (Kaul, Risinger, and Mooberry, 2019; Karahalil, Yardim-Akaydin, and Baytas, 2019). There are at least 6 binding sites on microtubules for MTAs, including taxane-binding site, vinca-binding site, colchicine-binding site, laulimalide-binding
site, maytansine-binding site and pironetin-binding site (Cermak et al., 2020; Wu, Q. Wang,
and W. Li, 2016; Han et al., 2020). Regardless of the mechanisms of action and different binding sites, most MTAs have a significantly similar effect on microtubule dynamics,
leading to mitotic arrest and ultimately cell death (Wu, Q. Wang, and W. Li, 2016; J. G.
Chen and Horwitz, 2002).

1.3

Challenges of MTAs in TNBC Therapy

For TNBC treatment, no targeted therapies have been approved, and chemotherapy is
a primary option due to the unfavorable prognosis and lack of receptor expression (AlMahmood et al., 2018; Kennecke et al., 2010). Usually, the taxanes, such as paclitaxel,
are used for the first-line treatment of neoadjuvant, adjuvant or metastatic TNBC patients
with a higher pCR, but acquired resistance to taxanes is commonly observed after repeated
exposure to TNBC patients, which lowers the OS rate and limits the use of paclitaxel-based
chemotherapy (Liedtke et al., 2008; Schiff, Fant, and Horwitz, 1979; Mustacchi and De
Laurentiis, 2015). Vinblastine and vincristine, most widely known members of the vinca
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alkaloids, are two common chemotherapeutics used to treat a panel of cancers. However,
a limitation for using vinblastine and vincristine is the emergence of multidrug resistance
(MDR), which is similar to paclitaxel or docetaxel (Ying Zhang, S.-H. Yang, and Guo, 2017).
Recently, Aleksandar et al. designed and synthesized a series of novel vinblastine analogs
by replacing the C20-OH functional group with ureas and amides. The results showed
that these analogs retained or exceeded the potency of vinblastine, displayed improved
anticancer activity against vinblastine-resistant cancer cell lines and exhibited continuous
activity to cancer cells overexpressing P-glycoprotein (P-gp) (Radakovic and Boger, 2018).
There are several underlying mechanisms involved in acquired chemoresistance.
Overexpression of ATP-binding cassette (ABC) transmembrane efflux transporters is one
major mechanism resulting in MDR. ABC transporters could increase the chemotherapeutic drug efflux and decrease drug uptake (Ambudkar et al., 1999; Polgar and S. E. Bates,
2005; Holohan et al., 2013). Acquired chemoresistance can also be caused by mutation or
alteration in microtubule system, such as α- and β-tubulin. For example, abnormal upregulated expression of β3-tubulin was detected in drug-selected NSCLC cells or patients
with taxane-resistant ovarian cancer, contributing the tumor aggressiveness and resistance
to chemotherapy (M. Kavallaris et al., 1997; Maria Kavallaris, 2010). The following mechanisms are also related to acquired chemoresistance: deregulated biological pathways such
as upregulation of antiapoptotic proteins or downregulation of proapoptotic protein involved in apoptosis, TNBC cells with cancer stem cells phenotypes that drive tumor regrowth after therapy and mitotic slippage (Visconti and Grieco, 2017; Lytle, Barber, and
Reya, 2018; P. Liu et al., 2013). Due to the multifactorial mechanisms existed in acquired
chemoresistance, much effort has been made to prevent or reverse taxane resistance. However, the progress is not going very well according to the complex possible mechanisms.

1.4

Tubulin Inhibitors Binding to Colchicine-binding Site

Colchicine-binding site inhibitors (CBSIs) target the interface between the α and β subunits
of tubulin heterodimers (A. E. Prota, Danel, et al., 2014; Dumontet and Jordan, 2010).
Plenty of preclinical studies have suggested that CBSIs are less vulnerable to transportermedicated drug resistance (e.g. overexpression of ABC-transporters) (Z. Wang et al., 2012;
Mangiatordi et al., 2017), have better aqueous solubility (Wu, Q. Wang, and W. Li, 2016),
possess potent anticancer effects against cancer cells overexpressing β3-tubulin (Stengel et
al., 2010; Karki et al., 2013) and show vascular disrupting activity on tumors that need angiogenesis for growth (Furst and Vollmar, 2013; Ji, Y. N. Liu, and Z. P. Liu, 2015), indicating
the significance of developing new chemotherapeutics that bind to the colchicine-binding
site for effective TNBC therapy. Here, we summarize some typical CBSIs that overcome
MDR based on their structures.
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Colchicine analogues

Colchicine (1), a natural product isolated from plants of the genus Colchicum, is a common
medication used for treating gout. Although colchicine is not clinically used to treat cancer
due to the high toxicity and development of MDR, its potent antiproliferative activity by
causing G2/M arrest and apoptosis in cancer cells through disrupting microtubule formation motivates the search for new colchicine analogues with improved anticancer activity
properties. It has been showed that colchicine was well tolerated and exhibited antitumor
activity in a variety of tumors with modifications of B-ring and C-ring illustrated in Figure
1.4. Cosentino et al. reported a semisynthetic colchicine derivative, 3,4-difluorobenzyl-N-

Figure 1.4: Structures of representative tubulin inhibitors targeting the
colchicine-binding site.
aminocolchicine (2), with B-ring modification on the colchicine (Cosentino et al., 2012). 2
maintained its mode of action through inhibiting tubulin polymerization and showed potent cytotoxic activity in resistant A2780AD ovarian carcinoma cells, which are known to
overexpress P-gp. To overcome P-gp mediated resistance of colchicine, intensive investigation efforts were focused on introducing polar substituents at the C-10 position or changing
substituents at the C-7 position of colchicine in C-ring. Singh et al. reported a colchicine
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analogue (S)-N-(10-((4-chloro-3-(trifluoromethyl)phenyl)amino)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide (3) modified at C-10 position of colchicine through incorporating 4-chloro-3-(trifluoromethyl)anilie (Singh et al., 2015). It exhibited decreased P-gp induction liability (more than 90% Rh123 accumulation in LS-180 cells)
compare to the colchicine (62% Rh123 accumulation in LS-180 cells). In addition, a series of
new colchicine derivatives with a variable triazole unit at C-7 position were designed and
synthesized by Thomopoulou’s group in 2016 (Thomopoulou et al., 2016). Among them,
(S)-4-fluorobenzyl 3-(1-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7yl)-1H-1,2,3-triazol-4-yl)propanoate (4) exhibited the most potent cytotoxic activity with
IC50 of 3.5 nM against solid tumor cell lines and chemotherapy resistant lung cancer cells.
The colchicine analog bearing phenylalanine moiety (5) showed strong anticancer activity
against H1975 small cell lung cancer cells that are recognized to have acquired resistance
to currently available tyrosine receptor kinase inhibitors. Thus, appropriate modification
of colchicine is able to partially attenuate the problems associated with MDR. However,
the underlying mechanism of action and exact binding mode of colchicine and P-gp must
be addressed by future studies to move the development of colchicine analogs forward
into relevant clinical regimens.

1.4.2

CA-4 analogs

Combretastatin A-4 (CA-4, 6) is a well-known tubulin-depolymerizing agent that binds
to the colchicine-binding site in β-tubulin. Although CA-4 exhibited potent cytotoxicity against various cancer cell lines including MDR, the use of CA-4 as an anticancer
drug is limited by its poor aqueous solubility and the proneness to isomerize from cisconfiguration to less active trans-configuration, which further results in a significant loss in
anticancer activity. To overcome these limitations, water soluble prodrug combretastatinA4 phosphate (CA4P, 7), serine prodrug of combretastatin amine (AVE8062, 8), cis-restricted CA-4 analogues by replacing the stilbene core with five membered heterocycles or introducing a variety of bridging functional groups (i.e. carbonyl, sulfonate) were designed and
synthesized to improve the performance of CA-4 in preclinical and clinical studies. 5-(4ethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-1H-1,2,3,4- tetrazole (9) is a derivative of CA-4
by replacing the double bond linker with a rigid tetrazole heterocyclic ring (Romagnoli et
al., 2012). It showed potent antiproliferative activity against a panel of cancer cell lines including multidrug resistant cells such as CEMVbl-100 and LovoDoxo cells overexpressing
P-gp. 9 also exhibited better anticancer activity than paclitaxel in A549/T12 cells, which
are MDR cells with α-tubulin mutation. 5-(quinolin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1Himidazol-2-amine (10) was generated by replacing the double bond in CA-4 with a 2aminoimidazole and it displayed more potent antiproliferative activity on drug resistant
mouse mammary cancer cells (EMT6/AR1) than CA-4 (Chaudhary et al., 2016).It also possesses drug-like properties such as aqueous solubility.
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Podophyllotoxin derivatives/analogues

Podophyllotoxin (PTOX, 11), a natural cyclolignan isolated from Podophyllum species, is
capable of disrupting the assembly of microtubules by binding to the colchicine-binding
site of tubulin (Sackett, 1993). Its application as antimitotic drug is limited by the high
toxicity and severe AEs. However, PTOX still acts as an attractive lead candidate because
PTOX and its analogues displayed potent anti-MDR activity against various drug-resistant
tumor cell lines (Roy et al., 2015). Most recent modifications of PTOX with improved pharmacological properties were focused on introducing additional moiety to C-4 position of
PTOX. PTOX derivatives (5-R,5aR,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9hexahydrofuro[3’,4’:6,7]naphtho[2,3-d][1,3]dioxol-5-yl furan-2-carboxylate (Z5, 12) and (5R,5aR,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydrofuro[3’,4’:6,7]naphtho[2,3-d][1,3]dioxol-5-yl 6-bromopicolinate (Y8, 13) were discovered by Wang’s group
(L. Zhang, Z. Zhang, et al., 2016; L. Zhang, F. Chen, et al., 2016). They showed potent
anticancer activities against drug-resistant K562/ADR cells with IC50 values of 0.032 µM
and 0.046 µM, respectively. It was also confirmed that Z5 inhibited the expression of Pgp in K562/ADR via ROS/MAPK pathways and Y8 stimulated the ERK1/2 signaling
and further reduced the expression of P-gp protein to overcome the MDR. Li et al. also
reported a similar PTOX analogue CIP-36 (14) by introducing additional fragment, (5Methoxy-1H-indol-3-yl)-oxo-acetic acid ester, to the C-4 position of PTOX. CIP-36 demonstrated potent anticancer activity against the MDR of K562/A02 cells by regulating Topo
IIα activity (Cao et al., 2015). (5R,5aR,8aS,9S)-9-(((5-nitrofuran-2-yl)methyl)amino)-5-(3,4,5trimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3’,4’:6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one(15) was discovered by Zou’s group as a novel CBSI in 2014 (Cheng et al., 2014). Although
it showed moderate antiproliferative activity against HeLa and K562 cell lines, it exhibited
potent cytotoxic activity against K562/A02 MDR cells with IC50 of 5.42 µM and inhibited
the expression of P-gp. Another PTOX analog, 4β-anilino-podophyllotoxin (16) acting as
less susceptible substrate of P-gp, showed potent activity for KB/VCR cells both in vitro
and in vivo (Hu et al., 2010). Thus, modifications on C-4 position of PTOX may generate
promising CBSIs, which displayed improved cytotoxicity and had the potential to overcome P-gp-mediated MDR.
Apart from the analogs described above, there are a number of CBSIs with diverse
structures reported in the past few years. The 2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene (T138067, 17) has been shown to bind covalently to a subset of the βtubulin isotypes. T138067 displayed potent cytotoxicity against MDR tumor cells both
in vitro and in vivo. The tight covalent ion between T138067 and the residue C239 from
β-tubulin blocked the dissociation of T138067 from tubulin and enhanced the efficacy
of T138067, further trigging the evasion of multidrug resistance in tumors (Shan et al.,
1999).Tivantinib (ARQ197, 18) was firstly reported as a non-ATP-competitive c-Met inhibitor for the treatment of various cancers such as non-small-cell lung and hepatocellular
carcinoma (Aoyama et al., 2014). A recent study demonstrated that tivantinib directly
bound to the colchicine-binding site of tubulin. It displayed comparable activity against
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both parental and MDR cells and could overcome ABC transporter-mediated MDR.
While the need for elucidating underlying drug resistance mechanisms seems clear,
major research efforts are still needed to find more CBSIs that are able to circumvent MDR
or not the substrates of MDR. By doing that, we are able to summarize a list of CBSIs based
on their structures and propose some main structure types that could overcome MDR. This
will contribute to the elucidation of the relationship between these drugs and MDR and
thus allow designing and developing more chemotherapeutic drugs with wider therapeutic windows, improved pharmacokinetic/pharmacodynamic properties, and improved efficacy. Discovery of new tubulin inhibitors with different inhibiting mechanisms, for example, targeting α-tubulin instead of targeting β-tubulin or targeting two different targets,
will initiate novel ways to bypass the problem of drug resistance. Another orientation is
to use hybrid chemotherapeutics that target different binding sites on tubulin through an
appropriate linker. The hybrid drugs are able to avoid drug resistance and improve the anticancer activity synergistically (H. Chen, Z. Lin, et al., 2017). Although deep MDR studies
over these years have produced many significant discoveries, drug resistance continues
to be a great challenge due to the multifactor and heterogeneity of tumors. Therefore, a
convergence to gain insight into tumor dependence and the relationship of the individual drug resistance effectors may assist in combating the complex phenomenon of MDR
(Konieczkowski, Johannessen, and Garraway, 2018).
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Chapter 2
An Orally Active Tubulin Inhibitor, VERU-111,
Suppresses Triple Negative Breast Cancer Tumor
Growth and Metastasis and Bypasses Taxane
Resistance 1

2.1

Introduction

Breast cancer is the second leading cause of cancer-related deaths in women in the United
States, leading to approximately 40,920 deaths in 2017 (Siegel, K. D. Miller, and Jemal,
2018). Approximately 15% of all breast cancer cases are classified as the TNBC subtype,
characterized by the absence of estrogen receptor, progesterone receptor, and HER2 (Yeh
et al., 2017). Conventional endocrine therapy or HER2-targeted therapy is effective for
the hormone receptor–positive or HER2-positive breast cancers, but not for TNBC due
to the lack of targets (Al-Mahmood et al., 2018; Kennecke et al., 2010). Thus, cytotoxic
chemotherapy is still a primary treatment regimen for patients with TNBC. TNBC is highly
aggressive and is characterized by poor prognosis due to relatively quick relapse after
chemotherapy (Lebert et al., 2018; Mustacchi and De Laurentiis, 2015), with enhanced
rates of visceral metastasis. Therefore, there is an urgent need to develop novel effective
therapeutics for the treatment of TNBC, particularly for chemorefractory disease.
Microtubules, composed of α- and β-tubulin heterodimers, are important for cell
structure maintenance, cell mitosis and intracellular transport (Dumontet and Jordan, 2010).
1 Modified from final submission with permission from American Association for Cancer Research. Shanshan Deng*, Raisa I. Krutilina*, Qinghui Wang, Zongtao Lin, Deanna N. Parke, Hilaire C. Playa, Hao Chen,
Duane D. Miller, Tiffany N. Seagroves, and Wei Li. An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance. Molecular
Cancer Therapeutics. 2020; 19 (2): 348-363.
*Equally contributing authors. https://doi.org/10.1158/1535-7163.MCT-19-0536.
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Interference with microtubule assembly arrests cell-cycle progression, and ultimately induction of cell death, making microtubules an attractive target in anticancer drug discovery (Lopus and Naik, 2015; Nakagawa-Goto et al., 2015). At least four major binding sites on the microtubules for antimitotic agents have been discovered: taxol-binding
site, vincristine-binding site, colchicine-binding site, and laulimalide-binding site (Wu, Q.
Wang, and W. Li, 2016). Existing tubulin inhibitors, such as paclitaxel, are highly successful in breast cancer treatment; however, due to poor aqueous solubility, they must be
intravenously infused. In addition, their clinical use is often limited by drug resistance
mediated by ABC transporters and neurotoxicities (Perez, 2009a; Perez, 2009b; Z. Wang
et al., 2012). Extensive preclinical studies have suggested that tubulin inhibitors targeting
the colchicine-binding site are significantly less vulnerable to transporter-mediated drug
resistance, and several of these agents have been tested in clinical trials (Wu, Q. Wang, and
W. Li, 2016; L. Li et al., 2018). However, up to this point, none of these CBSIs have gained
FDA approval, mainly due to toxicities and their lack of clinical benefit. Although targeting tubulin polymerization may involve inherent toxicity, for many of these CBSIs, the
major toxicities that led to clinical failures are related to their specific chemical structures
(Subbiah, Lenihan, and Tsimberidou, 2011; Tsimberidou et al., 2010). Developing a new
generation of CBSI with a unique chemical structure that possesses a good therapeutic index could lead to a new anticancer agent for safe and effective chemotherapy, particularly
for metastatic disease.
A series of novel compounds that target the colchicine-binding site, termed ABIIII chemotypes, were designed and synthesized on the basis of our previously reported
2-aryl-4-benzoyl-imidazole analogues (J. Chen, Ahn, et al., 2012). These ABI-III analogues
possessed nanomolar cytotoxicity against a panel of melanoma and prostate cancer cell
lines and they overcame multidrug resistance mediated by the ABC transporter P-gp (J.
Chen, Ahn, et al., 2012). Among these, VERU-111, also named ABI-231, showed the most
potent antiproliferative activity against five melanoma and prostate cancer cell lines and is
the clinical candidate for trials for advanced prostate cancer (NCT 03752099). Oral activity
and efficacy of VERU-111 were previously evaluated in paclitaxel- or docetax-el-resistant
tumor models; VERU-111 has favorable pharmacokinetic properties with acceptable oral
bioavailability, ranging from 21% to 50%, in mice, rats and dogs (C. M. Li et al., 2012).
Therefore, we investigated the antitumor activity of VERU-111 specifically for the treatment of metastatic TNBC. The in vitro efficacy of VERU-111 was assayed using two conventional TNBC cell lines (MDA-MB-231 and MDA-MB-468). Furthermore, VERU-111
inhibited cancer cell colony formation, cell migration, and invasion, likely through the
antiproliferative related mechanisms regulating microtubule assembly, G2–M cell-cycle
arrest, and induction of apoptosis. In a MDA-MB-231 xenograft model, orally administered VERU-111 inhibited TNBC xenograft tumor growth in a dose-dependent manner
with antitumor potency similar to paclitaxel and repressed visceral metastasis in both an
orthotopic setting and in an experimental metastasis model. To better understand the
effect of VERU-111 on taxane-resistant TNBC, we developed taxane-resistant TNBC cell
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sublines, namely MDA-MB-231/TxR, MDA-MB-468/TxR, SUM159/TxR, with acquired
resistance by exposing paclitaxel continually. MTS assay confirmed that VERU-111 maintained the potency against all taxane-resistant sublines, incluing two luciferase-labeled
TNBC primary cell lines derived from metastatic patient-derived xenograft (PDX) models created at the Huntsman Cancer Institute (HCI) (DeRose et al., 2013), HCI-2-Luc2
(treatment-naïve) and HCI-10-Luc2 (taxane refractory). We also found that VERU-111
arrested both MDA-MB-231 and MDA-MB-231/TxR cells at the G2–M checkpoint in a
concentration-dependent manner and induced ultimate cell death. In addition, relative to
paclitaxel, orally administered VERU-111 effectively inhibited the tumor growth in two aggressive taxane-resistant TNBC xenograft models, including a taxane-resistant PDX model.
VERU-111, but not paclitaxel, significantly repressed primary tumor growth, growth of
pre-established axillary lymph node metastases and repressed endpoint metastasis in mice
bearing HCI-10-Luc2 xenografts derived from the PDX model (El Ayachi et al., 2019). Collectively, these data position VERU-111 as a promising drug candidate for the more effective treatment of metastatic TNBC, potentially including patients who progress on taxanes.

2.2
2.2.1

Materials and Methods
Chemical compounds and cell lines

Colchicine was purchased from Sigma-Aldrich. Paclitaxel was purchased from LC Laboratories. VERU-111 was synthesized by a reported method (Q. Wang, K. E. Arnst, Y.
Wang, Kumar, Ma, H. Chen, et al., 2018); purity (≥ 98%) and identity were verified by
HPLC, HR-MS (Waters), and proton nuclear magnetic resonance (Bruker). MDA-MB-231
and MDA-MB-468 were purchased from ATCC and authenticated prior to use and then
authenticated every year at the University of Arizona Genetics Core. Cells were cultured
in DMEM-Hi (Mediatech, Inc.) supplemented with 10% fetal bovine serum (FBS) (Atlanta
Biologicals) and 1% antibiotic–antimycotic solution (Sigma-Aldrich) at 37 °C in a humidified atmosphere containing 5% CO2 . Spent media were routinely tested for Mycoplasma
using the MycoAlert Kit (Lonza). Paclitaxel-resistant TNBC cell sublines, named MDAMB-231/TxR, MDA-MB-468/TxR and SUM159/TxR, were generated by exposing paclitaxel continually. When the resistant cells were stable in grow media containing 100 nM
of paclitaxel, paclitaxel was removed and the cells were cultured in full growth media for
2 weeks before the test. The parental HCI-2 and HCI-10 PDX breast tumor lines (TNBC:
ER-/PR-/HER2-) were originally provided by Dr. Alana Welm and the Huntsman Cancer Institute (HCI) tissue resource and application core (DeRose et al., 2013). HCI-2-Luc2
and HCI-10-Luc2 patient-derived tumor xenograft lines were developed by transient cell
culture of parent primary PDX tumor cells in stem cell conditions with a lentivirus expressing luciferase-2 and puromycin, followed by transplant into and exclusive passage in
immunocompromised recipient mice, as described in (El Ayachi et al., 2019). Primary cell
lines generated from the Luc2-labeled tumor xenografts were grown in adherent conventional cell culture conditions and were maintained in M87 growth medium as in (DeRose
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et al., 2013; El Ayachi et al., 2019). Luciferase-labeled HCI PDX-derived primary cell lines
and subsequent tumor xenograft material were authenticated by matching to the original deidentified patient sample by whole genome expression profiling at the Huntsman
Cancer Institute.

2.2.2

Cell growth inhibition assay

A MTS assay was used to score for cell growth inhibition effects of an increasing concentration range of colchicine, paclitaxel, and VERU-111 in human melanoma (A375 and M14),
human HER2-positive breast (SKBR3) and TNBC (MDA-MB-231, MDA-MB-453, MDAMB-468, MDA-MB-231/TxR, MDA-MB-468/TxR and SUM159/TxR) cell lines for 72 h as
described previously (Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, H. Chen, et al., 2018).
HCI-2- or HCI-10-Luc2 patient-derived primary cell lines were seeded at 20,000 cells/well
and grown in the presence of drugs for six days. Drug response was normalized to untreated and vehicle-only controls, plotted on log scale, and analyzed using nonlinear regression best fit analysis modules in Prism 7.0. For all cell models, at least three biological
replicate experiments were averaged to calculate the grand mean IC50 ± SEM.

2.2.3

Colony formation assay

MDA-MB-231 or MDA-MB-468 cells were seeded into 12-well plates (250 or 500 cells/well,
respectively) and then treated 24 h later with increasing concentrations of colchicine, paclitaxel, and VERU (8, 16, or 32 nM). Medium was replaced with fresh drug once per week.
Cells were fixed with methanol and stained with 0.5% crystal violet, and colony morphology was visualized by a microscope and colonies quantified using ImageJ software (NIH,
Bethesda, MD).

2.2.4

Immunofluorescence staining

MDA-MB-231 (105 ) or MDA-MB-468 (2 x 105 ) cells were seeded in 6-well plates onto sterile
coverslips for 24 h prior to treatment with 16 nM of colchicine, paclitaxel, or VERU-111 for
18 h. For evaluating the effect of VERU-111 on paclitaxel-resistant TNBC cells, 105 MDAMB-231 or 2 x 105 MDA-MB-231/TxR cells were seeded on the sterile coverslips in 6-well
plates and incubated overnight. Then the cells were treated with 10 nM of colchicine, paclitaxel or VERU-111 for 24 h. For tubulin visualization, cells were washed with PBS, fixed
with 4% paraformaldehyde for 15 min, and permeabilized with 0.2% Triton X-100/PBS
for 15 min. Following blocking in 1.5% BSA, 0.1% Tween 20 in PBS for 1 h, coverslips
were incubated with anti–α-tubulin antibody (Thermo Fisher Scientific) in 1% BSA/0.1%
Tween 20/PBS overnight at 4 °C. Cells were then washed and incubated with Alexa Fluor
647 goat anti-mouse IgG (Molecular Probes) for 1 h at room temperature, mounted with
Prolong Diamond Antifade containing DAPI (Invitrogen), and images captured with a
Keyence BZ-X700 microscope.
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2.2.5

Cell migration and invasion assay

Cell migration and invasion were measured, respectively, using transwell 24-well plates
with a noncoated membrane insert (pore size 8 mm) or a Matrigel-coated insert (BD Biosciences). MDA-MB-231 and MDA-MB-468 cells were starved in serum-free medium for
24 h, followed by suspension of the cells (MDA-MB-231: 4 x 104 and MDA-MB-468: 105 ) in
serum-free medium containing 8 nM of VERU-111 and then plating in the top chamber of
the inserts. Medium containing 10% FBS was added to the lower chamber as a chemoattractant and cells were incubated for 24 h (MDA-MB-231) or 48 h (MDA-MB-468). The
chambers were fixed in cold methanol, stained with 0.5% crystal violet, and imaged. The
number of migrating or invading cells was counted using ImageJ software and normalized to the control group for each cell line (as 100%). Random cell migration was then
analyzed by a manual scratch wound healing assay. MDA-MB-231 cells (105 cells/well)
and MDA-MB-468 (2 x 105 cells/well) cells were seeded in 12-well plates and allowed to
adhere overnight. The following day, a scratch was made in the confluent cell monolayer
using a sterile 200 µL pipette tip. The cell culture medium was replaced by medium containing vehicle (DMSO), colchicine, paclitaxel, or VERU-111 (16 nM). At 12, 24, and 48 h,
wound width was imaged with an Evos Fl Imaging System (Life Technologies) and closure
expressed relative to the size of the original scratch width at each measured time point in
the drug-treated wells relative to the vehicle control.
The scratch assay was repeated with 8 nM VERU-111 treatment using IncuCyte
S3 live cell imager. Briefly, MDA-MB-231 (43000 cells/well) or MDA-MB-468 cells (90000
cells/well) were seeded in 96-well ImageLock plates (Essen BioScience) and allowed to
attach overnight. Then a WoundMaker™ (Essen BioScience) was used to create uniform
scratches in all the wells and cell debris was washed away with grow medium for three
times. Growth medium or medium containing 8 nM VERU-111 was added to each well
and the plates were monitored by IncuCyte every 2 hours for up to 4 days. Fresh medium
was replaced for every two days during the treatment. The relative wound density was
calculated using the IncuCyte™ Scratch Wound Software Module. We also did the scratch
assay for the MDA-MB-231 cells treated with an increasing concentration of VERU-111
using IncuCyte S3 live cell imager. The wound width was determined by the IncuCyte™
Scratch Wound Software Module. A similar scratch assay was performed on MDA-MB231 (41000 cells/well) and MDA-MB-231/TxR cells (45000 cells/well) with treatment of
colchicine (15 nM), paclitaxel (15 nM) or VERU-111 (5 nM, 10 nM and 15 nM) for 24 h. And
the wound width was calculated by the IncuCyte™ Scratch Wound Software Module.

2.2.6

Cell-cycle analysis

After treatment with each drug, cells were harvested by trypsinization, fixed, permeabilized, stained with anti–phospho-histone H3 (Ser10)-Alexa Fluor 488 antibody on ice for
1 h, and then incubated with freshly prepared propidium iodide/RNase solution for 30
min at room temperature per the manufacturer’s protocol (#FCCH025103, EMD Millipore
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Corporation). Stained cells were analyzed using a Bio-Rad ZE5 instrument (Bio-Rad) and
data were analyzed using FlowJo version 10 (FlowJo, LLC) in the University of Tennessee
Health Science Center (UTHSC) Flow Cytometry and Cell Sorting core. First, total cells
were gated, followed by gating out cell doublets and debris. Cells in sub-G1, G1, S, and
G2 phases were then gated according to DNA content, as determined from histogram plots
of propidium iodide (PI) staining-area. Cell populations were defined and analyzed from
the bottom half of G1 peak, middle of the S-phase, and the top half of G2 peak, respectively.
Cells in the M-phase were identified by comparing the compensation control sample with
the phospho-histone H3-Alexa Fluor 488–stained samples and gated only for phosphorhistone H3–stained cells.

2.2.7

Detection of apoptosis

MDA-MB-231 and MDA-MB-468 cells were seeded in 6-well plates (2 x 105 /well). The
next day, cells were treated with 100 nM of VERU-111 for 24, 48, or 72 h. Alternatively, cells
were treated with increasing concentrations of VERU-111 for 24 h. Similarly, for detecting
the effect of VERU-111 on paclitaxel-resistant TNBC cells, MDA-MB-231 and MDA-MB231/TxR cells were seeded in 6-well plates (2 x 105 /well) and treated with colchicine (20
nM), paclitaxel (20 nM) or VERU-111 (5 nM, 10 nM and 20 nM) for 24 h after overnight
incubation. At harvest, 105 cells were suspended in 185 µL of Annexin-V-FITC binding
buffer (eBioscience) and 5 µL of Annexin-V-FITC (eBioscience) and 10 µL propidium iodide
were added, followed by incubation for 10 min at room temperature, and analysis in the
UTHSC Flow Cytometry and Cell Sorting core.

2.2.8

Caspase-3/7 activity assay

Apoptosis induced by VERU-111 was measured using the Caspase Glo 3/7 assay system
(Promega; (M. Xiao et al., 2015)). Cells (5000 cells/well) were seeded into a 96-well plate
and treated with either colchicine, paclitaxel, or VERU-111 (20 nM) for 24 h, and caspase3/7 activity was normalized by total protein content.

2.2.9

Western blotting

Cells grown to 70% confluence were incubated with increasing concentrations of VERU111 or 100 nM colchicine or paclitaxel for 24 h. For time-dependent studies, cells were
exposed to 100 nM VERU-111 for 24, 48, or 72 h. At harvest, cells were washed with
ice-cold PBS, lysed in RIPA buffer (25 mM Tris pH 7.6, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS) in the presence of Halt protease and phosphatase inhibitor (Thermo Fisher Scientific), and centrifuged at 13000 rpm at 4 °C for 10 min. Protein
concentration was determined by the BCA Protein Assay (Thermo Fisher Scientific). Denatured protein samples were separated by SDS-PAGE gradient gels (Bio-Rad, #456-1083)
and transferred to PVDF membrane. Membranes were blocked in 5% nonfat milk in TBST
solution at room temperature for 1 h, incubated with primary antibodies overnight at 4 °C,
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and incubated with secondary antibody for 1 h (1: 2000, either #7074 or #7076, Cell Signaling Technology). Primary antibodies included: rabbit anti-cleaved-PARP (1: 1000), rabbit
anti-cleaved-caspase-3 (1: 1000), rabbit anti-GAPDH HRP conjugate (#9532; #5625; #9661;
#3683, respectively, Cell Signaling Technology), and mouse anti-P-gp (MA1-26528, Thermo
Fisher Scientific). Proteins were detected using Clarity Western ECL Substrate (Bio-Rad,
#1705060) and visualized by the ChemiDoc-It2 Imager system (UVP, LCC).

2.2.10 In vivo orthotopic MDA-MB-231 xenograft model
All protocols and methods were approved by the UTHSC Animal Care and Use Committee
(ACUC), consistent with the Guide for the Care and Use of Laboratory Animals, 8th edition
(protocols #17-080 and #17-056). Female NOD scid gamma (NSG) mice at 5 to 6 weeks
of age were housed with a 12: 12 hour light/dark cycle and fed a breeder chow diet.
MDA-MB-231 cells suspended in 10 µL of HBSS (2.5 x 105 ) were surgically inoculated
into the left and the right inguinal mammary gland fat pads of deeply anesthetized NSG
mice using a Hamilton syringe mounted with a 1/2” 26G PT2 point needle (Fan et al.,
2013). Mice were palpated and measured with digital calipers weekly until the average
tumor size per mouse was 100 mm3 . Mice were then randomly divided into 5 groups
such that the mean tumor volumes were equivalent across cohorts (Cohort 1: vehicle, 1:
1 ratio of PEG 300: water, orally, n = 14 mice; Cohort 2: 5 mg/kg VERU-111, orally, n =
8 mice; Cohort 3: 10 mg/kg VERU-111, orally, n = 8 mice; Cohort 4: 12.5 mg/kg VERU111, orally, n = 8 mice; Cohort 5: 12.5 mg/kg paclitaxel, intraperitoneally, n = 8 mice).
Animals in the vehicle and VERU-111 MDA-MB-231 xenograft cohorts were dosed orally
five times per week (Monday–Friday), and animals treated with paclitaxel were dosed
every other day (intraperitoneally). Primary tumor size was monitored twice a week and
the body weight of the mice was recorded daily. Tumor volume was calculated by the
formula volume = (width2 x length)/2. All animals were euthanized when total tumor
volume in the vehicle control group exceeded 1000mm3 (after 18 days on therapy). Excised
tumors were photographed, and final tumor volume was calculated from ex vivo caliper
measurements. Tumors were then divided in half and either flash frozen or fixed overnight
at room temperature in buffered formalin. Lungs were harvested after inflation with saline
and post fixed in formalin overnight prior to downstream histologic analysis using the
UTHSC Research Histology Core.
For the orthotopic MDA-MB-231/TxR xenograft model, 2.5 x 105 MDA-MB-231
or MDA-MB-231/TxR cells were similarly inoculated into the left and the right inguinal
mammary gland fat pads. Once the tumor volume reached 100 mm3 , mice were randomized into 3 groups according to different tumor types: Vehicle group (3: 7 ratio of PEG
300: water, orally, n = 6), 10 mg/kg paclitaxel treatment group (1: 1: 18 ratio of ethanol:
Cremophor EL: saline, intraperitoneally, n = 7) and 20 mg/kg VERU-111 treatment group
(3: 7 ratio of PEG 300: water, orally, n = 7). All the mice were dosed three times per week,
and the tumor volume and mice body weight were monitored during the therapy. After
22 days of treatment on mice bearing MDA-MB-231 tumors (25 days of treatment on mice

Chapter 2. An Orally Active Tubulin Inhibitor, VERU-111, Suppresses Triple Negative
23
Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
bearing MDA-MB-231/TxR tumors) the mice were euthanized and the tumors and lungs
were collected as above mentioned.

2.2.11

Experimental lung metastasis model

NSG female mice (7–8 weeks old) were injected with 2 x 105 MDA-MB-231 cells in 100 µL
of HBSS via tail vein. Twenty-four hours later, mice were treated with either vehicle, 10
mg/kg of VERU-111, or 10 mg/kg paclitaxel (n = 7 mice/group) using the same dosing
regimen as the orthotopic xenograft model. Body weight was monitored weekly. After
23 days, mice were sacrificed, and lungs, livers, kidneys, and spleens were photographed
and then fixed in formalin overnight.

2.2.12

Histology and immunohistochemistry analysis

Fixed tumors and organs were embedded in paraffin and unstained slides were prepared
for immunostaining or stained with hematoxylin/eosin (H&E). immunohistochemistry
(IHC) staining was performed as described previously (Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, H. Chen, et al., 2018). Primary antibodies included rabbit anti-Ki67 (1: 400), rabbit anti-CD31 (1: 100; #9027; #77699, Cell Signaling Technology), rabbit anti-cleaved-PARP
(1: 50) and rabbit anti-cleaved-caspase-3 (1: 200), detected by a biotinylated horse antirabbit IgG antibody (BA-1100, Vector Laboratories Inc.) secondary antibody. Anti–humanspecific mitochondria IHC staining (AbCAM, cat#ab92824) was performed at a 1: 1000
dilution to visualize metastases. All slides were developed with DAB Impact (Vector
Labs), counterstained in Gill’s hematoxylin (Vector Labs), and mounted with Cytoseal
XYL mounting media. Tissue images were acquired with a Keyence BZ-X700 microscope.
Quantification of metastatic burden was performed by digital scanning of whole stained
slides using a Pannoramic FLASH III system (3D Histech), followed by manual counting
of metastatic lesions present in the tissue section. Quantification of Ki67-, CD31-, cleavedPARP-, and cleaved-caspase-3–positive tumor cells was performed by calculating the area
of positive cells in 4 to 5 representative fields per section using the Keyence Hybrid Cell
Count module.

2.2.13

Patient-derived xenograft models

The parental HCI-10 PDX model was originally derived from a pleural effusion of a heavilytreated patient diagnosed with metastatic breast cancer (DeRose et al., 2013). To facilitate
whole-body bioluminescent imaging, this model was previously labeled with firefly luciferase as described (El Ayachi et al., 2019). After transient cell culture in stem cell culture
conditions to achieve viral transduction and reporter labeling, HCI-10-Luc2 cells were implanted into a donor female NSG mouse and then serially re-transplanted and/or cryopreserved to maintain the line. Tumor fragments from a donor tumor-bearing mouse were
bilaterally implanted into the cleared inguinal mammary fat pads of recipient NSG female
mice (4-6 weeks of age). Primary tumor growth and metastasis were monitored bi-weekly
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by caliper measurement and bio-imaging (Perkin Elmer XMRS) (1x/week) beginning two
weeks post-surgery. Body weights were recorded every other day. As soon as one tumor per mouse grew to ~100 mm3 , mice were randomized such that mean tumor volumes
were equivalent in each cohort: Cohort 1: vehicle (PO, five consecutive days/week, n =
12 mice), Cohort 2: 10 mg/kg paclitaxel (intravenous (IV), 1x/week, n = 13 mice) and
Cohort 3: 10 mg/kg VERU-111 (PO, 5 consecutive days /week, n = 13 mice). Mice were
then bio-imaged the day before treatment to screen for pre-existing AxLN metastases. All
bio-imaging data are shown as total flux (photons/s), calculated using Living Image software. After 8 weeks on treatment, when mean tumor volume in the vehicle control group
was ~500 mm3 , all animals were euthanized. All organs were collected and bio-imaged
ex vivo to confirm location of metastatic signals observed in intact mice and to quantitate
metastatic burden specific to that organ. Collected tumors and organs were processed for
histology as described above.

2.2.14

Statistical analysis

All data were analyzed using GraphPad Prism 7. In vitro experiments were repeated using
at least three technical replicates per group and each assay performed over three biological replicates. One-way or two-way ANOVA tests were first employed for experiments
comparing more than two groups/conditions, followed by pairwise, two tailed Student t
tests or a Dunnett multiple comparison test. Student t tests were used to compare treatment group with the control group for the in vitro migration and invasion assays. One-way
ANOVA analyses followed by the Dunnett test was used to evaluate differences between
treatments and controls for the in vitro colony formation, scratch, and cell apoptosis detection assays, as well as all in vivo xenograft studies. Significance levels are defined as *, p <
0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

2.3
2.3.1

Results
VERU-111 attenuates proliferation of breast cancer cells and impairs microtubule assembly and mitotic spindle organization

VERU-111 (Figure 2.1A) has an average IC50 of 4 nM in melanoma cells (J. Chen, Ahn,
et al., 2012). We evaluated whether VERU-111 could inhibit the growth of HER2+ (SKBR3)
and TNBC breast cancer cells (MDA-MB-231, -468 and -453 cells). VERU-111 had potent
antiproliferative effect in all cells, with IC50 values in the low nM range: SKBR3 (14 nM)
and 8-14 nM in TNBC cells (Table 2.1). The tubulin-destabilizing agent colchicine and the
tubulin-stabilizing agent paclitaxel were then compared to VERU-111 using two TNBC
cell lines (Figure 2.1B). All three inhibitors inhibited cell proliferation. Mean IC50 values
of colchicine, paclitaxel and VERU-111 ranged from 9.8-17.5 nM, 3.1-4.6 nM and 8.2-9.6
nM, respectively, depending on the model. VERU-111 reduced colony formation of TNBC
cells in a concentration-dependent manner (Figure 2.1C). In MDA-MB-231 cells, paclitaxel
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Figure 2.1: Efficacy of VERU-111 versus paclitaxel in two TNBC cell
lines, MDA-MB-231 and MDA-MB-468. (A) Chemical structure of
VERU-111. (B) The antiproliferative effect of VERU-111 relative to
colchicine and paclitaxel controls determined by MTS assay. (C)
Representative pictures of a colony formation assay using MDA-MB-231
(left panel) and MDA-MB-468 (right panel) cells treated with colchicine,
paclitaxel and VERU-111. (D) Representative immunofluorescence
anti-tubulin staining images of the microtubule network in MDA-MB-231
(top panel) and MDA-MB-468 (lower panel) cells treated with vehicle
(Control), colchicine (16 nM), paclitaxel (16 nM) and VERU-111 (16 nM) for
16 h. Images were obtained at ×20 magnification.
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Table 2.1: Anti-proliferating effects of VERU-111 against various human
cancer cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.

completely repressed colony formation at a concentration as low as 8 nM. In contrast,
colony formation was reduced, but not eliminated, at an equivalent concentration of either colchicine or VERU-111, although 16 nM of VERU-111 was more effective than 16 nM
of colchicine. Similar results were observed in MDA-MB-468 cells.
VERU-111 demonstrates robust antitumor activity by destabilizing tubulin polymerization through targeting the colchicine-binding site (J. Chen, Ahn, et al., 2012). Thus,
we performed immunofluorescence staining to visualize the microtubule network after
treatment with colchicine, VERU-111 and paclitaxel. Control cells showed intact microtubule fibers and typical microtubule organization (Figure 2.1D). As expected, treatment
with paclitaxel produced aggregation and condensation of microtubules due to increased
tubulin polymerization. Similar to colchicine, cells treated with VERU-111 were smaller
and the cell shape changed from spindle-like to round and irregular, and the microtubules
were depolymerized, confirming that VERU-111 disrupts tubulin polymerization in TNBC
cells.

2.3.2

VERU-111 inhibits TNBC cells migration and invasion

VERU-111 (8 nM) inhibited cell migration by 44% in MDA-MB-231 cells and by 37% in
MDA-MB-468 cells relative to the control (set to 100%) (Figure 2.2A). Likewise, VERU111 reduced invasion through Matrigel membrane by 50% in MDA-MB-231 and by 45%
in MDA-MB-468 cells (Figure 2.2B). Similar results on invasion potential were obtained
when cells were exposed to 16 nM of VERU-111 (Figure A.1). VERU-111, colchicine and
paclitaxel showed effective inhibition of wound healing in a scratch wound assay at 16
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Figure 2.2: VERU-111 represses TNBC cell migration and invasion.
Directed migration (A) or invasion (B) of MDA-MB-231 (upper panel) and
MDA-MB-468 (lower panel) cells was determined using a transwell 24-well
plate assay following treatment with VERU-111 (8 nM) for 24 h and 48 h,
respectively. (C) The effect of VERU-111 on MDA-MB-231 (left panel) and
MDA-MB-468 (right panel) on wound healing was determined by the
scratch assay after treatment for 24 h and 48 h, respectively. All data (A-C)
are presented as the grand mean ± SEM of three independent experiments,
with p values determined relative to the Control group (normalized to
100%). All images are shown with a scale bar = 200 µm.
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nM (Figure 2.2C). After 24 h, the average rates of migration in colchicine, paclitaxel and
VERU-111-treated MDA-MB-231 cells were 67.3%, 43.3% and 44.9%, respectively, relative
to vehicle control (DMSO). Similarly, after 48 h treatment, colchicine, paclitaxel and VERU111 reduced the average migration of MDA-MB-468 cells by 15.8%, 14.5% and 17.9%, respectively. Images of wounds are shown in Figure A.2. We also verified that lowering the
concentration of VERU-111 to 8 nM also inhibited wound healing in TNBC cells (Figure
2.3A and B). Finally, the ability of VERU-111 to inhibit wound healing in a concentrationdependent manner over time was shown using MDA-MB-231 cells grown in the IncuCyte
S3 live cell imaging system (Figure 2.3C). In summary, although VERU-111 impaired cell
migration, invasion and wound healing, it is not possible to rule out the impact of VERU111-dependent effects on growth inhibition and/or cytotoxicity on these assays.

2.3.3

VERU-111 blocks TNBC cells at G2/M checkpoint and induces cell apoptosis

Microtubule disruption typically leads to the mitotic arrest of growing cells in metaphase,
ultimately causing cell death (Mollinedo and Gajate, 2003; Kulshrestha et al., 2017). To examine whether VERU-111 induces cell cycle arrest, cells treated with 100 nM of colchicine
or paclitaxel and increasing concentrations of VERU-111 for 24 h were profiled by flow
cytometry. Each compound showed divergent effects on cell cycle progression in each cell
line. In MDA-MB-231 cells, VERU-111 treatment induced a G2/M block in a concentrationdependent manner, with a concomitant reduction in cells in the G1 and S phases. Colchicine
and paclitaxel, also arrested MDA-MB-231 cells in the G2 and M phases, as expected
(Figures 2.4A and A.3A). Likewise, VERU-111 induced a G2 phase arrest in MDA-MB468 cells, reducing the population of cells G1, with little effect on the S phase. In contrast
to VERU-111, paclitaxel arrested MDA-MB-468 cells in the G2 and M phases (Figure 2.4A).
VERU-111 treatment caused a significant G2/M accumulation at a concentration of 20 nM
in MDA-MB-231 cells, and at 50 nM in MDA-MB-468 cells, with maximum accumulation
observed in response to a concentration of 100 nM.
The potential of VERU-111 to induce apoptosis in TNBC cells was analyzed using
Annexin-V-FITC/PI co-staining. VERU-111 initiated apoptotic cell death in a concentrationdependent manner, as indicated by the appearance of Annexin-V+/PI- cells, AnnexinV+/PI+ cells and Annexin-V-/PI+ cells (Figures 2.4B and A.3B). The potency of VERU-111
to induce apoptosis was identical to colchicine but required a higher concentration for paclitaxel. MDA-MB-231 and MDA-MB-468 cells treated with 100 nM VERU-111 for 24, 48
and 72 h underwent apoptosis in a time-dependent manner as shown in Figures 2.4C and
A.3C. Caspases and PARP play an important role in the initiation and execution of programmed cell death (P. Xu et al., 2016; W. Wang et al., 2017). To determine whether VERU111 triggers apoptotic cell death through these pathways, expression of cleaved-caspase-3
and cleaved-PARP in TNBC cells treated by VERU-111 were analyzed by western blotting (Figure 2.4D and E), revealing increased expression of cleaved-caspase-3 and cleavedPARP in a concentration-dependent manner after 24 h treatment, although cleavage was
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Figure 2.3: The IC50 dose of VERU-111 inhibits wound healing of TNBC
cells in a scratch wound healing assay. (A) Representative images of
MDA-MB-231 cells treated with 8 nM of VERU-111 at 12 h and 24 h
post-scratch as compared to untreated cells. (B) Representative images of
MDA-MB-468 cells treated with 8 nM of VERU-111 at 48 h and 96 h
post-scratch as compared to untreated cells. (C) The concentrationdependent effect of VERU-111 on MDA-MB-231 cell wound healing over
time was measured. All data are presented as the grand mean ± SEM of
three independent experiments.
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Figure 2.4: VERU-111 induces G2/M cell cycle arrest and apoptosis in
TNBC cells. (A) Cell cycle distribution was determined by flow cytometry
after staining with phospho-Histone H3 (Ser10) and propidium iodide. (B)
Apoptosis was compared after treatment with the same drugs by
Annexin-V/PI co-staining. (C) Flow cytometry analysis of apoptotic cells
detected by Annexin-V/PI staining in TNBC cells treated with vehicle, or
VERU-111 at 100 nM for 24, 48, or 72 h. (D) Cleaved-caspase-3 and PARP
cleavage were determined by western blotting after treatments as in A. (E)
Cleaved-caspase-3 and PARP cleavage by western blotting following
VERU-111 treatment (100 nM) for 24, 48 and 72 h. (F) Caspase 3/7 activity
following treatment with 20 nM of each drug for 24 h in MDA-MB-231 (left
panel) and MDA-MB-468 (right panel) cells.
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overall lower than in cells treated with paclitaxel. Colchicine also induced the upregulation
of cleaved-caspase-3 and cleaved-PARP in MDA-MB-468 cells after 24 h treatment (Figure
2.4D). There was also a clear, time-dependent increase in cleaved-caspase-3 and cleavedPARP expression after VERU-111 treatment (Figure 2.4E). Caspase 3/7 activity was next
evaluated in each cell line using the Caspase Glo 3/7 assay, including colchicine and paclitaxel as positive controls (Figure 2.4F). VERU-111, colchicine and paclitaxel displayed up
to 4-fold higher caspase 3/7 activity levels relative to the control, consistent with induction
of apoptosis effectors shown in Figure 2.4B and C.

2.3.4

VERU-111 inhibits TNBC primary tumor growth

We next tested the antitumor activity of VERU-111 in an orthotopic metastatic TNBC
mouse model (MDA-MB-231). Since paclitaxel is one of the most widely used chemotherapeutics for stage IV breast cancer, we incorporated paclitaxel as the comparison treatment.
NSG mice bearing MDA-MB-231 xenografts were treated with either vehicle, 5-, 10- or
12.5 mg/kg of VERU-111 (PO) or 12.5 mg/kg paclitaxel (intraperitoneally, IP). Relative to
vehicle treated mice, mean tumor size was significantly decreased in the 10 mg/kg and
12.5 mg/kg VERU-111 cohorts and in the paclitaxel-treated groups, whereas VERU-111
given at 5 mg/kg showed less potent inhibition (Figure 2.5A). No significant loss of body
weight was observed in the VERU-111 treated groups, although 12.5 mg/kg dosing of
VERU-111 did appear to inhibit the weight gain observed in the other treatment groups
over the course of the treatment. In contrast, the body weight of mice in the paclitaxel
treatment group was significantly decreased (-10%), suggesting an accumulated toxicity
(Figure 2.5B). Relative to controls, each dose of VERU-111 significantly reduced mean tumor volume and mean wet weight with the largest effect observed at 12.5 mg/kg (Figure
2.5C and D). Moreover, VERU-111 had comparable efficacy to paclitaxel since there were
no significant differences between the means of the two groups at the same dose (276.61
mm3 vs. 254.32 mm3 ) (Figure 2.5C). Similar changes were observed when the mean final tumor weights were compared (Figure 2.5D). Both VERU-111 and paclitaxel treatment
significantly reduced overall tumor size as compared to the vehicle control (Figure 2.5E).

2.3.5

VERU-111 induces tumor necrosis, anti-angiogenesis and apoptosis in
vivo

Paraffin-embedded tumor sections were then stained with H&E and with Ki67, CD31,
cleaved-PARP and cleaved-caspase-3 by IHC (Figure 2.6A). As necrotic areas would be
expected in the tumor centers due to hypoxia, all H&E and IHC pictures were imaged
near the tumor margins. Both VERU-111 and paclitaxel treatment increased the number
of necrotic tumor cells with pyknosis, indicated by the nuclear shrinkage (Figure 2.6A).
The percentage of tumor area occupied by necrotic cells was not statistically significant
between vehicle and the 5 mg/kg dose of VERU-111 (Figure 2.6B); however, necrosis
significantly increased in response to 10 mg/kg or 12.5 mg/kg of VERU-111. Approximately half of tumor area in the 12.5 mg/kg VERU-111-treatment group was necrotic,
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Figure 2.5: Antitumor effect of VERU-111 in orthotopic MDA-MB-231
xenografts. (A) The mean percent increase ± SEM in tumor volume relative
to initial tumor volume when drug treatment began (tumors ~100 mm3 )
following dosing with 5, 10, or 12.5 mg/kg VERU-111 (5 times/week, PO)
or 12.5 mg/kg paclitaxel (every other day, IP). (B) Mean percent change in
mouse body weight ± SEM relative to body weight at the time of initiating
drug treatment. Dashed lines indicate weight relative to the baseline (y axis
= 0) and 20% weight gain. (A-B) Time is expressed as days post-injection of
MDA-MB-231 cells to the mammary fat pad. (C-D) Scatter plots of final
tumor volume ± SEM of excised tumors measured ex vivo with calipers (C)
and final tumor weight wet (D) ; the mean is indicated above each
treatment group. (E) Images representative of tumors for each cohort’s
mean final tumor volume and wet weight. For all comparisons, one-way
ANOVA was performed followed by Dunnett’s multiple comparisons
testing and all p values are relative to the vehicle control group at
experimental endpoint.
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Figure 2.6: VERU-111 therapy induces tumor necrosis, represses
proliferation and angiogenesis, and induces apoptosis in vivo. (A)
Representative images of H&E-stained whole tumor sections bisected at
the widest width and representative stained slides following
immunostaining with Ki67, CD31, cleaved-PARP and cleaved-caspase-3.
Images were captured at either 20x or 40x magnification, scale bar = 50 µm.
Inserts show low power images. (B) Quantification of the mean percentage
of necrotic area ± SEM of H&E sections as scored by an experienced
pathologist, expressed relative to the vehicle control. (C-F) Quantification
of the mean percentage ± SEM of Ki67 (C), CD31 (D), cleaved-PARP (E)
and cleaved-caspase-3 (F)-positive cells relative to the vehicle control
group (100%), the mean value is indicated above each group.
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which was comparable to the necrotic area in response to paclitaxel (41.5%). All doses
of VERU-111 treatment significantly decreased, in a dose-dependent manner, the number
of Ki67-positive cells and CD31-positive cells relative to the vehicle-treated tumors. Paclitaxel has been previously shown to inhibit breast tumor angiogenesis (Bocci, Di Paolo, and
Danesi, 2013). Therefore, in vivo, like paclitaxel, VERU-111 inhibited the proliferation of
TNBC cells and disrupted the tumor vasculature (Figure 2.6C and D). A dose-dependent
increase in the percentage of cells expressing both cleaved-PARP and cleaved-caspase-3
was also observed, confirming that VERU-111 efficiently induces apoptosis in vivo (Figure
2.6E and F). As expected, tumor growth suppression, tumor vasculature disruption and
apoptotic cell death induction were also evident for the paclitaxel treatment group (Figure
2.6C-F). Overall, we conclude that the antitumor activity of VERU-111 is equivalent to
paclitaxel in vivo, but without evidence of toxicity.

2.3.6

VERU-111 inhibits metastasis either from the mammary fat pad or in an
experimental metastasis model

The lungs were harvested from the same cohort of MDA-MB-231 mammary-tumor bearing
mice shown in Figure 2.5 for each dose of VERU-111 and for paclitaxel. Lung macrometastases visible to the naked eye after H&E staining were only detected in the vehicle group
(Figure 2.7A). In the 5 mg/kg VERU-111 group, 2 of 8 treated mice did not develop any visible lung metastases, increasing to 4 of 8 mice in the 10 mg/kg VERU-111 treatment group
and to 7 of 8 mice in the 12.5 mg/kg VERU-111 group. In comparison, no lung metastases
were observed by either H&E staining or IHC in the 12.5 mg/kg paclitaxel-treated group
(0 of 8 mice developed metastases).
To test if VERU-111 represses the conversion of seeded tumor cells into lethal lung
macrometastases, an experimental metastasis (tail vein) model was used. Because mice
subjected to experimental metastases typically lose weight as metastases develop, the dose
of VERU-111 and paclitaxel was lowered to 10 mg/kg. As expected, metastases were readily detectable in all lungs from the vehicle group, whereas the lungs in VERU-111- and paclitaxel treated groups exhibited considerably fewer metastases, which were also smaller
in area (Figure 2.7B). Both VERU-111 and paclitaxel were also highly effective in repressing metastasis to the kidney, where no metastases were detected in any mice. In contrast,
VERU-111 appeared to be more effective than paclitaxel to repress liver metastases, as
fewer lesions were observed (Figure 2.7B). Importantly, the body weight (Figure A.4A)
and the physical activity of mice were normal in VERU-111-treated group. In fact, only
the VERU-111 treated mice gained weight over the course of the experiment. As expected,
mice in the vehicle treatment group lost weight over time. In the paclitaxel-treated group,
mice lost ~10% of their initial body weight, demonstrating the relative toxicity of paclitaxel versus VERU-111. H&E staining also showed that multiple metastases with varying
sizes were observed in the lung, liver, and kidney of vehicle treated mice, whereas the
metastases in the VERU-111 and paclitaxel-treated mice were overall less frequently observed and were smaller (Figure A.4B). Collectively, these results support our conclusions
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Figure 2.7: VERU-111 treatment suppresses metastasis formation in an
orthotopic xenograft model and in an experimental lung metastasis
model using MDA-MB-231 cells. (A) Representative H&E stained sections
of lung metastases derived from orthotopically implanted MDA-MB-231
cells. Lung metastases are indicated by yellow arrows in the H&E-stained
slides, 4x magnification, scale bar = 100 µm. Lung metastatic burden of
each section from each mouse was quantified after scanning whole slides.
(B) Anti-human specific mitochondria IHC staining to detect metastases in
lung, liver and kidney sections, scale bar is 200 µm for primary figures and
50 µm for inserts. Scatter plots of mean ± SEM show the quantification of
metastases present in the lung, liver and kidney (A and B). The number
above each treatment group correspond to the mean.
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that VERU-111 shows comparable efficacy to paclitaxel in suppressing metastasis of TNBC
cells at equivalent doses, but without significant toxicity to mice, and with the distinct advantage of being orally bioavailable.

2.3.7

VERU-111 shows efficacy in a panel of taxane-resistant TNBC cell lines

To determine the effect of VERU-111 against taxane-resistant TNBC cells, we generated
MDA-MB-231/TxR, MDA-MB-468/TxR and SUM159/TxR sublines that were resistant to
paclitaxel. When the cells were resisting 100 nM of paclitaxel, a simple MTS assay was
used to confirm the paclitaxel resistance of each cell subline to each compound and detect the cross resistance (Table 2.2). The resistance index (RI) calculated by dividing IC50
Table 2.2: Antiproliferative effects of VERU-111 on several
paclitaxel-resistant TNBC cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.

of the resistant cells by that of the matching parental cells of paclitaxel was over 175 on
all three cell sublines, suggesting the successful generation of three resistant sublines of
TNBC. Since several studies reported that a key characteristic of taxane chemoresistance
was the overexpression of P-gp (Ho et al., 2007; Muthusamy et al., 2016), herein, we included colchicine, which is also a substrate of P-gp as paclitaxel (Singh et al., 2015; Q.
Shen, Y. Wang, and Y. Zhang, 2011), to investigate the cross-resistance on resistant cell
lines. Results showed that the efficacy of colchicine was affected by paclitaxel resistance
in MDA-MB-468/TxR and SUM159/TxR cells, but not in MDA-MB-231/TxR, suggesting
that the cause of paclitaxel resistance was not simply induced by overexpression of P-gp
but having more complex mechanisms (Table 2.2). However, even with the complex mechanisms underlying paclitaxel resistance, VERU-111 still maintained the efficacy against all
three TNBC cell lines, demonstrating the potential of VERU-111 in overcoming TNBC paclitaxel resistance.
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2.3.8

VERU-111 affects the microtubule assembly and the migration capacity
of paclitaxel-resistant TNBC cells

Due to the stronger antiproliferative activity of VERU-111 displayed on MDA-MB-231/TxR
cells over MDA-MB-468/TxR or SUM159/TxR cells, we selected the MDA-MB-231/TxR
cell subline for further mechanistic studies of VERU-111 on paclitaxel resistance. We first
treated the MDA-MB-231 or MDA-MB-231/TxR cells with 10 nM of paclitaxel, colchicine
and VERU-111 for 24 h to visualize the microtubule networks after VERU-111 treatment
(Figure 2.8A). As expected, paclitaxel treatment induced microtubule condensation in par-

Figure 2.8: VERU-111 maintains its mechanism of action and
anti-migration ability on MDA-MB-231/TxR cells. (A) Representative
microtubule and spindle images of parental MDA-MB-231 and
paclitaxel-resistant MDA-MB-231 cells treated with 10 nM of colchicine,
paclitaxel and VERU-111 for 24 h. The microtubule networks of cells were
visualized by staining with α-tubulin. (B) Anti-migration effect of VERU
on MDA-MB-231 and MDA-MB-231/TxR cells were determined by a
scratch assay. Cells were treated with colchicine (15 nM), paclitaxel (15 nM)
and VERU-111 (5, 10 and 15 nM) for 24 h. During the treatment, the wound
gap was imaged by IncuCyte every 2 hours.
ental MDA-MB-231 cells, while it had limited effect on MDA-MB-231/TxR cells. Due to the
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low concentration used, 10 nM of colchicine had no effect on both cells. However, VERU111 treatment induced the microtubule distribution of both MDA-MB-231 parental and
MDA-MB-231/TxR cells changed from organized to irregular and disorganized, and the
microtubules were depolymerized (Figure 2.8A). In addition, in both MDA-MB-231 and
MDA-MB-231/TxR cells, VERU-111 treatment produced multipolar spindles in the splitting cells, causing spindle defects and abnormal spindle assembly. We also determined
the anti-migration effect of VERU-111 on MDA-MB-231/TxR cells and compared its effect
with colchicine and paclitaxel. As shown in Figure 2.8B, when the TNBC cells became
resistant to paclitaxel, colchicine and paclitaxel lost the anti-migration abilities on MDAMB-231/TxR cells at the concentration of 15 nM, while VERU-111 retained the migrationinhibiting effect on both MDA-MB-231 parental and MDA-MB-231/TxR cells. And it was
able to suppress the migration of both cell sublines following a concentration-dependent
manner (Figure 2.8B).

2.3.9

VERU-111 also arrests paclitaxel-resistant TNBC cells in G2/M phase and
induces cell apoptosis

After confirming the mechanism of action of VERU-111 in paclitaxel-resistant TNBC cells,
we further studied the effects of VERU-111 on cell cycle distribution and cell apoptosis
using MDA-MB-231/TxR cells. This time, we lowered the highest dose of VERU-111 to
20 nM, and we also reduced the concentration of positive controls, colchicine and paclitaxel, to 20 nM (Figure 2.9). Results showed that at 20 nM, VERU-111 could arrest
both MDA-MB-231 parental and MDA-MB-231/TxR cells into G2/M phase and cell death,
while colchicine could not induce both cells into G2/M phase arrest or cell apoptosis and
paclitaxel was only effective on parental MDA-MB-231 cells (Figure 2.9). These studies
indicated that VERU-111 was not only potent to cause cell cycle arrest and cell apoptosis
in taxane-sensitive TNBC cells, but also worked effectively in taxane-resistant TNBC cells.

2.3.10

VERU-111 overcomes paclitaxel resistance in vivo

Since we have successfully developed MDA-MB-231 TxR subline, and all above in vitro assays showed that VERU-111 maintained similar efficacy over taxane-resistant MDA-MB231 cells as compared to taxane-sensitive MDA-MB-231 cells, we then evaluated the ability
of VERU-111 in overcoming paclitaxel resistance using an orthotopic TNBC cancer model
by surgically inoculating MDA-MB-231/TxR cells into the inguinal mammary gland fat
pads of NSG mice. We also included an orthotopic TNBC model by inoculating MDA-MB231 parental cells as a comparison. Similarly, when the average tumor size per mouse from
either MDA-MB-231 parental group or MDA-MB-231/TxR group reached 100 mm3 , mice
were divided into 3 groups for each cell subline and started the treatment (vehicle: 1: 1
ratio of PEG 300: water, PO, 3 times/week; VERU-111 (20 mg/kg): 1: 1 ratio of PEG 300:
water, PO, 3 times/week; paclitaxel (10 mg/kg): 1: 1: 18 ratio of Cremophor EL: ethanol:

Chapter 2. An Orally Active Tubulin Inhibitor, VERU-111, Suppresses Triple Negative
39
Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Figure 2.9: VERU-111 blocks cell cycle at the G2/M phase and induces
cell apoptosis. (A) PI stained cell cycle distribution of MDA-MB-231 and
MDA-MB-231/TxR cells treated with colchicine (20 nM), paclitaxel (20 nM)
and VERU-111 (5, 10 and 20 nM) for 24 h. (B) The percentage of apoptotic
MDA-MB-231 and MDA-MB-231/TxR cells after the same treatment in A.
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saline, IP, 3 times/week). While paclitaxel was potent against the tumor growth of taxanesensitive MDA-MB-231 tumors, it was weak in inhibiting the taxane-resistant MDA-MB231/TxR tumors (Figure 2.10A and B). Relative to paclitaxel, VERU-111 significantly inhibited tumor growth in paclitaxel-resistant tumor model, demonstrating the role of VERU111 to overcome paclitaxel resistance developed in TNBC in vivo (Figure 2.10A and B). At
the study endpoint, all the tumors and lungs in this study were collected and stained with
H&E to determine the effect of VERU-111 in tumor necrosis and spontaneous lung metastasis. As displayed in Figure 2.10C, both VERU-111 and paclitaxel induced TNBC tumor
necrosis significantly, as indicated by blue arrows, which was consistent as the conclusion
we made before. While tumor necrosis was only found in the mice bearing MDA-MB231/TxR tumors treated with VERU-111. In taxane-sensitive TNBC xenograft model, there
were a lot of lung metastases found in vehicle-treated mice, while the lung metastases in
paclitaxel and VERU-111 treated mice were sparse and little, which suggested that VERU111 could significantly reduce the metastasis of sensitive-TNBC (Figure 2.10C). Relative
to parental MDA-MB-231 tumors, there were less and smaller size of metastasis detected
on lungs in vehicle or paclitaxel treated mice bearing MDA-MB-231/TxR tumors, while
the lungs from VERU-111 treated mice were all clean. So here we showed that VERU-111
treatment induced tumor necrosis in vivo, and it could inhibit lung metastasis originating
from fat-pad tumors.

2.3.11

VERU-111 suppresses the TNBC growth and metastases in a taxane-resistant PDX model

To determine if VERU-111 is effective in a taxane-resistant PDX TNBC model, we first utilized two primary cell lines derived from well-characterized TNBC PDX models to compare colchicine, paclitaxel and VERU-111 efficacy in vitro, a treatment-naïve TNBC model
(HCI-2-Luc2) and a taxane-resistant TNBC model (HCI-10-Luc2). Because both primary
cell lines double slowly, approximately every 3 days (El Ayachi et al., 2019), the duration
of drug treatment was six days. As expected, the HCI-10 cells were more resistant to paclitaxel treatment than HCI-2 cells (grand mean IC50 39.27 ± 5.40 nM vs. 6.20 ± 1.70 nM)
(Figures 2.11A and A.1).
However, for VERU-111, the IC50 concentration in each cell model was nearly equivalent (mean IC50 11.89 ± 2.76 nM versus 10.78 ± 1.20 nM), suggesting that VERU-111
maintained its efficacy to suppress growth of a taxane-resistant TNBC model. Colchicine
is included as an assay control, although it is not clinically approved for breast cancer
chemotherapy due to high toxicity. The HCI-10 cell line appeared to be refractory to
colchicine compared to the HCI-2 cell line (46.08 ± 5.53 nM versus 36.93 ± 10.57 nM), which
is likely because relative to HCI-2 cells, HCI-10 cells over-expresses P-gp, which effluxes
colchicine (Figure A.5A) (J. Chen, Ahn, et al., 2012; Taub et al., 2005).
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Figure 2.10: VERU-111 suppresses the taxane-resistant
MDA-MB-231/TxR tumor growth in vivo. (A) NSG mice bearing
MDA-MB-231 tumors (100 mm3 ) were treated with vehicle, 10 mg/kg
paclitaxel and 10 mg/kg VERU-111 for 3 weeks. The tumor volumes were
monitored during the treatment and the % of tumor volume growth at the
indicated days was calculated. The endpoint tumor volume and endpoint
tumor weight were measured. (B) The animal study with NSG mice
bearing MDA-MB-231/TxR tumors (100 mm3 ) was carried out with the
same treatment as A, and the % of tumor growth curve, endpoint tumor
volume bar and endpoint tumor weight bar were plotted. (C)
Representative H&E stained tumor or lung images from the animal models
in A and B were shown. Blue arrows indicate the necrotic area in tumors
and yellow arrows indicate the lung metastases.
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Figure 2.11: Antitumor efficacy of VERU-111 in the taxane-resistant
HCI-10-Luc2 TNBC xenograft model. (A) Antiproliferative effects of
colchicine, paclitaxel and VERU-111 were measured in vitro. The bar
graphs represent the grand mean ± SEM of the calculated IC50 values from
independent drug dosing experiments (n = 4) as calculated by the MTS
method and validated by IncuCyte S3 live cell imaging (Figure A.5). (B)
The mean ± SEM tumor volume based on weeks on therapy in response to
vehicle, 10 mg/kg VERU-111, PO (5 times/week) or 10 mg/kg paclitaxel,
IV (1x/week). At all-time points beginning at week 1.5 of therapy, the
differences between vehicle or paclitaxel versus VERU-111 are statistically
significant; two-way ANOVA followed by multiple comparisons test. (C)
Mean percent change in mouse body weight ± SEM during therapy relative
to the starting body weight at week 0. Dashed lines indicate weight
decreases below baseline (y axis = 0) and +10% increase in body weight.
(D-K) For all experiments, statistically significant differences were
determined by one-way ANOVA followed by Dunnett’s multiple
comparison test at experimental endpoint; only those pairwise analyses
that are significant (p < 0.05) are shown. The cohort mean is shown above
each treatment group. For panels G-H, data is plotted on a log-scale along
the y-axis, and for panels I-K, LOG10 -transformed data are plotted. (D)
Scatter plot of ex vivo final tumor volume ± SEM. (E) Scatter plot of final
tumor wet weight ± SEM of excised tumors. (F) Images of tumors
representative of each group’s final tumor volume and wet weight. (G)
Mean ± SEM of total photon flux of AxLN metastases present in intact mice
one day prior to administration of drug therapy, after assignment to a
cohort; data are significant at experimental endpoint between either the
vehicle control or the paclitaxel-treated group compared to VERU-111
(solid bracket). The colored dashed brackets compare the baseline AxLN
signal of each group from week 0 to week 8. (H) Mean ± SEM of total
photon flux of AxLN metastases present at experiment endpoint. (I-K)
Mean ± SEM of LOG10 -transformed total photon flux of lung (I), liver (J)
and leg bone (K) metastases as measured ex vivo at experiment endpoint.
(J) Of note, whereas no signal for liver metastases was detectable in the
VERU-111 treatment group, paclitaxel treatment significantly enhanced
liver metastasis relative to the vehicle control.
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In an independent assay method, using the IncuCyte S3 live cell imager and measuring confluence by phase contrast, similar IC50 values and differential responses to treatment with paclitaxel and VERU-111 between the two primary cell lines were also observed
(Figure A.5B). The use of PDX xenograft models derived from patients and primarily passaged in mice are preferred xenograft models due to their conserved similarities to original patient material (DeRose et al., 2013; Tentler et al., 2012; Siolas and Hannon, 2013). We
engrafted HCI-10-Luc2 patient-derived tissue fragments into female NSG mice and each
recipient entered a treatment cohort when the tumor volume was ~100 mm3 . VERU-111
(10 mg/kg, PO) significantly suppressed xenograft growth over the entire course of the
study, whereas there were no significant changes in tumor volume between the vehicletreated or paclitaxel-treated (10 mg/kg, 1x week, IV) cohorts at any time point (Figure
2.11B). It should be noted that the dosing regimen for paclitaxel was changed for the HCI10 xenograft model since the tumor fragments grow slower in vivo than MDA-MB-231
cells. Paclitaxel was provided 10 mg/kg IV 1x/week instead of 12.5 mg/kg IP every other
day as in Figure 2.5 to reduce potential cumulative toxicity due to the extended treatment
regimen (~5 weeks longer duration of treatment than used for MDA-MB-231 xenografts)
(Liapis et al., 2016). As observed for MDA-MB-231 xenograft model, there was no significant body weight loss during VERU-111 treatment (Figure 2.11C). All animals were euthanized after 8 weeks of drug treatment. As expected, tumors in VERU-111 treated mice
were significantly smaller than vehicle-treated mice, with reduced mean tumor volume
and tumor weight by 73.7% and 72.0%, respectively (Figure 2.11D and E). In contrast, paclitaxel treatment slightly increased mean tumor volume and tumor weight relative to the
vehicle controls (Figure 2.11D and E). Representative tumors of the mean tumor volume
from vehicle-treated, paclitaxel-treated and VERU-111-treated mice are shown in Figure
2.11F.
A major clinical challenge is to treat established metastases of the stage IV patient.
The HCI-10-Luc2 model metastasizes during early tumor outgrowth to the axillary lymph
nodes (AxLNs) (El Ayachi et al., 2019). Therefore, by bio-imaging mice the day prior to
drug treatment, after cohorts were randomized, we were able to identify a subset of mice
in each cohort with pre-established AxLN mets prior to drug treatment and then to follow
metastatic growth during treatment. There was exponential increase in AxLN metastatic
signal measured by total photon flux comparing week 0 on therapy to week 8 on therapy at
endpoint between the vehicle and paclitaxel cohorts (100- and 65-fold, respectively, Figure
2.11G). In contrast, AxLN metastatic signal increased by only 3.1-fold for the VERU-111
group over the course of the study (p = 0.006). Therefore, VERU-111 strongly repressed
the growth of pre-established metastases. Furthermore, relative to the vehicle group, paclitaxel had no significant impact on the growth and expansion of pre-established AxLNs
metastases. Moreover, analysis of ex vivo bio-imaging data collected at the experiment endpoint also revealed that only VERU-111 significantly repressed total photon flux within the
AxLNs (Figure 2.11H), lungs (Figure 2.11I) or leg bones (Figure 2.11K). Consistent with
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our observations in the MDA-MB-231 model, VERU-111 had the most potent effect on repression of liver metastases and, in fact, paclitaxel treatment significantly enhanced liver
metastatic burden relative to vehicle controls (Figure 2.11I). Representative images of ex
vivo imaging data are shown in Figure A.5C-E.

2.4

Discussion

The five-year survival rate of patients diagnosed with metastatic TNBC is less than 30%
(Blows et al., 2010; Oba and Ito, 2018; Tate et al., 2012). Challenges for TNBC patients are a
lack of effective targeted therapies and a more rapid onset of chemoresistance to conventional cytotoxic therapies. Chemotherapy is the primary systemic treatment for patients
with TNBC, with the goal of inhibiting cancer cell growth and dissemination (Montagna
et al., 2013). Dynamic microtubule organization is one of the most successful targets due
to the critical roles of the microtubule network in cell proliferation, particularly cell division (Field, Kanakkanthara, and J. H. Miller, 2014). FDA-approved drugs, such as paclitaxel, are effective in treating neoadjuvant, adjuvant or metastatic TNBC, but intrinsic or
acquired resistance to taxanes is commonly observed. Moreover, paclitaxel needs to be formulated as an albumin-bound formulation or with a vehicle containing Cremophor EL due
to poor aqueous solubility and then delivered intravenously by slow infusion (Mustacchi
and De Laurentiis, 2015; Stage, Bergmann, and Kroetz, 2018). There are also neurotoxicities associated with taxane agent use, including persistent peripheral neuropathies, which
significantly impact the patient’s quality of life. As alternatives to paclitaxel, microtubuletargeted agents that bind to the colchicine-binding site of tubulin have attracted recent
attention. Several colchicine-binding site inhibitors, including VERU-111, are currently
undergoing clinical trials. In contrast, the CBSI combretastatin A-4 phosphate has been
evaluated in clinical trials for over a decade and is not yet FDA-approved (L. Li et al.,
2018; Garon et al., 2016).
We previously reported a series of novel 2-aryl-4-benzoyl-imidazoles and derivatives that target the colchicine-binding site with potent cytotoxicity, have improved aqueous solubility and overcome multidrug resistance, including P-gp overexpression (J. Chen,
Ahn, et al., 2012; J. Chen, Z. Wang, et al., 2010; J. Chen, C. M. Li, et al., 2011). We evaluated VERU-111, the most potent 2-aryl-4-benzoyl-imidazole analog, in the treatment of
TNBC, as its antiproliferative efficacy was not previously defined, using colchicine and paclitaxel as positive controls. We assessed the efficacy of VERU-111 against MDA-MB-231
and MDA-MB-468 TNBC cell lines. VERU-111 showed strong antiproliferative activity in
all these models with an IC50 value in the low nanomolar range. In a colony formation
assay, VERU-111 reduced the clonogenic survival of TNBC cells. VERU-111 efficacy was
superior to colchicine, although less potent than paclitaxel at the equivalent concentration
to repress clonogenic survival.
Most of the microtubule-stabilizing agents enhance microtubule polymerization by
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targeting taxane-binding site located at the interior surface of the microtubules, while microtubule depolymerizing agents inhibit microtubule polymerization by binding in one
of two domains on tubulin (Dumontet and Jordan, 2010). To confirm that VERU-111 depolymerizes microtubules, we stained for α-tubulin in TNBC cells treated with VERU111, which showed that VERU-111-treated cells displayed aberrant microtubule network
arrangement and organization, similar to results obtained with colchicine-treated TNBC
cells. Therefore, VERU-111 is a novel microtubule-depolymerizing agent. Due to the pivotal role of asymmetric regulation of microtubule dynamics and stability played in cell
migration and invasion, we then investigated the effect of VERU-111 using cell migration
and invasion assays (Etienne-Manneville, 2013; Lupo et al., 2016). Our results showed that
VERU-111 inhibited TNBC cell motility and invasion potently.
Several anti-mitotic agents have been reported to target microtubules, disrupt microtubule dynamics, induce cell cycle arrest and cause eventual cell death (GanansiaLeymarie et al., 2003; Choi et al., 2015). We found that VERU-111 arrested MDA-MB231 cells at the G2/M checkpoint in a concentration-dependent manner. The effects of
colchicine, paclitaxel and VERU-111 were similar in MDA-MB-231 cells, with accumulated cells at the G2/M checkpoint; VERU-111 also induced cells into the M phase in a
concentration-dependent manner. However, VERU-111 or colchicine primarily induced
a G2 phase arrest in MDA-MB-468 cells, whereas paclitaxel arrested cells in both the G2
and M phase. One reason for this result may be that MDA-MB-231 cells are a “type A”
cell line that displays prominent mitotic arrest, whereas the MDA-MB-468 cell line is a
“type B” cell line, displaying less prominent mitotic arrest, but possessing significant mitotic arrest at higher concentrations of microtubule-targeting agents (Blajeski et al., 2002).
It is widely believed that anti-mitotic agents cause apoptosis along with cell cycle arrest
(D. Bates et al., 2016; Qi et al., 2018). Cleaved-caspase-3 is an effector caspase involved in
both intrinsic and extrinsic apoptosis pathways; it can cleave its downstream target PARP,
which conducts DNA damage repair (Swindall, Stanley, and E. S. Yang, 2013; Harrington et al., 2008). VERU-111 induced cell apoptosis in a time-and concentration-dependent
manner, and it promoted the cleavage of caspase-3 and PARP in MDA-MB-231 and MDAMB-468 cells. Together, these results indicate that VERU-111 induces cell cycle arrest and
ultimately apoptosis in TNBC cells.
The chemotherapeutic strategies for treating TNBC primarily include DNA-damaging agents, anti-mitotic agents and targeted anti-angiogenic therapy. For example, the
combination uses of carboplatin, paclitaxel and bevacizumab, respectively, is recommended
as a first-line or second-line therapy for TNBC treatment (Wahba and El-Hadaad, 2015;
Guarneri et al., 2015; Saloustros et al., 2018). However, novel chemotherapies are required
to improve the survival rates for TNBC due to taxane-induced dose-limiting neurotoxicities or cardiotoxicities and acquired resistance to taxanes (Twelves et al., 2016). We evaluated the antitumor effect of orally delivered VERU-111 versus paclitaxel (provided IP or
IV) in three orthotopic, highly metastatic TNBC models to determine if VERU-111 is an efficacious novel anti-tubulin inhibitor to treat TNBC. For the MDA-MB-231 xenograft model,
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for which cells were not previously exposed to taxanes, VERU-111 inhibited TNBC tumor
growth in a dose-dependent manner without reducing body weight, and with equivalent
efficacy to paclitaxel to reduce tumor volume/wet weight. Both drugs were observed to
increase tumor necrosis, to decrease cancer cell proliferation, to reduce angiogenesis and to
cause apoptotic cell death via increased the expression of cleaved-caspase-3 and cleavedPARP.
TNBC frequently progresses to stage IV, metastatic disease, the leading cause of
breast cancer-associated mortality (Mayer et al., 2014). In the MDA-MB-231 model, either
paclitaxel or VERU-111 inhibited the formation of lung metastasis from the mammary pad,
reducing the total number and size of metastases that had completed the entire metastatic
cascade. One limitation in this experiment is that the tumors were not equal sizes at the
time of euthanasia and lung harvest (both paclitaxel- and VERU-111-treated tumors were
smaller than vehicle-treated tumors). Therefore, to bypass primary tumor growth, we
supplemented these results by a tail vein assay in which mice were treated with either
VERU-111 or paclitaxel 24 h after tumor cell injection. Fewer metastases were observed
in lungs, livers and kidneys by H&E or IHC following VERU-111 or paclitaxel treatment.
Although both drugs appeared equally effective to repress lung and kidney metastasis,
VERU-111 appeared to be more effective than paclitaxel in reducing liver metastasis.
Finally, we have shown in vitro that VERU-111 is efficacious at nM concentrations in
vitro for a panel of paclitaxel-resisitant TNBC cell lines, a taxane-resistant patient-derived
primary cell line (HCI-10-Luc2) and a treatment-naïve patient-derived primary cell line
(HCI-2-Luc2). In contrast, the IC50 concentrations of paclitaxel required to inhibit the
growth of MDA-MB-231/TxR, MDA-MB-468/TxR and SUM159/TxR were 175-fold higher
that on the parental cells, and to inhibit the growth of HCI-10 cells, the IC50 concentration
of paclitaxel required was between 6.33 and 8.5-fold higher than for HCI-2 cells. These data
provide rationale that VERU-111 likely bypasses taxane resistance in breast cancer, as we
have previously shown for VERU-111 in prostate cancer models (C. M. Li et al., 2012).
MDA-MB-231TxR cell subline was selected to test the efficacy of VERU-111 in taxaneresistant TNBC cells due to the lower IC50 concentration of VERU-111 needed to inhibit
the proliferation of taxane-resistant TNBC cells. The disorganized microtubule distribution, cell cycle arrest at G2/M phase and cell apoptosis were all observed in both parental
MDA-MB-231 and MDA-MB-231/TxR cells treated with VERU-111, showing the potency
of VERU-111 on taxane-resistant TNBC cells in vitro. VERU-111 potency was then tested
in vivo using an orthotopic MDA-MB-231/TxR taxane-resistant model and a luciferaselabeled HCI-10 PDX model. VERU-111 therapy was highly effective in blocking primary
tumor growth, whereas paclitaxel treatment was completely ineffective relative to vehicletreated controls at all time points. In addition, in the PDX model, VERU-111 treatment significantly reduced outgrowth of pre-established AxLN metastases over the course of drug
treatment and the endpoint metastatic burden for AxLNs, lung, and bone while blocking
liver metastasis. Collectively, these data strongly suggest that VERU-111 may also be an
effective second line therapy for TNBC patients who progress on taxanes (i.e. develop

Chapter 2. An Orally Active Tubulin Inhibitor, VERU-111, Suppresses Triple Negative
48
Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
taxane resistance).

2.5

Conclusion

In summary, we have shown in vivo in three aggressive TNBC xenograft models that a
novel microtubule-targeting agent that binds to the colchicine-binding site, VERU-111,
which is orally bioavailable and well-tolerated, displays potent anti-breast cancer activity, including anti-metastatic potential. VERU-111 has been previously reported to inhibit
tubulin polymerization and to effectively overcome P-gp-mediated multidrug resistance,
which frequently develops in patients treated with conventional taxanes (J. Chen, Ahn,
et al., 2012). The distinct advantages of VERU-111 therapy include equivalent efficacy as
paclitaxel in vitro and the ability to effectively treat TNBC in vivo. Moreover, compared to
taxanes, VERU-111 analogs do not induce peripheral neuropathy in mice and dogs (Ahn
et al., 2010), addressing a currently unmet clinical challenge impacting patient quality of
life. A Phase 1/2 clinical trial of VERU-111 has begun for patients with advanced prostate
cancer, including patients who have already failed taxane-based therapies. Our results
suggest that clinical trials for stage IV metastatic breast cancer patients, including patients
diagnosed with TNBC, are also supported by strong preclinical data.
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Chapter 3
Efficacies of Novel 6-Aryl-2-benzoylpyridines as
Potent Microtubule Destabilizing Agents in Treating
Melanoma and TNBC 1

3.1

Introduction

Cancer is one of the leading causes of death worldwide (Bray et al., 2018). Chemotherapy has been a major treatment for patients with cancer, often used as a single standard
of care or as a part of combination treatments (Hamis, Nithiarasu, and Powathil, 2018).
Microtubule-targeting agents are tubulin-targeted chemotherapeutics that disrupt microtubule dynamics by binding to tubulin in proliferating cells that are an important and
successful class of chemotherapeutic drugs (Gerhards et al., 2018; Steinmetz and A. E.
Prota, 2018). Microtubule dynamics are crucial in cellular structure maintenance, intracellular transport, and cell division that act by extending or shortening the microtubules
(Steinmetz and A. E. Prota, 2018; Kueh and Mitchison, 2009; Borowiak et al., 2015). During cancer cell mitosis, interference with microtubule dynamics by MTAs discourages the
correct segregation of the chromosomes guided by the mitotic spindle, thus leading to
disruption of cell cycle progression and even cell death (Zich and Hardwick, 2010; Field,
Kanakkanthara, and J. H. Miller, 2014).
There are two classes of MTAs according to their variation in mechanisms of action: microtubule-stabilizing agents (e.g. taxanes) and microtubule-destabilizing agents
(e.g. vinca alkaloids) (Gerhards et al., 2018; Tangutur et al., 2017; Baig et al., 2018; H. Chen,
Z. Lin, et al., 2017). Despite substantial clinical success, the application of MTAs is often
limited by development of drug resistance and poor aqueous solubility (Maria Kavallaris,
2010; Miltenburg and Boogerd, 2014; Wu, Q. Wang, and W. Li, 2016). To overcome these
1 Modified

from final submission with permission from American Chemical Society. Hao Chen*, Shanshan
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challenges, extensive studies have been carried out which suggest that tubulin inhibitors
targeting the colchicine-binding site are candidates for better clinical benefits (Stengel et
al., 2010; Lai et al., 2018). CBSIs target the interface between the α and β subunits of tubulin
heterodimers (A. E. Prota, Danel, et al., 2014; Jimenez et al., 2015). They are less vulnerable to transporter-mediated drug resistance (e.g. overexpression of ABC-transporters) (Z.
Wang et al., 2012), have better aqueous solubility (Wu, Q. Wang, and W. Li, 2016), and possess potent anticancer effects against cancer cells overexpressing β3-tubulin (Stengel et al.,
2010).
We have previously reported the discovery of a series of 2-aryl-4-benzoyl-imidazoles
(ABIs) as potent antiproliferative agents for the treatment of melanoma and prostate cancer
(J. Chen, Z. Wang, et al., 2010; J. Chen, C. M. Li, et al., 2011; J. Chen, Ahn, et al., 2012). Compared with existing tubulin-targeting agents such as paclitaxel or colchicine, the ABI compounds with structural optimizations of the benzoyl, aryl, and imidazole moieties have
comparable in vitro and in vivo potency but can effectively overcome P-gp-mediated drug
resistance (Z. Wang et al., 2012; Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, H. Chen, et
al., 2018). The high-resolution X-ray crystallographic investigation of ABI-231 suggested
that the water bridge near Ser178 and Asn347 residues is important for mediating the tight
hydrogen bond interactions between tubulin and CBSIs. In addition, their co-crystal structures showed the pocket near the central ring might accommodate a larger moiety (Q.
Wang, K. E. Arnst, Y. Wang, Kumar, Ma, White, et al., 2019). Therefore, we hypothesize
that replacing the central 5-membered ring with a substituted heterocyclic 6-membered
ring could extend the compounds to reach out to Ser178 and Asn347 residues and form a
direct hydrogen bond with tubulin (Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, H. Chen, et
al., 2018). However, the 6-membered analog of ABI-231 (3a) showed relatively less potency
compared to ABI-231, and it did not replace the mediating function of the water molecule
based on the molecular modeling studies (Figure B.1). We solved the crystal structure of
a potent ABI analogue ABI-274 that we previously reported (Z. Wang et al., 2012). The
co-crystal structure of ABI-274 with para-methylphenyl moiety overlapped very well with
the binding site of ABI-231 and showed additional van der Waals interactions due to the
4-methyl group. These results provided us with insight on optimizing the structure of
ABI-274 by simply substituting the middle imidazole ring with pyridine ring to generate compound 4a (Figure 3.1). The average IC50 of compound 4a was 5.5 nM among 3
melanoma cell lines and 3 breast cancer cell lines. Further structural modifications of 4a
led to the generation of highly potent 6-aryl-2-benzoyl-pyridine (ABPs) analogues. Among
all the analogues synthesized, analogue 4v (Figure 3.1) with the hydroxyl and methyl substitutions at the 3- and 4- positions of the A ring showed the strongest antiproliferative
activities. Interestingly, the X-ray crystallographic analyses of compound 4v in complex
with tubulin showed a direct hydrogen bonding between the 3-hydroxy and Val181 rather
than the previously water mediated hydrogen bonding in ABI-231. By using an in vitro
tubulin polymerization assay, we further confirmed that the interaction mechanism of 4v
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Figure 3.1: Chemical structures of compounds 4a and 4v.

was via induction of tubulin depolymerization. We also found that 4v exerted its antiproliferative function in vivo and induced tumor necrosis and suppressed both angiogenesis
and apoptosis significantly.
We also determined the efficacy of 4v on TNBC. 4v maintained its potency in inhibitng the growth and migration of two TNBC cell lines, MDA-MB-231 and MDA-MB468, at the concentration of 4 nM. By performing immunofluorescence staining, We observed that TNBC cells treated with 4v had shrunken and the cell shape was changed
from spindle to round, irregular, and microtubules were dissolving, confirming 4v as a
potent microtubule depolymerizing agent. Further in vitro studies demonstrated that 4v
strongly induced apoptosis and G2/M phase cell cycle arrest in TNBC cells in a dosedependent manner, and at the same time remarkably suppressed the migration and invasion of TNBC cells. In vivo, 4v significantly inhibited TNBC tumor growth and metastasis
in a dose-dependent manner in an orthotopic xenograft model.

3.2
3.2.1

Materials and Methods
Chemical compounds and cell culture

Colchicine and paclitaxel were purchased from Sigma-Aldrich and LC Laboratories, respectively. Compound 4v (purity >98%) was synthesized according to previously reported
method (H. Chen, S. Deng, et al., 2020). Human melanoma cell lines A375, RPMI7951,
and M14 and its multidrug-resistant daughter line M14/LCC6MDR1, human breast cancer cell lines MDA-MB-231, MDA-MB-453, MDA-MB-468 and SKBR3 (ATCC, Manassas,
VA) were grown at 37 °C in Dulbecco’s modified Eagle’s medium (Mediatech, Inc., Manassas, VA) containing 10% FBS (Atlanta Biologicals, Lawrenceville, GA) and 1% antibioticantimycotic solution (Sigma Aldrich, St. Louis, MO). Parental prostate cancer PC3, its paclitaxelresistant daughter line PC3/TxR, parental prostate cancer DU-145, and its paclitaxelresistant daughter line DU-145/TxR were generously provided by Dr. Evan Keller at the
University of Michigan Medical School (Ann Arbor, MI). PC3 and DU-145 were grown at
37 °C in an RPMI 1640 medium (Thermo Fisher Scientific, Pittsburgh, PA) containing 10%
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FBS and 1% antibiotic-antimycotic solution. All cell lines were maintained in a humidified
atmosphere with 5% CO2 . Paclitaxel-resistant MDA-MB-231 subline (MDA-MB-231/TxR)
or MDA-MB-468 subline (MDA-MB-468/TxR) was generated by treating parental MDAMB-231 or MDA-MB-468 cells with paclitaxel gradually until the cells were stable in media
containing 100 nM of paclitaxel. The PDX lines, HCI-2 (treatment-naïve line) and HCI-10
(taxane-resistant line), were generously provided by Dr. Alana Welm and the HCI tissue
resource and cultured in M97 growth medium supplemented with 10% FBS and 1% antibiotic–antimycotic solution in 5% CO2 at 37 °C (Shanshan Deng, Krutilina, et al., 2020).

3.2.2

Growth inhibition assay

The antiproliferative effects of compounds were assessed using MTS cell proliferation assay according to the manufacturer’s instructions (Promega, Madison, WI). Cells in the
logarithmic growth phase were seeded in 96-well culture plates at a density of 3500-5000
cells/well depending on the doubling time of each cell line and cultured overnight. All
compounds were dissolved in dimethyl sulfoxide (DMSO, SigmaAldrich, St. Louis, MO)
to make 20 mM stock solutions. Prior to treatment, the stock compound solutions were
mixed in a cell culture medium to achieve the desired doses ranging from 0.1 nM to 3 µM.
The final DMSO concentration in each well is less than 0.15%, which is well tolerated to all
of the cells tested. Then, the increased concentrations of compounds were added into the
96-well culture plates, and the cells were incubated for 72 h in four replicates. MTS reagent
was then added to the medium and incubated for 1-1.5 h. The absorbance was read at 490
nm using a SYNERGY 4 Microplate Reader (BioTek Instruments Inc., Winooski, VT). IC50
values were calculated by GraphPad Prism 7 software via transforming the concentration into log scale followed by nonlinear regression with the module of “log (inhibitor)
vs. response with variable slope”. The IC50 values were read directly from the analysis,
and the SEM values were calculated based on the overall standard errors obtained from
the analysis. For testing the antiproliferate activities of 4v on TNBC cells, MDA-MB-231,
MDA-MB-468 and their paclitaxel-resistant daughter cells were seeded into 96-well plates
at cell densities ranging from 3000-7500 cells/well depending on the growth rate of each
cell line and then treated with colchicine, paclitaxel and 4v at various concentrations (0.1
nM to 3 µM). After 72 h incubation, MTS reagent was added and incubated for 1 to 1.5 h.
HCI2 and HCI10 cells were seeded 20000 cells /well into 96-well plates and incubated with
colchicine, paclitaxel and 4v at indicated concentrations for 5 days. At the end point, MTS
reagent was added and incubated for 2 h. During the treatment, HCI-2 and HCI-10 cells in
each well were imaged by IncuCyte, and representative images at the start point and end
point were captured. IC50 values were calculated based on the absorbance acquired from
SYNERGY 4 Microplate Reader (BioTek Instruments Inc., Winooski, VT) using GraphPad
Prism (GraphPad Software, San Diego, CA). The experiment was conducted in three biological replicates.
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Molecular docking of 3a

To examine the binding mode of 3a with tubulin, molecular modeling study was performed using Schrödinger Molecular Modeling Suite 2019 (Schrödinger LLC, New York,
NY) described previously (Kinsie E. Arnst, Yuxi Wang, et al., 2018). Briefly, both 3a and
original ligand ABI-231 were built and prepared using LigPrep module. The X-ray crystallographic structures of tubulin (PDB ID: 6O61) was selected as the receptor model and
the protein structure was prepared using the Protein Preparation Wizard. Water molecule
that is involved in the binding was maintained during protein preparation. The tubulin
receptor grid was generated based on the native ligand binding site using the Receptor
Grid Generation. Then all ligands were docked into tubulin receptor grid generated at the
same colchicine binding pocket using Glide Docking module. Hydrogen bonds and data
analysis were performed using Maestro interface of Schrödinger software.

3.2.4

In vitro tubulin polymerization assay

According to the method described by (Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, H.
Chen, et al., 2018), porcine brain tubulins (>97% pure) (Cytoskeleton, Denver, CO) were
mixed with general tubulin buffer (80 mM PIPES, 2.0 mM MgCl2 , 0.5 mM EGTA, and 1
mM GTP) to reach a final concentration of 3 mg/mL at 4 °C. The tubulin polymerization
assay was incubated at 37 °C in a SYNERGY 4 Microplate Reader immediately after mixing
tubulin protein solution and the test compounds in a 96-well plate and monitored every
30 sec for 65 min at 340 nm. The experiment was performed in duplicates with paclitaxel
as a positive control for tubulin polymerization, and colchicine and ABI-274 as positive
controls for tubulin depolymerization.

3.2.5

Protein expression and purification

Porcine brain tubulin (Catalog #T-238P) was obtained from Cytoskeleton, Inc. (Cytoskeleton, Denver, CO). The stathmin-like domain of RB3 (RB3-SLD) expression vector was
transformed into and overexpressed in E. coli. The protein was purified by anion-exchange
chromatography and gel filtration chromatography. The peak fractions flowed through gel
filtration column were concentrated to 10 mg/mL and stored at -80 °C (Ravelli et al., 2004;
Benoît Gigant et al., 2000). Briefly, the recombinant protein was expressed in E. coli using
LB, purified through Ni-NTA affinity chromatography and gel filtration chromatography
(buffer: bis-Tris propane pH 6.5, 200 mM NaCl, 2.5 mM MgCl2 , 5 mM β-mercaptoethanol,
1% glycerol). The peak fractions of the target protein were concentrated to 20 mg/mL
and stored at -80 °C. The purity of RB3 and TTL was checked on sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Porcine brain tubulin was supplied at 10
mg/mL in G-PEM (general tubulin buffer: 80 mM PIPES pH 6.9, 2 mM MgCl2 , 0.5 mM
EGTA, and 1 mM GTP) as a frozen liquid and saved at -80 °C until use.
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Crystallization, data collection, and structure determination

Crystals of the T2R-TTL complex were grown by the sitting-drop vapor diffusion method.
The detailed process to obtain crystals of T2R-TTL was as previously described (Yuxi
Wang, Yu, et al., 2017; Andrea E. Prota et al., 2013; Yuxi Wang, H. Zhang, et al., 2016).
In brief, the protein complex containing tubulin (10 mg/mL), TTL (20 mg/mL), and RB3
(10 mg/mL) at a molar ratio of 2: 1.3: 1.2 (tubulin: RB3: TTL) was incubated on ice with additional 1 mM AMPPCP, 5 mM tyrosinol, and 10 mM DTT, and then the final sample was
concentrated to 20 mg/mL at 4 °C. Crystallization of the T2R-TTL complex was carried out
in sitting-drop plates at 20 °C. The drop in each well consisted of equal volumes of protein
complex and crystallization buffer containing 6% poly(ethyleneglycol) (PEG), 5% glycerol,
0.1 M MES, 30 mM CaCl2 , 30 mM MgCl2 , pH 6.7. Seeding was used to optimize the crystal
quality. Initial crystals appeared after 2 days of incubation and reached their final size of
200-300 µm within 3-5 days. Crystals with good shape were selected and frozen in liquid
nitrogen in the presence of a cryoprotectant. For compound soaking of the crystals, compound 4v was dissolved in DMSO at a 10 mM concentration. The crystals were soaked in
0.1 µL at 20 °C for 2-24 h. The crystals were quickly immersed in the cryoprotectant (6%
PEG, 5% glycerol, 0.1 M MES, 30 mM CaCl2 , 30 mM MgCl2 , pH 6.7) before being frozen in
liquid nitrogen.
The crystals of the T2R-TTL complexes were mounted in nylon loops and flashfrozen in a cold nitrogen stream at 100 K. Diffraction data were collected on a beamline
BL19U1 at the Shanghai Synchrotron Radiation Facility (SSRF), Shanghai, China. The
datasets were indexed, integrated, and scaled using the HKL2000 program (Otwinowski
and Minor, 1997). The structures of the T2R-TTL-ligand complexes were solved by molecular replacement using the program PHASER with the T2R-TTL structure (PDB ID: 4I55)
or T2R-TTL-colchicine complex (PDB ID: 5XIW) as the search model. The manual model
building was performed with Coot (Paul Emsley and Cowtan, 2004). Alongside the manual building process, the refinement was performed with Phenix.refine (P. D. Adams et al.,
2002). The model qualities were checked with the PROCHECK program and showed good
stereochemistry according to the Ramachandran plot (Laskowski et al., 1996). The atomic
coordinates and the structure factors were deposited in the PDB (www.rcsb.org) with the
accession codes of 6PC4 (ABI-274) and 6AGK (4v).

3.2.7

SPR for affinity assay

Binding affinity with tubulin was analyzed using SPR technology in a Reichert4SPR system (Reichert Technologies, Depew, NY) equipped with a dextran SPR sensor chip (Reichert Polycarboxylate Hydrogel Chip P/N 13206067). Then, 50 µg/mL tubulin (Cytoskeleton, T240) was immobilized to the sensor chip surface to attain 12000 µRIU. One of the four
flow cells on the chip was left free as a negative control. 4v or colchicine at different concentrations was injected over the sensor chip surface for association analysis, followed by
dissociation analysis. The experiment data were obtained at 25 °C with a running buffer
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PBST (8 mM Na2 HPO4 , 136 mM NaCl, 2 mM KH2 PO4 , 2.6 mM KCl, and 0.05% (v/v)
Tween 20, pH 7.4). The equilibrium dissociation constant (KD) was calculated by a steadystate fitting mode with TraceDrawer software.

3.2.8

In vivo xenograft model in NSG mice to evaluate the efficacy of 4v

The antitumor activity of 4v was assessed in vivo in a 2-week xenografted-tumor mouse
model. All animal studies were performed in adherence to the NIH Principles of Laboratory Animal Care, and protocols were approved by the Institutional Animal Care and Use
Committee at the University of Tennessee Health Science Center (protocol #17-056). Male
NSG mice, 5-6 weeks old, were purchased from Jackson Laboratories (Bar Harbor, ME)
and used in this study. Logarithmic growth phase A375 cells were resuspended in phenol
red-free, FBS-free DMEM media and mixed with Matrigel with a 2: 1 ratio. Cells (2 x 106
cells/100 µL) were subcutaneously injected into the flanks of NSG mice immediately. Once
the tumor volume of each mouse was close to 100 mm3 , the mice were randomly divided
into three groups. Group 1 is the control group that was treated with vehicle (4: 1: 10 ratio
of PEG300: Tween 80: PBS solution, n = 5). Group 2 was treated with 4v (10 mg/kg, n =
5). Group 3 was treated with 4v (20 mg/kg, n = 6). Treatment was initiated 5 days a week
through IP injection (100 µL per mouse weighed 20 g). Tumor sizes were monitored using
a digital caliper, and the body weight of the mice was recorded three times a week during
the treatment. Tumor volumes were calculated as V = (width2 × length)/2, where “width”
is the smallest diameter and “length” is the largest diameter. Animals were anesthetized
by CO2 and sacrificed when tumors reached approximately 1000 mm3 . Tumors from each
mouse were harvested, measured, and collected in a 10% buffered formalin phosphate solution for histological analysis. Tumor volumes of the treatment groups were compared
with that of the vehicle control group using one-way analysis of variance (ANOVA) followed by multiple comparisons. Significance levels were defined as follows: **p < 0.01,
***p < 0.001, ****p < 0.0001.

3.2.9

Histology and immunohistochemistry

Fixed tumors were paraffin-embedded, sectioned (4 µm) by a microtome, and stained using H&E and IHC. H&E staining was used to visualize the extent of necrosis affected by
drug treatment. IHC was used to measure the expression of proliferative marker Ki67,
angiogenesis marker CD31, and apoptotic marker cleaved-PARP. Antigen retrieval was
performed with an H3300 antigen unmasking solution (Vector Laboratories, Burlingame,
CA). Primary antibodies, rabbit anti-Ki67 (1: 400), rabbit anti-CD31 (1: 100), and rabbit
anti-cleaved-PARP (1: 50) (#9027; #77699, #5625, Cell Signal Technology) were added to
the sections following an ABC method. Slides were incubated overnight at 4 °C. Then,
the slideswere incubated with biotinylated horse antirabbit IgG antibody (BA1100, Vector
Laboratories Inc., Burlingame, CA). Diaminobenzidine was used for staining, and hematoxylin was used to counterstain the nuclei of tumor sections. Images were acquired with
a Keyence BZX700 microscope.
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Colony formation assay

MDA-MB-231 or MDA-MB-468 cells were seeded in 12-well plates at a density of 500 or
800 cells per well and treated with colchicine, paclitaxel and 4v (1, 2 and 4 nM) once one
single cell proliferated to 4 cells. The medium was replaced three days per week. After
1 week of incubation for MDA-MB-231 cells (2 weeks for MDA-MB-468 cells), cells were
fixed with cold methanol, stained with 0.5% crystal violet, imaged by the ChemiDoc-It2
Imager system (UVP, LCC) and quantified by ImageJ. The experiments were repeated by
treating MDA-MB-231 cells or MDA-MB-468 cells with 4v (2.5, 5 and 10 nM), cells were
fixed, stained, imaged and quantified. The experiment was conducted in two biological
replicates with three technical replicates.

3.2.11

Immunofluorescent staining

105 MDA-MB-231 cells or 2 x 105 MDA-MB-468 cells were seeded onto the coverslips in the
6-well plates and allowed to attach overnight. The other day, the growth medium containing 2.5 nM or 5 nM of colchicine, paclitaxel or 4v was added into each well and treated the
cells for 24 h. At harvest, cells were washed, fixed, permeabilized with 0.2% of Triton X-100
and incubated with anti-α-tubulin antibody (#62204, Invitrogen) overnight at 4 °C. Then
the cells were stained with Alexa Fluor 647 goat anti-mouse secondary antibody (Molecular Probes) for 1 h at the room temperature, transferred to the slides and mounted with
Prolong Diamond mounting medium supplementing DAPI (Invitrogen). After drying for
15 min, the slides were sealed and imaging using a Keyence BZ-X700 immunofluorescence
microscope.

3.2.12

Western blot analysis

Cells grown to 70% confluence were treated with colchicine (10 nM), paclitaxel (10 nM)
or 4v (2.5 nM, 5 nM and 10 nM) for 24 h. Then the cells were washed, scraped off the
dishes, centrifuged and lysed in RIPA buffer containing Halt™ protease and phosphatase
inhibitor (Thermo), 1 mM PMSF and 10 mM de-ubiquitin inhibitor. After centrifugal, each
supernatant was collected and quantified using Bradford method. 30 ug of each protein
sample was loaded in the gel and executed electrophoresis. Next, the proteins were transferred into the PVDF membranes using a wet tank, blocked in 5% nonfat milk at room
temperature for 1 h and incubated with primary antibodies (rabbit anti-cleaved-PARP (1:
1000), mouse anti-acetyl-α-tubulin (#12152, 1: 1000, Cell Signaling Technology), mouse
anti-α-tubulin (#62204, 1: 2000, Invitrogen), rabbit anti-cleaved-caspase-9 (#7237, 1: 1000,
Cell Signaling Technology), rabbit anti-cleaved-caspase-3 (#9661, 1: 1000, Cell Signaling
Technology), mouse anti-β-actin (#3700, 1: 2000, Cell Signaling Technology), rabbit antiGAPDH HRP conjugate (#3683, 1: 2000, Cell Signaling Technology), Bax (#2772, 1: 1000,
Cell Signaling Technology), Bcl-2 (#sc-7382, 1: 500, Santa Cruz Biotechnology)) overnight.
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After incubation with anti-mouse or anti-rabbit secondary antibody for 1 h at room temperature, the membranes were incubated with ECL followed by the development and visualization onto the films.

3.2.13

Migration and invasion

The potential of 4v to inhibit migration or invasion of TNBC cells was investigated by
using Transwell noncoated inserts or Transwell chambers coated with Matrigel. Cells (5
x 104 for MDA-MB-231 and 105 for MDA-MB-468) containing pure growth medium or
4 nM of 4v were seeded in the center of each insert or chamber and cultured for 24 h
for MDA-MB-231 or 48 h for MDA-MB-468 cells. At the indicated end point, inserts or
chambers were collected and washed with cold PBS, and the cells in the inner bottom of
each insert or chamber were removed by cotton sticks. Then the migrated or invaded
cells on the outside of each insert or chamber were fixed with cold methanol and stained
with 0.5% crystal violet. The representative migrated or invaded cells were imaged and
quantified using Keyence microscope and its hybrid cell counting module. The experiment
was conducted in two biological replicates with three technical replicates.

3.2.14

Wound assay

The anti-migration effect of 4v was further evaluated in comparison with the colchicine
or paclitaxel treatment by using a scratch assay. In brief, an even scratch wound on the
confluent cells was created by using a sterile 200 µL tip. After washing with the growth
medium for two times, cells were treated with 4 nM of colchicine, paclitaxel or 4v for 24 h
(MDA-MB-231) or 48 h (MDA-MB-468). Representative wound images were acquired with
an Evos microscope (Life Technologies) during the treatment. Would gaps were quantified
by ImageJ. The experiment was conducted in two biological replicates with three technical
replicates.

3.2.15

Cell apoptosis and cell cycle analysis

Cells were incubated with colchicine (10 nM), paclitaxel (10 nM) and 4v (2.5 nM, 5 nM
and 10 nM) for 24 h and stained with 5 µL of Annexin-V-FITC (eBioscience) and 10 µL
of propidium iodide in 100 µL of Annexin-V-FITC binding buffer for 10 min after collection. Then apoptotic cells were detected by flow cytometry (Bio-Rad) in the UTHSC
Flow Cytometry and Cell Sorting core. For cell cycle distribution, cells with the same
treatment as apoptosis assay were harvested, washed and fixed. After permeabilization,
cells were stained with anti–phospho-histone H3 (Ser 10) antibody (#9701, Cell Signaling
Technology) for 1 h at room temperature followed by 30 min incubation with Alexa Fluor
488-conjugated secondary antibody. After wash, cells were resuspended in propidium
iodide/RNase staining solution and detected by flow cytometry after 5 min incubation.
Cells in sub-G1, G1, S, and G2 phases were gated by a reported method (Shanshan Deng,

Chapter 3. Efficacies of Novel 6-Aryl-2-benzoylpyridines as Potent Microtubule
Destabilizing Agents in Treating Melanoma and TNBC

58

Krutilina, et al., 2020). The experiment was conducted in three biological replicates with
three technical replicates.

3.2.16 In vivo efficacy of 4v in an orthotopic MDA-MB-231 xenograft model
The efficacy of 4v was assessed in an orthotopic TNBC xenograft model as previously
reported (Shanshan Deng, Krutilina, et al., 2020). All the protocols and treatments were
in accordance with the NIH guide and the IACUC of UTHSC (protocol #: 17-080). Briefly,
0.25 million of MDA-MB-231 cells in HBSS were orthotopically injected into the left and
right sides of each female mouse’s fat pad (aged 5 to 6 weeks). When the average tumor
volume reached 100 mm3 , all the mice were randomized into 4 groups (Group 1 (vehicle
control): PEG300: Tween 80: saline = 4: 1: 10, n = 6; Groups 2: 5 mg/kg 4v, n = 6; Groups
3: 10 mg/kg 4v, n = 6; Groups 4: 20 mg/kg 4v, n = 7) based on the tumor volume and
mouse body weight. 4v treatment and vehicle were applied 5 times per week for 18 days.
During the treatment, the tumor volume (2 times/week) and body weight (3 times/week)
of each mouse were recorded and monitored. On day 18, when the tumor volume reached
1000 mm3 , mice were euthanized. Tumors and major organs were removed, imaged and
fixed in 10% of neutralized formalin. Lungs were sent to the UTHSC Research Histology
Core to embed and section, and the lung slides were stained with H&E to visualize the
anti-metastasis effect of 4v.

3.2.17

Statistical analysis

All the experimental data were expressed as the mean ± SEM and analyzed by one-way or
two-way ANOVA followed by the Dunnett’s multiple comparisons test using GraphPad
Prism 7. Statistical significance is presented as *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001.

3.3
3.3.1

Results and Discussion
Antiproliferative activities of ABP analogues in a panel of melanoma and
breast cancer cell lines

The antiproliferative activities of ABP compounds were evaluated in human melanoma
cell lines (A375, M14, and RPMI7951) and human breast cancer cell lines (MDA-MB-231,
MDA-MB453, and SKBR3) using ABI-274 and one of our best compounds, ABI-231 (also
termed VERU-111), as reference controls as described in Tables 3.1 and 3.2. First, we prepared compound 3a by replacing the imidazole with a pyridine in ABI-231, and it exhibited relatively less potency with an IC50 value of 18.1 nM as compared to 10.5 nM of
ABI-231 (if not specified, the IC50 value for each analogue is expressed as the average of
all six cancer cell lines). On the other hand, replacing the imidazole with a pyridine in
ABI-274 produced compound 4a, which exhibited high cytotoxicity with an IC50 value
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Table 3.1: Cytotoxic effects of 6-aryl-2-benzoyl-pyridine analogues
against three human malignant melanoma cell lines and three breast
cancer cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.
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Table 3.2: Continued evaluation of 6-aryl-2-benzoyl-pyridine analogues
against three human malignant melanoma cell lines and three breast
cancer cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.
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of 5.5 nM, and was more potent than the prototype compound ABI-274 bearing an imidazole ring (IC50 value of 13.5 nM). We continued this series of comparisons by making
ortho-methyl substitution (4b) and meta-methyl substitution (4c) in the A phenyl ring and
testing their antiproliferative activities. 4b and 4c showed similar cytotoxic activity against
human melanoma and breast cancer cell lines with IC50 values of 58.7 and 62.8 nM, respectively. 4b and 4c were about 10-fold less active than 4a with the para-methyl functional
group, implying that the ortho-, meta-, and para-methyl substitutions in the A phenyl ring
showed different activities, and the ortho- and metamethyl substitutions were unfavorable to the antiproliferative activity. To investigate the effects of other functional groups
substituted at the ortho-, meta-, and para-positions in A ring on improving cytotoxicity,
analogues 4d-4l with various substituents, such as -OMe, -NH2 , -OH, and -NO2 , on different positions of the A phenyl ring were prepared and evaluated. Compound 4d, with a
para-OMe group, displayed similar activity as 4e, with a meta-OMe group, with the IC50
values of 29.3 and 37.8 nM, respectively. The para-OMe moiety was then replaced by 3,4,5trimethoxy groups in the A phenyl ring to generate 4f; this modification led to a total loss
of cytotoxic activity against both melanoma and breast cancer cell lines. The para-NH2
compound 4g was moderately active with an IC50 of 15.2 nM, while the meta-NH2 compound 4h was less potent with an IC50 of 31.1 nM (Table 3.1). Compounds 4i (para-OH)
and 4j (meta-OH) showed comparable activity against human melanoma cell lines (A375,
M14, and RPMI7951) and human breast cancer cell lines (MDA-MB-231 and MDA-MB453) with IC50 values ranging from 22.2 to 42.4 nM. 4i and 4j, however, were much less
active against the human breast cancer cell line SKBR3, with IC50 values of 385.9 nM and
100.6 nM, respectively. 4k with para-NO2 was found to have potent activity with an IC50
value of 9.4 nM, while 4l (meta-NO2 ) exhibited poor activity with an IC50 value of 399.8
nM. Furthermore, we introduced different para-substitutions with electron-withdrawing
functional groups, such as -CF3 (4m), -F (4n), and -CN (4o) to the A phenyl ring. 4m,
4n, and 4o displayed comparable antiproliferative activity with IC50 values ranging from
14.7 to 23.7 nM. Replacement of the para-methyl group with a larger group, such as ethyl
(4p), -COCH3 (4q), and carbamoyl (4r), led to a decrease of the antiproliferative activity
in comparison to para-methyl. These results suggested that the para-methyl moiety of the
A phenyl ring played an important role in improving the cytotoxicity. Inspired by these
observations, a series of combinations of the para-methyl and some other substitutions in
the A phenyl ring were synthesized and evaluated. Compound 4s, with 3,4-dimethyl, and
compound 4u, with 3-chloro-4-methyl, in the A phenyl ring demonstrated less potency
than compound 4a with para-methyl. Compound 4t, with 3-fluoro-4-methyl group, displayed similar activity with an IC50 value of 5.9 nM compared to the parent compound
4a. However, compound 4x with 2,4,6-trimethyl was inactive (Table 3.2). The presence of
a combination of para-methyl and meta-NH2 or OH functional groups led to a dramatic
increase in antiproliferative activity, and analogue 4v, with 3-hydroxy-4-methyl, turned
out to be the most active compound with IC50 values of 1-3 nM against all cancer cell lines
tested. To investigate whether the A phenyl ring played an indispensable role in the antiproliferative potency, we removed the phenyl ring at the 6-pyridine position to produce
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compound 5a. Analogue 5a did not show any cytotoxicity against any of the cancer cell
lines tested. It is interesting that the replacement of the A phenyl ring with a different
heteroaromatic ring resulted in differential effects on cytotoxicity. Replacement of the A
phenyl ring by 4-indole (5b) and 5-indole (5c) retained the potency of ABPs against the
tested cancer cell lines (IC50 values = 11.4 to 13.5 nM). However, introducing thiophene
(5d) or pyrrole (5e) as a replacement for the A phenyl ring showed moderate activity with
IC50 values of 38.6 and 43.8 nM for 5d and 5e, respectively. Moreover, 3-pyridine (5f) and
3-carbazole (5h) were less active with IC50 values of 74.1 and 302.9 nM, respectively. Four
other compounds, 4-pyridine (5g), 5-pyrimidine (5i), 4-quinoline (5j), and 4-isoquinoline
(5k), were found to be inactive on all examined cancer cell lines.
Based on our extensive A ring modification studies on the ABP template, we next
changed the pyridine ring B with benzene and 3-fluorobenzene and synthesized compounds 9 and 13. This resulted in decreased potency as shown in compounds 9 and 13
with the IC50 values of 21.8 and 79.4 nM, respectively. These results suggested that the
pyridine in ring B might be detrimental to the cytotoxic activity. Afterward, we shifted
the nitrogen position and prepared compounds 17 and 22. Compounds 17 and 22 demonstrated less activity than their prototype compounds 4a or 4v. In addition, we introduced
substituents on the pyridine ring B of 4v and 4a and made compounds 26 and 31. The
presence of methyl and hydroxyl groups at the para-position of pyridine ring B led to a
decrease in cytotoxic activity. Compound 26 showed moderate activity with an IC50 value
of 17.9 nM, while 31 was inactive. We also replaced the carbonyl linker between B and C
rings in compound 4a with a terminal double bond to obtain compound 32. Compound
32 was about 30-fold less active than 4a, implying that the carbonyl linker played an indispensable role in the antiproliferative activity. Further modification of the linker by inserting a double bond between B and C rings generated 35. Compound 35 did not exhibit
cytotoxicity in any examined cancer cell line.

3.3.2

Effects of the most potent compound 4v on taxane-resistant cell lines

Taxanes, such as paclitaxel, are highly successful in treating patients with various solid tumors; however, their clinical uses are often limited by narrow therapeutic windows, poor
aqueous solubility, and multidrug resistance. CBSIs are less susceptible to multidrug resistance and thus have therapeutic advantages over taxanes (Kinsie E. Arnst, Yuxi Wang, et
al., 2018; Dumontet and Jordan, 2010). As a CBSI, we hypothesize that 4v would maintain
its mode of action to circumvent taxane resistance. To test our hypothesis, the taxaneresistant cancer cell lines PC3/TxR, DU-145/TxR, and M14/LCC6MDR1 were selected for
antiproliferative study. Of note, PC3/TxR and DU-145/TxR cells are drug-selected taxaneresistant cells. Overexpression of P-gp is the main reason to cause paclitaxel resistance
in DU-145/TxR cells, while the upregulation of P-gp and microtubule-related regulators
and downregulation of calcium-binding protein contribute to the paclitaxel resistance in
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PC3/TxR (Takeda et al., 2007). M14/LCC6MDR1 cells with P-gp overexpression was generated by Dr. Robert Clarke’s lab via transducing a retroviral vector regulating the expression of MDR1, and it is widely used for assessing the effects of drugs to overcome
P-gp-mediated multidrug resistance (Leonessa et al., 1996). As outlined in Table 3.3, 4v
Table 3.3: Antiproliferative activities of compound 4v against three
taxol-resistant cancer cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.

exhibited potent cytotoxic activity against the taxane-resistant cancer cell lines PC3/TxR,
DU-145/TxR, and M14/LCC6MDR1 with IC50 values of 2.5, 2.8, and 1.4 nM, respectively,
and the RIs are ranging from 0.8 to 1.5. These results clearly indicate that 4v represents
the most active compound, effectively overcoming taxane resistance, and also represents a
promising new generation of chemotherapeutic drugs, which deserve further study.

3.3.3

Inhibitory effect of 4v on tubulin polymerization

To further confirm the molecular mechanism of action of synthesized compounds on tubulin, compounds 4a and 4v were investigated for their tubulin polymerization inhibitory
activities in a standard tubulin polymerization assay (Figure 3.2A). In this study, paclitaxel, colchicine, and the lead compound ABI-274 were used as reference compounds.
Paclitaxel induces tubulin polymerization, causing an increase in absorbance over time
as compared to control, as we had hypothesized. As tubulin polymerization inhibitors,
colchicine and ABI-274 decrease the polymerization of tubulin with reduced absorbance
compared to control. Similar to colchicine and ABI-274, 4a and 4v also abated absorbance
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Figure 3.2: In vitro tubulin polymerization assays of 4v. (A) Effects of
paclitaxel, colchicine, ABI-274, 4a, and 4v at 10 µM on tubulin
polymerization. Porcine brain tubulins (3 mg/mL) were mixed with 10 µM
of the test compounds in a 96-well plate, and polymerization of tubulin
was incubated at 37 °C immediately and monitored every 30 sec for 65 min
at 340 nm. The experiment was carried out in duplicate with paclitaxel,
colchicine, and ABI-274 as positive controls. (B) Dose-dependent effect of
4v on tubulin polymerization after treatments as in A.
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intensity, demonstrating that these compounds are also inhibitors of tubulin polymerization in a mode similar to that of colchicine and ABI-274. A tubulin polymerization assay
was carried out to detect the dose-dependent effect of 4v in the inhibition of tubulin polymerization. Similarly, we incubated the tubulin with an increasing concentration of 4v. As
shown in Figure 3.2B, 4v inhibited the increase in absorbance of tubulin at 340 nm in a
dose-dependent manner with IC50 between 5 and 10 µM, further confirming that 4v was a
potent tubulin polymerization inhibitor.

3.3.4

X-ray crystal structures of 4v and ABI-274 targeting the colchicine-binding
site

The colchicine-binding site can accommodate structural diversity due to high inherent
flexibilities of loop α-T5 (Ala174-Val182) in the α-tubulin and loop β-T7 (Phe242-Asp249)
in the β-tubulin. High-resolution X-ray crystallographic investigations of the complex
between tubulin and colchicine-binding site inhibitors provide elucidation of the structural basis of the structure-activity relationships (SARs), as well as the opportunity to design more efficacious and/or more selective inhibitors. We recently reported the highresolution X-ray crystal structure of ABI-231 in complex with αβ-tubulin (PDB ID: 6O61)
(Figure 3.3A) (Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, White, et al., 2019). The Xray crystal structure of protein-ligand complexes reveals that the water bridge is mediating a hydrogen bond interaction between the indole NH and Asn347 residue. In addition, their cocrystal structures showed a larger pocket near the central imidazole ring
that might accommodate a larger moiety. Moreover, we previously reported the discovery of a potent compound, ABI-274, which exerted its antitumor effect through inhibiting
tubulin polymerization by interacting with the colchicine-binding site of tubulin (Z. Wang
et al., 2012). To understand the antiproliferative potency of the compound AB-274 and
to correctly determine its detailed molecular interactions, we first determined the crystal
structure of ABI-274 in complex with T2R-TTL (consisting of a/β-tubulin, the stathmin-like
protein RB3, and tubulin tyrosine ligase) at a resolution of 2.6 Å (PDB ID: 6PC4) (Ravelli
et al., 2004; Benoît Gigant et al., 2000; A. E. Prota, Magiera, et al., 2013). Details of Xray diffraction data and refinement statistics are summarized in Table 3.4. As anticipated,
the binding site of ABI-274 was located at the colchicine-binding site at the interface between α- and β-subunits of the tubulin dimer and extended slightly into β-subunit opposite the GTP molecule that is bound in a pocket in the α-tubulin (Figure 3.3B). The ring C
(2,3,4-trimethoxyphenyl) is sandwiched between Cys239 and Leu253. In addition, a water
molecule bridges the hydrogen bond interaction from the oxygen of its trimethoxy group
to the main chain -NH of Cys239 and the main chain -C=O of Gly235 (Figure 3.3B). The
keto group of ABI-274 forms a weak hydrogen bond with the main chain -NH of Asp249.
Ring B (the imidazole ring) is sandwiched between the side chains of Leu246 and Asn256,
while the imidazole NH forms a hydrogen bond with the main chain -C=O of Thr179
from α-tubulin. The hydrophobic ring A (p-methyl-Ph) is accommodated in a pocket created by the side chains of Met257 and Asn256 from β-tubulin and Val181 from α-tubulin.
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Figure 3.3: High-resolution X-ray crystal structures of T2R-TTL in
complex with ABI-231 and ABI-274. (A,B) Detailed interactions of
ABI-231 (pink sticks, resolution 2.6 Å, PDB ID: 6O61) and ABI-274 (green
sticks, resolution 2.6 Å, PDB ID: 6PC4) at the colchicine-binding site. (C)
Superimposition of tubulin bound with ABI-231 and ABI-274 showing
very similar binding poses. (D) 90° rotation of (C).
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Table 3.4: Crystallographic data and refinement statistics for 4v.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.
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Moreover, the cocrystal structures of ABI-274 and ABI-231 showed very similar binding
poses and they overlapped very well (Figure 3.3C and D). The para-methylphenyl moiety of ABI-274 fills a small cavity bounded by the side chains of Met257 and Asn256 from
β-tubulin and Val181 from α-tubulin, which might be attributed to an additional van der
Waal interaction. These studies of molecular interactions between ABI-274, ABI-231, and
tubulin protein open the door to the structure-based design of better and more selective
CBSI 4v, whose structure contains a larger middle 6-membered ring and 3-OH, 4-methyl
in the A phenyl ring.
To understand the superior potency of 4v, we also solved the crystal structure of
compound 4v in complex with tubulin protein at a resolution of 2.8 Å (PDB ID: 6AGK). The
crystallographic data and structure refinement statistics for 4v in complex with tubulin are
also shown in Table 3.4. Similar to colchicine, 4v binds at the colchicine-binding site at the
interface of α- and β-tubulins (Figure 3.4A). In the crystallographic complex, there are two
pairs of α-tubulin and β-tubulin, and the interface of both is occupied by this compound.
4v is mostly confined to a deep pocket in β-tubulin at the interface of α- and β-tubulins
(Figure 3.4A). The interactions of ring C (3,4,5-trimethoxyphenyl) are similar to that of
ABI-274. Ring B (pyridine ring) is also sandwiched between the side chains of Leu246
and Lys350 from one side and that of Asn256 from the opposite side. Pyridine, being
a larger ring with no hydrogen bond accepting group, causes Thr179 from α-tubulin to
move away by 2.6 Å. Ring A (m-OH, p-CH3 -Ph) is located in the same pocket as that
observed in ABI-274 surrounded by Met257 and Asn256 from β-tubulin and Val181 from
α-tubulin. The hydroxyl group is within the hydrogen-bonding distance from the main
chain of Val181 (Figure 3.4B and C), unlike ABI-231 where the hydrogen bond is mediated
by a water bridge. 4v overlaps very well with colchicine, and the main conformational
changes are observed in two helixes (βH7/βH8) and one loop (βT7). The shifts of Asp249
(β-tubulin) and Val181 (α-tubulin) residues caused 4v to occupy a slightly upper position
and thus induced a minor conformational change of the βT7 loop. Microtubule assembly is
known to be related to a tubulin conformational change in which a straight conformation
is adopted (Igaev and Grubmuller, 2018). Colchicine targets the β-subunit of tubulin and
prevents the formation of a straight conformation, thus inhibiting microtubule assembly
(Figure 3.4D and E).

3.3.5

Binding kinetics of 4v to tubulin

The Reichert4SPR system (Reichert Technologies, Depew, NY) was used to analyze the
affinity of 4v and tubulin interaction. A dextran SPR sensor chip (Reichert Polycarboxylate
Hydrogel Chip P/N 13206067) with glucan on the surface was used to immobilize tubulin. Then, 4v or colchicine at different concentrations was injected over the sensor chip
surface for binding detection. For these two compounds, the resonance units increased in
a concentration-dependent manner (Figure 3.5A and B). As determined by a steady-state
fitting model, the equilibrium dissociation constant KD of 4v was 2.66 µM. For colchicine,
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Figure 3.4: Structure of the T2R-TTL-4v complex. (A) Pictorial
representation of the overall structure of T2R-TTL in complex with 4v. The
α units of T2R-TTL complex are colored in light blue, while the β units are
colored in cyan; GTP and 4v molecules are shown in green and yellow
spheres, respectively. (B) Close-up view of 4v. The electron density is from
the 2 Fo-Fc map (in blue) contoured at 1.5 σ. (C) 90° rotation of (B). (D)
Superimposition of tubulin bound with 4v and colchicine (shown in dark
green sticks) (PDB ID: 4O2B). (E) Interference of 4v with the tubulin
straight conformation (PDB ID: 6AGK). The ligand molecule 4v is shown in
yellow. Nitrogen and oxygen atoms are shown in blue and red,
respectively.
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Figure 3.5: Comparing the binding kinetics of 4v and colchicine. (A)
Binding kinetics of colchicine (1.25, 5, 2.5, 10 and 20 µM) to tubulin (12000
µRIU) were determined by SPR technology. (B) Binding kinetics of 4v (1.25,
2.5, 10, 20 and 40 µM) to tubulin.
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the KD value was 11.3 µM. These results demonstrate that both 4v and colchicine could
interact with tubulin at a similar magnitude.

3.3.6

In vivo antitumor efficacy of 4v

Based on its potent antiproliferative activity, 4v was selected to evaluate the in vivo efficacy using a human melanoma A375 xenograft model in NSG mice. Once the average
tumor size reached 100 mm3 in size and was palpable, 4v was dosed with a vehicle at
10 or 20 mg/kg intraperitoneally for 14 days. Results indicated that the administration
of 4v resulted in an obvious tumor growth suppression in a dose-dependent manner in
this model (Figure 3.6A). When compared with the vehicle-treated control group, treatment with neither 10 nor 20 mg/kg 4v induced a significant decrease in body weight loss,
suggesting an absence of acute toxicity of compound 4v in these mice (Figure 3.6B). A
statistically significant tumor inhibition was observed in 4v treatment groups at the study
endpoint, as indicated by the results that treatment with 10 mg/kg 4v reduced both the
average tumor volume and weight by 58.54 and 48.81%, respectively, and treatment with
20 mg/kg 4v decreased the average tumor volume and tumor weight by 88.50 and 83.33%,
respectively, compared to the same measures in the vehicle-treated group (Figure 3.6C and
D). The efficacy of 4v in mice bearing A375 tumors was further confirmed by the reduced
tumor size observed in mice treated with either dose of 4v compared to that of the vehicletreated group as demonstrated by tissue macroscopic analysis Figure 3.6E. Following the
in vivo xenograft study, we further excised the tumors and conducted H&E and IHC staining as shown in Figure 3.7. Images of H&E-stained tissue revealed more necrotic cells in
4v-treated tumors as compared to those from vehicle-treated animals, suggesting that 4v
induced A375 tumor necrosis. The number of necrotic cells observed increased as the dose
of 4v increased from 10 to 20 mg/kg. Tumor growth suppression by both 4v doses was also
evident from the IHC histological results using the cell proliferation marker Ki67, as indicated by the reduced number of Ki67-positive tumor cells observed in a dose-dependent
manner. The anti-vascular activity of 4v was evaluated using the prognostic angiogenic
marker CD31. Decreased CD31 staining suggested that tumors in 4v-treated groups had
less microvessel density and that 4v was able to disrupt tumor vasculature development.
In addition, 4v-treated tumors showed increased expression of cleaved-PARP, an apoptotic marker, suggesting that 4v may be a potent inducer of tumor cell apoptosis (Figure
3.7). Together, these results confirmed the role of 4v in tumor necrosis induction, tumor
anti-angiogenesis, and tumor apoptosis in vivo. Thus, the results of this study showed that
compound 4v is a potent tubulin depolymerizing agent. Most likely, the efficacious ability
of 4v to inhibit tumor growth suggests that the 6-aryl-2-benzoylpyridines are a promising
new generation of potent tubulin inhibitors for the treatment of malignant cancers.

3.3.7

Antiproliferative effect of 4v on TNBC cells in vitro

The antiproliferative activity of 4v was further evaluated on two TNBC cell lines and their
paclitaxel-resistant daughter sublines. The MTS assay results showed that 4v inhibited the
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Figure 3.6: In vivo antitumor activity of compound 4v in mice bearing
the A375 xenograft. (A) 4v was administered five times per week by IP
injection at the doses indicated. Tumor volumes were measured two times
per week and data represented mean ± SEM for each treatment group. (B)
% change in mouse body weight was measured three times per week
during treatment. Data are shown as mean ± SEM. Tumor volumes (C) or
tumor weights (D) measured after 2 weeks of 4v or vehicle treatment. The
bar graph shows the mean ± SEM calculated from tumors in each group.
(E) Representative tumor images of A375 xenografts.
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Figure 3.7: 4v induces tumor necrosis, anti-angiogenesis and apoptosis in
vivo. Representative images of tumor sections stained with H&E, Ki67,
CD31, and cleaved-PARP. Keyence microscope magnification, 20x for H&E,
CD31 and forward Ki67 and cleaved-PARP staining images, 40x for
backward Ki67 and cleaved-PARP staining images. Scale bar = 50 µm.
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TNBC cell growth with an average IC50 of 2.5 nM (Table 3.5). And it could overcome paTable 3.5: Cytotoxicity of 4v on a panel of TNBC cell lines including
paclitaxel-resistant cell sublines and PDX lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.

clitaxel resistance with similar cytotoxicity, which the potency of colchicine and paclitaxel
were mitigated in paclitaxel-resistant TNBC cells (Table 3.5). We also compared the effects of 4v to that of colchicine or paclitaxel on two primary cell lines derived from TNBC
patients. After 5 days of treatment, 4v (2.5 nM) inhibited the proliferation of HCI-2 and
HCI-10 cells significantly, while colchicine treatments showed limited effects in suppressing the growth of both HCI-2 and HCI-10 cells at the concentration of 10 nM (Figure 3.8A).
As 10 nM of paclitaxel showed remarkable effects in reducing the expansion of HCI-2 cells,
it had no efficacy in suppressing the growth of HCI-10 cells. We then treated the MDAMB-231 and MDA-MB-468 cells with 4v, colchicine and paclitaxel in the low nanomolar
range (1 to 4 nM) to determine the anti-colony formation effects. As shown in Figure 3.8B,
4v was potent in reducing the colony formation ability of both TNBC cell lines significantly
at the concentration of 4 nM. Consistent with the IC50 values, colchicine had no effect in
inhibiting colony formation of TNBC cells at all concentrations, while paclitaxel robustly
restrained the colonies formed in both cell lines, and even affected the MDA-MB-231 cells
at 1 nM. We also treated the MDA-MB-231 and MDA-MB-468 cells with higher doses of
4v, and results showed that 4v was able to repress the colony formation in a concentrationdependent manner (Figure B.2).

3.3.8

4v interferes with microtubule stability in TNBC cells

Next, we determined the effects of 4v to disturb the microtubule assembly in TNBC cells.
We treated the MDA-MB-231 cells with 2.5 nM and 5 nM of 4v using colchicine and paclitaxel as controls. As a microtubule-polymerizing agent, paclitaxel at the concentration of
either 2.5 nM or 5 nM was able to condense the microtubules in both MDA-MB-231 cells
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Figure 3.8: Anti-proliferating effects of 4v on TNBC cells. (A)
Representative images showing the effect of 4v in treating HCI-2
(treatment-naïve PDX line) cells or HCI-10 (taxane-resistant PDX line) cells
with colchicine and paclitaxel treatments as controls. Images were
acquired by IncuCyte after 5 days of drug treatments. (B) The graphs show
the anti-colony formation effects of 4v on MDA-MB-231 or MDA-MB-468
cells compared to colchicine and paclitaxel in the low nanomolar range (1
to 4 nM). % of colony area in each treatment group was quantified by
comparing to the colony area formed in control group.
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during interphase and mitotic phase (Figure 3.9A). Cells treated with 2.5 nM of colchicine

Figure 3.9: 4v affects microtubule organization and stability of TNBC
cells. (A) 2.5 nM or 5 nM of colchicine, paclitaxel or 4v-treated
MDA-MB-231 cells were imaged by a Keyence microscope. Low-right
inserts show the cells in mitosis. (B) Expression of α-tubulin and
acylated-α-tubulin in 4v-treated MDA-MB-231 cells were determined by
Western blot. GAPDH is the loading control. (C-D) Immunocytochemical
and Western blot experiments were repeated in MDA-MB-468 cells with
similar treatments as in (A) and (B).
showed similar organized and intact microtubule structure as untreated cells, suggesting
the limited potency of colchicine in affecting the microtubule assembly at a concentration of 2.5 nM. As expected, 5 nM of colchicine caused disseminated and depolymerized
microtubules arranged in MDA-MB-231 cells during interphase, although it could not dissolve the microtubules in the mitotic cells. 4v-treated cells showed similar disorganized
and damaged microtubule networks as 5 nM of colchicine-treated cells, and 2.5 nM of 4v
could induce unpolymerized microtubules in both interphase and mitotic MDA-MB-231
cells. Acetylation on Lys40 of α-tubulin was reported to stabilize the microtubules, thus,
we determined the protein levels of acylated-α-tubulin and α-tubulin on MDA-MB-231
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cells treated with 4v (2.5 nM, 5 nM and 10 nM) by Western blot (Garnham and Roll-Mecak,
2012; Eshun-Wilson et al., 2019). Expectedly, high concentration of 4v (10 nM) downregulated the expression of acylated-α-tubulin and α-tubulin significantly, suggesting that 4v
was able to interfere the microtubule stability at high doses (Figure 3.9B). Similar results
were obtained in MDA-MB-468 cells treated with 4v (Figure 3.9C and D).

3.3.9

4v suppresses TNBC cell migration and invasion

Since microtubules are very important in the process of cell migration (Garcin and Straube,
2019; Bance et al., 2019; X. Wang et al., 2019), we then investigated the ability of 4v in influencing the cell migration in both MDA-MB-231 and MDA-MB-468 cells. By using a scratch
wound assay, we compared the effect of 4v with colchicine and paclitaxel in filling the
wounds of TNBC cells. As displayed in Figure 3.10A, after 24 h of incubation, the wound
in untreated MDA-MB-231 cells was about to close, and 4 nM of colchicine treated cells
exhibited similar wound closure trend as untreated control cells. However, 4v showed
comparable anti-wound healing effects as paclitaxel, a very potent tubulin polymerizing
agent in treating TNBC. Similar results were obtained in MDA-MB-468 cells treated with
colchicine, paclitaxel and 4v. We further performed the Transwell assays to confirm the potency of 4v in the inhibition of TNBC cell migration and invasion (Figure 3.10B and C). As
anticipated, 4 nM of 4v inhibited the migration and invasion of TNBC cells significantly,
with 70% and 63% of migration inhibition in MDA-MB-231 and MDA-MB-468 cells, respectively, and 69% and 53% of invasion suppression in MDA-MB-231 and MDA-MB-468
cells, respectively.

3.3.10

4v treatment causes G2/M phase arrest and apoptosis of TNBC cells

We have previously reported that VERU-111 as a tubulin-destabilizing agent induced TNBC
cells or lung cancer cells into G2/M cell cycle arrest and apoptosis (Shanshan Deng, Krutilina, et al., 2020; Mahmud et al., 2020). As a structurally modified analogue of VERU-111,
4v was then evaluated in cell cycle disruption and apoptosis induction in TNBC cells. We
treated the MDA-MB-231 and MDA-MB-468 cells with different concentrations of 4v, 10
nM of colchicine and 10 nM of paclitaxel for 24 h. As displayed in Figures 3.11A and
B.3A, 4v treatment brought both TNBC cells into G2/M phase arrest in a concentrationdependent manner, with MDA-MB-231 cells mainly arrested into M phase and MDA-MB468 cells accumulated into G2 phase. Colchicine treatment did not have much effects on
TNBC cells, while paclitaxel remarkably arrested the cells into M phase and subG1 phase,
which was consistent with its strong cytotoxicity in vitro. We also determined the effects of
4v in inducing apoptosis using Annexin-V/PI costaining kits (Figures 3.11B and B.3B). Results showed that 4v caused the cell apoptosis significantly at the concentration of 10 nM.
And its efficacy is stronger than colchicine or paclitaxel. Next, western blot analysis was
carried out to determine if 4v treatment led to the TNBC cell apoptosis through controlling
PARP, a known cell death protein (Y. Xu et al., 2006; Jubin et al., 2016). A clear upregulation of the cleaved-PARP was observed in 4v-treated TNBC cells along with a concomitant
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Figure 3.10: 4v inhibits migration and invasion of TNBC cells. (A)
Wound healing assay showed the effects of colchicine, paclitaxel and 4v on
preventing the wound closure at the concentration of 4 nM. The wound
was created by a sterile 200 µL tip and representative images were captures
at the 0 h, 12 h and 24 h after drug treatments for MDA-MB-231. For
MDA-MB-468 cells, images were acquired at the 0 h, 24 h and 48 h after
treatments. (B) Transwell migration assay was carried out on TNBC cells
treated with 4 nM of 4v. (C) Transwell invasion assay was performed on
TNBC cells treated with 4 nM of 4v. Migration or invasion capacity of
4v-treated TNBC cells were calculated as the percentage of migrated or
invaded cells relative to the cells in the control group.
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Figure 3.11: Cell cycle arrest and cell apoptosis induction by 4v in
MDA-MB-231 and MDA-MB-468 cells. (A) Effects of different
concentrations of 4v (2.5 nM, 5 nM and 10 nM), 10 nM of colchicine (COL)
and 10 nM of paclitaxel (PTX) on TNBC cell cycle distribution for 24 h were
detected by phospho-histone H3 (Ser10)/PI costaining. (B) Annexin-V/PI
costaining was carried out to determine the apoptosis of TNBC cells with
the same drug treatments in A. (C) Western blot analysis was repeated with
24 h of 4v treatments (2.5 nM, 5 nM and 10 nM) to determine the full length
(PARP) as well as the cleaved counterpart (cleaved-PARP) expressions.
β-actin was used as a loading control. (D) Expression of cleaved-PARP was
determined in both TNBC cell lines by Western blot after treatments as in
A. GAPDH was used as a loading control. (E) Protein levels of
apoptosis-related proteins were exhibited in MDA-MB-231 cells after 4v
treatments for 24 h. GAPDH and β-actin were used as loading controls.
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downregulation of full length PARP, indicating 4v caused apoptosis through the cleavage
of PARP (Figure 3.11C). We then compared the capacity of 4v to induce the cleavage of
PARP with colchicine and paclitaxel (Figure 3.11D). In accordance with the Annexin-V/PI
costaining results shown in Figure 3.11B, 4v was robust in triggering the expression of
apoptotic protein cleaved-PARP, and it was more influential than either colchicine or paclitaxel at the concentration of 10 nM. Bax is one of the pro-apoptotic proteins and Bcl-2
is one of the anti-apoptotic protein, they are all involved in the endogenous mitochondrial mediated-apoptosis pathway (Boulares et al., 1999; Westphal, Kluck, and Dewson,
2014; Y. Yang et al., 2017). We further conducted the western blot analysis to detect the
expression of these apoptosis-related proteins in MDA-MB-231 cells treated with 4v (2.5
nM, 5 nM and 10 nM). As displayed in Figure 3.11E, 4v upregulated the expression of Bax,
cleaved-caspase-3 and cleaved-caspase-9 following a concentration-dependence manner,
and it was able to decrease the protein level of Bcl-2, demonstrating that 4v induced the
apoptosis in MDA-MB-231 cells through the intrinsic apoptotic pathway.

3.3.11

Effect of 4v on an orthotopic MDA-MB-231 xenograft model

To evaluate the antitumor effects of 4v on TNBC in vivo, we used an orthotopic TNBC
xenograft model by inoculating the MDA-MB-231 cells into the fat pad of female mice
orthotopically. Once the tumor volume reached 100 mm3 , 24 NSG mice were randomly
divided into 4 groups and treated with vehicle, 5 mg/kg 4v, 10 mg/kg 4v and 20 mg/kg
4v by IP injections with the dose frequency as 5 times/week, respectively. During the
treatment, the tumor size and body weight of mice were monitored. After 19 days of treatment, the average tumor volume in 4v-treated mice was significantly smaller than that of
the vehicle group, and 4v inhibited the TNBC tumor growth following a dose-dependent
manner (Figure 3.12A). There was no obvious body weight loss observed in the treatment
groups, showing the absence of acute toxicity of 4v in this model (Figure 3.12B). As soon
as the tumors in vehicle group reached 1000 mm3 , all tumors were excised after euthanizing the mice. Compared to the vehicle control, the reduced mean final volume and mean
final weight of tumors in 4v treatment groups confirmed the potency of 4v in vivo, and
the maximum inhibition effect of 4v was observed at the dose of 20 mg/kg (Figure 3.12C
and D). A photo of representative excised tumors relative to the mean final tumor volume
and tumor weight of each group is shown in Figure 3.12E. All these results demonstrate
the strong growth inhibition effect of 4v on TNBC in vivo. As discovered in Chapter 2,
MDA-MB-231 xenografts always metastasize to the lungs. And 4v was shown to inhibit
the migration and invasion of TNBC cells in vitro, we then did the H&E staining for all
the lungs collected from this model to evaluate the therapeutic outcome of 4v in breast
cancer metastasis in vivo. As displayed in Figures 3.12F and B.4, multiple lung metastases
with large size of nodules were visibly observed in vehicle group. 5 mg/kg 4v treatment
reduced the average number of nodules detected on lung sections from 48 to 36 without
statistically significance. However, 10 mg/kg 4v treatment and 20 mg/kg 4v treatment
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Figure 3.12: 4v with IP administration inhibits the orthotopically
MDA-MB-231 TNBC xenografts growth. When the average tumor
volume reached 100 mm3 , mice were randomized into 4 groups and the
treatments initialed. Mean tumor volume ± SEM (A) and mouse body
weights ± SEM (B) of each group was monitored 2 times/week during the
therapy. At the study endpoint, ex vivo tumor volume ± SD (C) and tumor
weight ± SD (D) were measured. Mean values are showed above each bar
graph. (E) Tumor images representative for each group’s mean ex vivo
tumor volume and tumor weight. (F) Lung metastases ± SD of each group
were quantified manually through H&E stained lung sections. Mean
number of metastases are showed above each bar.
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markedly suppressed the lung metastasis originated from fat pad tumors with the number of lung metastases as 16 and 4, respectively, and there were only sparse and small
tumor nodules observed in 20 mg/kg 4v-treated lungs. Collectively, these studies suggest
that 4v represents a promising new generation of tubulin inhibitors that could inhibit the
growth and metastasis of TNBC and worth for further investigations.

3.4

Conclusion

In summary, we have reported the design and synthesis of new analogues of our previously reported lead compound ABI-274. Among a series of novel 6-aryl-2-benzoylpyridines synthesized, compound 4v with 3-hydroxyl-4-methyl functional groups showed
the strongest antiproliferative activity with IC50 values of 1-3 nM against a panel of human
melanoma and breast cancer cell lines. Here, we described the high-resolution crystal
structures of the representative compounds ABI-274 and 4v in complex with tubulin, confirming their direct binding to the colchicine-binding site in tubulin and providing further
insight into their molecular interactions with tubulin. Moreover, 4v was able to induce
tubulin depolymerization. We also found that 4v exerted a substantial antiproliferative
effect in vivo in a dose-dependent manner and induced tumor necrosis, anti-angiogenesis,
and apoptosis significantly. In addition, these desirable in vivo effects were not accompanied by any observed toxicity in this xenografted tumor mouse model. Most interestingly,
4v could inhibit colony formation, migration and invasion of TNBC cells, and it induced
G2/M arrest and apoptosis of two TNBC cell lines significantly. And 4v inhibited the
growth of TNBC xenografts significantly following a dose-dependent manner and it was
able to inhibit spontaneous TNBC metastasis. Thus, 4v represents a promising new generation of chemotherapeutic agents that deserve further investigation.
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Chapter 4
Biological Evaluation of Metabolically Stable
6-Aryl-2-benzoyl-pyridines as Potential Anticancer
Agents

4.1

Introduction

MTAs are a successful class of chemotherapeutic drugs that are commonly classified into
two major categories: microtubule-stabilizing agents (e.g. taxanes and epothilones) and
microtubule-destabilizing agents (e.g. vinca alkaloids and colchicine) (Tangutur et al.,
2017; Baig et al., 2018). MTAs bind to tubulin in proliferating cells via three major binding sites: taxanes-, vinca alkaloid-, and colchicine-binding sites and disrupt microtubule
dynamics (Jordan and Wilson, 2004; H. Chen, Z. Lin, et al., 2017). Antimitotic agents that
interact with the taxanes- or vinca alkaloid-binding sites in tubulin are highly successful
in cancer therapy, but their applications are often limited by the development of drug resistance and/or poor aqueous solubility (Maria Kavallaris, 2010; Wu, Q. Wang, and W. Li,
2016; Kinsie E Arnst et al., 2019; Miltenburg and Boogerd, 2014). However, tubulin inhibitors that target the colchicine-binding site show promises by overcoming transportermediated drug resistance (e.g. overexpression of ABC transporters) (Lu, Jianjun Chen, Min
Xiao, et al., 2012; Z. Wang et al., 2012; Stengel et al., 2010; Lai et al., 2018).
Our previous studies have identified ABPs (Figure 4.1A) as a new generation of
chemotherapeutic agents that target tubulin by binding to the colchicine-binding site. These
agents show low nanomolar inhibition on a panel of human melanoma and breast cancer cell lines and can effectively overcome taxane resistance (H. Chen, S. Deng, et al.,
2020). However, pharmacokinetic (PK) studies have shown that these compounds have
low bioavailability and low metabolic stability. The half-life time of CH-2-1 (also termed
4a in Chapter 4) is 4 min in human liver microsomes (HLM), while the half-life time of
CH-2-77 (also termed 4v in Chapter 4), the most potent compound in this class (average
IC50 = 2.5 nM) is 10 min in HLM (Figure 4.1A). The short half-life of these compounds
might be due to the reduction of the carbonyl linker and demethylation in the trimethoxy
phenyl (TMP) group by HLM. The centrally located carbonyl linker in ABPs is important
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Figure 4.1: Recently developed ABPs that target the colchicine-binding
site. (A) Structures of compounds 4a and 4v. (B) Structure of compound
60c.

in forming hydrogen bonding interactions with the β-Asp249 (H. Chen, S. Deng, et al.,
2020). However, this group is susceptible to nucleophilic attack, which leads to a change
in the compounds’ geometry and thus loss of bioactivity. Thus, we attempted to cyclize
the carbonyl with the B ring to generate a new D ring for the purpose of blocking the
metabolic reduction of the ketone linker to a secondary alcohol and thus improving the
metabolic stability while retaining the efficacy. The TMP group in C ring of ABPs is a common moiety shared by many CBSIs, and it has been shown to be experimentally important
in maintaining potency of CBSIs (Raphael et al., 1991; J. Chen, Ahn, et al., 2012; R. Yang et
al., 2019). However, the methoxy group undergoes o-demethylation in vivo leading to the
less active as well as more toxic phenol moiety. Thus, we hypothesize that replacing the
methoxy moiety with more stable functional groups would result in enhanced metabolic
stability and improved safety profiles.
In this chapter, we report new and successful strategies to reduce the metabolic
liability and potentially increase the bioavailability of ABPs, while maintaining or improving their antiproliferative activities. We made a series of modifications focused on blocking methyl oxidation in the A ring, ketone reduction, demethylation in the C ring, and
modifying of the B ring of the ABP template. We produced derivatives with comparable
or improved metabolic stability in HLM. Among all of the analogues synthesized, compound 60c (Figure 4.1B) with 3-hydroxy-4-methyl in the A phenyl ring, is the most active
compound with an average IC50 value of 2.4 nM against all cancer cell lines tested. In
addition, its half-life time in HLM is ~30 min. The in vitro tubulin polymerization assay
confirmed the interaction mechanism of 60c, which is via induction of tubulin depolymerization. Furthermore, 60c could overcome P-gp mediated multiple drug resistance and
paclitaxel resistance, and it significantly inhibited the proliferation and colony formation
of A375/TxR cells dose-dependently, arrested cells in the G2/M phase, and induced cell
apoptosis. In vivo study showed that 60c suppressed the growth of A375/TxR xenografts
with limited systemic toxicity. And 60c was able to inhibited lung and liver spontaneous
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metastasis significantly. Together, our results substantiated that compound 60c is a potent colchicine-binding site tubulin inhibitor with low systemic toxicity and may serve as
a good drug candidate in cancer treatment.

4.2
4.2.1

Materials and Methods
Cell culture

Human breast cancer cell lines (MDA-MB-231, MDA-MB-453 and SKBR3) and human malignant melanoma cell lines (A375, RPMI7951 and M14) were purchased from the American Type Culture Collection (Manassas, VA). The cancer cell lines were cultured in Dulbecco’s modified Eagle’s medium (Mediatech, Inc., Manassas, VA) supplemented with
10% FBS (Atlanta Biologicals, Minneapolis, MN) and 1% antibiotic-antimycotic solution
(Sigma-Aldrich, St. Louis, MO) at 37 °C in a humidified atmosphere containing 5% CO2 .
A375/TxR and MDA-MB-231/TxR cells were developed by the continuous exposure of
parental cells to increasing concentrations of paclitaxel gradually. Paclitaxel was removed
from the media for paclitaxel-resistant A375/TxR and MDA-MB-231/TxR cells for at least
1 week before in vitro or in vivo testing.

4.2.2

Antiproliferative activity

The cytotoxic effects of newly proposed ABP compounds against a panel of cancer cell
lines were evaluated by MTS cell proliferation assay as previously described (H. Chen, S.
Deng, et al., 2020). Briefly, cells were seeded in 96-well plates at a density of 3500-5000
cells/well depending on the doubling time of each cell line and incubated for 24 h. Testing
compounds were dissolved in DMSO (ATCC) to get 20 mM stock solutions. Compounds
were diluted with cell culture medium, added to the well at 10 different concentrations
ranging from 0.1 nM to 3 µM and incubated for 72 h in four replicates. Cells were then
treated with MTS for 1 to 1.5 h in the dark. The absorbance was recorded at 490 nm using a
plate reader (BioTek Instruments Inc., Winooski, VT). Cell growth inhibition of 50% (IC50 )
was calculated from concentration-response curves by GraphPad Prism 7. The RI was
calculated by dividing the IC50 of 60c obtained on the resistant cells by that of parent cells.

4.2.3

Protein expression and purification

The double mutant (Cys14Ala and Phe220Trp) stathmin-like domain of RB3 (RB3-SLD)
gene was kindly provided by Dr. Benoît Gigant (Université Paris-Saclay, France). The
RB3-SLD was expressed and purified as described previously (Nawrotek, Knossow, and
B. Gigant, 2011; Dorleans, Knossow, and B. Gigant, 2007; Yuxi Wang, Yu, et al., 2017).
Briefly, the RB3-SLD was overexpressed in E. coli and purified by thermal denaturation,
nucleic acid precipitation, anion-exchange chromatography and gel filtration chromatography. The purified protein was concentrated to 12 mg/mL in 10 mM HEPES, pH 7.2, 150
mM NaCl and stored at -80 °C until use. The subtilisin-treated tubulin (sT) was generated
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as described previously (Nawrotek, Knossow, and B. Gigant, 2011; Knipling, J. Hwang,
and Wolff, 1999). Briefly, porcine brain tubulin (Catalog #T-240, Cytoskeleton, Inc.) was
resuspended at 50 mg/mL in MAB (MES assembly buffer: 100 mM MES pH 6.9, 1 mM
MgCl2 , 1 mM EGTA) and diluted to 5 mg/mL in distilled water, then GTP (final concentration 1 mM) was added. After preincubation of the sample at 25 °C for 5 min, subtilisin
(P8038, Sigma-Aldrich) was added in a weight ratio of 1/100. After 45 min of incubation at
25 °C, the reaction was stopped by adding PMSF (final concentration 0.05%). MES, MgCl2 ,
and EGTA were added to the above sample to final concentrations of 100 mM, 1 mM, and 1
mM, respectively. The sample was incubated on ice for 40 min. The supernatant containing
subtilisin-treated tubulin was collected after centrifugation.

4.2.4

Crystallization, data collection, and structure determination

The tubulin/RB3-SLD complex (sT2R) was prepared as described previously (Nawrotek,
Knossow, and B. Gigant, 2011; Yuxi Wang, Yu, et al., 2017; Andrea E. Prota et al., 2013).
Subtilisin-treated tubulin and RB3-SLD were mixed at molar ratios of 2: 1.3 (tubulin: RB3SLD) and concentrated to 15 mg/mL at 4 °C . To obtain sT2R-colchicine, sT2R-40a and
sT2R-60c complex structures, the complexes were pre-formed in solution and then crystallized. The compounds were dissolved in DMSO at 100 mM concentration and the sT2R
complex was incubated with 1 mM of each compound, and the undissolved compound
was removed by centrifugation. Crystals were grown using the sitting drop vapor diffusion method at 20 °C with the reservoir solution 0.1 M tri-sodium citrate, pH 5.6, 0.2 M
ammonium sulfate, and 12~15% PEG 4000. For data collection, crystals were immersed in
cryo-protectant (0.1 M tri-sodium citrate, pH 5.6, 0.2 M ammonium sulfate, 10 mM MgCl2 ,
15% PEG 4000, 0.2 mM compound, and 30% glycerol) and flash frozen in liquid nitrogen.
For the sT2R-colchicine complex structure, diffraction data were collected at the beamline 8.2.1 at the Advanced Light Source (ALS). For the sT2R-40a, and sT2R-60c complex
structures, diffraction data were collected at the beamline 22-BM at the Advanced Photon Source. All diffraction data were processed using HKL2000 (Otwinowski and Minor,
1997). Structures were solved by molecular replacement using the tubulin-RB3 of the T2RTTL-colchicine complex (PDB ID: 5XIW) as the search model. Structures were refined and
optimized using PHENIX and COOT, respectively (Afonine et al., 2012; P. Emsley et al.,
2010). The atomic coordinates and structure factors have been deposited in the Protein
Data Bank. The electron density maps are shown in Figure C.1. Data collection and refinement statistics are summarized in Table C.1 together with the PDB accession codes. For
the figures, all structures were rendered using PyMOL version 2.3.0 (Schrödinger, LLC).

4.2.5

Western blot analysis of P-gp

Parental A375, MDA-MB-231 and paclitaxel-resistant A375/TxR, MDA-MB-231/TxR cells
were washed with ice-cold PBS and lysed in RIPA lysis buffer (25 mM Tris pH 7.6, 150
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing Halt protease and
phosphatase inhibitors (Thermo Fisher Scientific) for 30 min. After centrifugation, the
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supernatants were collected, and the protein concentrations were determined by the Bradford method. Denatured protein samples were separated by 8% SDS-PAGE electrophoresis
and subsequently transferred to PVDF membranes. The membranes were blocked with 5%
nonfat milk for 1 h and then incubated with anti-P-gp (MA1-26528, Thermo Fisher Scientific) and anti-β-actin (#3700, Cell Signaling Technology) at 4 °C overnight. The other day,
after incubation with the secondary antibody (#7076, Cell Signaling Technology) for 1 h,
the membranes were detected with Clarity™ Western ECL Substrate (Bio-Rad, #1705060)
and exposed to X-ray films for visualizing the protein bands.

4.2.6

Tubulin polymerization assay

The cell-free tubulin polymerization assay was carried out by using a tubulin polymerization assay kit (Cytoskeleton, Denver, CO) according to the manufacturer’s protocol. Assay
mixtures containing tubulin protein (3 mg/mL) and 1mM GTP were prepared in general
tubulin buffer on ice, and the polymerization reactions were initialed at 37 °C when adding
10 µM of testing compounds into the assay mixtures in a 96-well plate. The absorbance kinetics for each sample were record using a SYNERGY 4 Microplate Reader by measuring
the turbidity at 350 nm every 30 sec for 1 h.

4.2.7

Colony formation

A375/TxR cells (1000 cells/well) at the logarithmic phase were seeded in 6-well plates and
incubated for 24 h. Then the cells were treated with 2.5 nM, 5 nM and 10 nM of colchicine,
paclitaxel, CH-2-77 and 60c, respectively, for a week. Culture medium or medium containing drugs was changed every three days. At the end of the experiment, colonies resulting
from the surviving cells were washed with PBS, fixed with cold methanol, stained with
0.5% crystal violet and counted using a Keyence BZ-X700 microscope (Itasca, IL). The assay was performed once in triplicate.

4.2.8

Cell cycle analysis

The DNA contents of A375/TxR cells treated with colchicine (10 nM), paclitaxel (10 nM),
CH-2-77 (10 nM) and 60c (2.5 nM, 5 nM and 10 nM) in complete growth medium were
analyzed to study the cell cycle distribution by staining with PI. 2 × 106 cells/dish were
seeded in 100 mm dishes and incubated overnight. Following the treatment with either of
the drug listed above for 24 h, cells were washed with PBS, fixed in ice-cold 70% ethanol,
incubated with 100 µg/mL RNase A for 1 h at 37 °C and exposed to PI for 5 min in dark.
Analysis of cell cycle population was performed by a Bio-Rad ZE5 in the UTHSC Flow
Cytometry and Cell Sorting core and the results were analyzed using the ModFit LT™
software (Verity Software House, Topsham, ME). The experiment was carried out once in
triplicate.
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Cell apoptosis detection

The effect of 60c on apoptosis was analyzed using a FITC Annexin-V apoptosis detection
kit (eBioscience, San Diego, CA). Following the same compound treatments as cell cycle
analysis, 105 cells were harvested and stained with anti-Annexin-V-FITC and PI according
to the manufacturer’s instructions. After 10 min of incubation in the dark, the samples
were diluted with 1x binding buffer and the analysis was performed by Bio-Rad ZE5. Data
were processed and graphs were generated by FlowJo software.

4.2.10 In vivo antitumor efficacy and systemic toxicity studies in NSG mice
Five to six-week old NSG male and female mice were obtained from Jackson Laboratories (Bar Harbor, ME) and used for these studies. All animals’ treatments were performed
according to the rules of the NIH Principles of Laboratory Animal Care, and protocols
were approved by the Institutional Animal Care and Use Committee at the University of
Tennessee Health Science Center (protocol #17-056). 2.5 × 106 A375/TxR cells grown in
logarithmic growth phase were resuspended in FBS-free DMEM media and Matrigel (1:
1 ratio) and injected subcutaneously into the right flank of the NSG mice. After implantation, the tumor growth was monitored with a caliper and calculated as tumor volume
(mm3 ) = (length × width2 )/2, where “length” is the largest diameter and “width” is the
smallest diameter. When the tumor volume reached ~100 mm3 , mice were randomized
into 4 groups, each containing 3 male mice and 3 female mice. Group 1 is the vehicle group
that was treated with vehicle (3: 1: 6 ratio of PEG300: Tween 80: saline). Group 2 is the 10
mg/kg 60c treatment group and group 3 is the 20 mg/kg 60c treatment group. Group 4 is
the 10 mg/kg paclitaxel group (1: 1: 18 ratio of ethanol: Cremophor EL: saline). The mice
were injected intraperitoneally with the indicated compound and dosed 3 times per week,
and the tumor volume and body weight of each mouse were recorded before the treatment. The experiment was terminated when the xenograft in vehicle group approached
1000 mm3 . Tumor volumes and tumor weights of the treatment groups were compared
with that of the vehicle group using one-way ANOVA followed by multiple comparisons.
The mouse tumors and principle organs were collected, fixed in 4% paraformaldehyde,
embedded in paraffin wax and used for hematoxylin–eosin staining for histological examination. H&E slides were digitally scanned by a Pannoramic FLASH III system (3D
Histech), and tissue images were captured by CaseViewer. Metastatic burden was manually quantified by counting the number of metastatic lesions present in the whole tissue
section.

4.2.11

Statistical analysis

All the experimental data were expressed as the mean ± SEM and analyzed by one-way or
two-way ANOVA followed by the Dunnett’s multiple comparisons test using GraphPad
Prism 7. Statistical significance is presented as *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001.
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Results and Discussion
Antiproliferative activities of ABPs analogues in a panel of melanoma
and breast cancer cell lines

We focused our efforts on preparing four series of modifications of 6-aryl-2-benzoyl-pyridines. The first three series of compounds were carefully designed in an attempt to overcome
the major metabolism-related liabilities: methyl oxidation in the A ring, ketone reduction,
and demethylation in the C ring. The last series of compounds were obtained by replacing the pyridine B ring of the ABP template with imidazole, pyrazine, pyrimidine, and
substituted pyridine.
First, we designed and synthesized compound 4a by replacing the methyl group
with difluoromethyl in CH-2-1, and it exhibited comparable potency with an average IC50
value of 3.8 nM as compared to 3.7 nM of CH-2-1 (Table 4.1). However, the metabolic
stability of 4a is similar to that of CH-2-1 (4a, HLM t1/2 = 5 min; CH-2-1, HLM t1/2 = 4
min) (Table 4.2). We continued this series of comparisons by making 4b with indoline
in A ring and testing its antiproliferative activity. 4b showed similar cytotoxic activity
against human melanoma and breast cancer cell lines with an average IC50 value of 5.5
nM. Interestingly, the metabolic stability of 4b is slightly improved comparing to that of
CH-2-1 (4b, HLM t1/2 = 15 min; CH-2-1, HLM t1/2 = 4 min) (Table 4.2). The para-methyl
moiety was then replaced by a N,N-dimethyl group in the A phenyl ring to generate 4c;
this modification led to 13-fold reduced antiproliferative activity (an average IC50 value of
48.7 nM) when compared to that of CH-2-1 (Table 4.1).
The second aim was focused on modifying the para position at the C ring. One
purpose of this approach is to bypass the potential metabolic instability caused by the
o-demethylation. Our previous attempts to modify the TMP moiety have showed that
modifying of the para-position of C ring or linking the two adjacent methoxy moieties
into a conformationally restricted ring system exhibited comparable or improved cytotoxic
activity (Q. Wang, K. E. Arnst, Y. Wang, Kumar, Ma, H. Chen, et al., 2018; Lu, Jianjun
Chen, J. Wang, et al., 2014). Based on our extensive studies on the trimethoxy template,
we next modified the ring C and synthesized compounds 7 (para-2-methoxyethoxy) and
10 (3-methoxybenzo[4,5]-dioxane). 7 and 10 displayed similar activities with an average
IC50 value of 5.9 nM and 6.5 nM, respectively, compared to the parent compound CH-2-1.
However, compared with their parent compound CH-2-1 (HLM t1/2 = 4 min), 7 and 10
did not exhibit improvement in the metabolic stability in human liver microsomes, with
t1/2 values of 9 min and 7 min, respectively (Table 4.2). Introducing an ethyl (13) at the
para-position showed moderate activity with an average IC50 value of 18.3 nM, but this
derivative demonstrated enhanced metabolic stability in human liver microsomes with
t1/2 = 54 min compared to 10 min for CH-2-77 (Table 4.2). This result is consistent with
our hypothesis that the para-methoxy moiety seems to be unstable after exposure to liver
microsomes.
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Table 4.1: Cytotoxic effects of new 6-aryl-2-benzoyl-pyridine analogues
against three human malignant melanoma cell lines and three breast
cancer cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.
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Table 4.2: Microsomal stability study of tested compounds in liver
microsome of different species.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.
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The third aim was focused on blocking the ketone reduction by introducing a new
D ring. We replaced the carbonyl linker between the B and C rings in compound CH-2-1
with a pyridine-fused to pyrrole to generate 16. Compound 16 did not exhibit cytotoxicity in any examined cancer cell line. Further modification of the linker by introducing
pyridine-fused to pyrazole resulted in compound 22. Compound 22 demonstrated a 18fold improved half-life in human liver (22, HLM t1/2 = 180 min) (Table 4.2), indicating that
the metabolic stability of ABPs can be extended by blocking ketone reduction. However,
these modifications resulted in decreased antiproliferative activities.
In the last aim, we modified the B ring of the ABP template since the ABI template showed improved metabolic stability along with its high potency (Q. Wang, K. E.
Arnst, Y. Wang, Kumar, Ma, White, et al., 2019). Thus, we integrated the imidazole ring
into the ABP template and obtained 28a, 28b and 29. Replacement of the B ring pyridine
group with a 5-member imidazole group resulted in compounds 28a (imidazole), 28b (2methylimidazole) and 29 (2-bromo-imidazole), and these compounds had decreased antiproliferative activities comparing to 6-membered pyridine. Further modification of the
B ring of the ABP template by inserting pyrazine generated 35, 40a, 40b and 40c. Compounds 35 and 40a displayed similar activities with average IC50 values of 4.2 nM and 9.2
nM, respectively, compared to the parent compounds CH-2-1 and CH-2-77. It is interesting
to note that 40a with a pyrazine heteroaromatic ring resulted in a significant improvement
in the metabolic stability in human liver microsomes (40a, HLM t1/2 = 48 min; CH-2-77,
HLM t1/2 = 10 min) (Table 4.2). Inspired by these observations, we continued this series of
comparisons by making pyrimidine in B ring and thus generated 46a and 46b. Compound
3-hydroxy-4-methly in the A phenyl ring 46a showed comparable activity with an average
IC50 of 8.2 nM, while the 3-indole A ring compound 46b was less potent with an average
IC50 of 26.3 nM comparing to CH-2-77 (Table 4.1). 46a showed comparable metabolic stability in human liver microsomes, with t1/2 value of 9 min compared to 10 min for CH-2-77
(Table 4.2).
To investigate the effects of substitutions at the ortho-, meta- and para- positions in
the pyridine B ring of ABPs on the metabolic stability and the antiproliferative potency,
analogues 50a, 50b, 54a and 55b with various substituents, such as -OMe, -Me and -F, on
different positions of the B pyridine ring were prepared and evaluated (Tables 4.1 and 4.2).
Compound 50a, with a para-methyl in B pyridine ring, displayed similar activity as 50b,
with average IC50 values of 7.7 nM and 5.8 nM, respectively. The para-Me moiety in 50a
was then replaced by para-methoxy group in the B ring to generate 54a, which was comparable in potency to 50a (54a average IC50 = 7.0 nM) (Table 4.1). However, Compound
55b with one more hydroxyl group in A ring of 54a showed reduced antiproliferative activity with average IC50 value of 17.7 nM. It is a fascinating reminder that compounds 50a,
54a and 55b demonstrated a 3-4-fold improved half-life in human liver (50a, 54a and 55b;
HLM t1/2 = 43 min, 28 min and 43 min, respectively) (Table 4.2). Compounds with fluorine
substitution at the site of metabolic attack can prevent oxidative metabolism since the C–F
bond is more resistant to attack than the C–H bond. Compounds 59a, 59b and 60c, with
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meta-F in B ring were prepared and showed comparable activities against tested human
melanoma and breast cancer cell lines with average IC50 values ranging from 1 to 5 nM.
Compound 60c with 3-hydroxy-4-methyl in the A phenyl ring, turned out to be the most
potent compound with an average IC50 value of 2.4 nM against all cancer cell lines tested.
The metabolic stability in human liver microsomes for 59a, 59b and 60c is 10 min, 33 min,
and 30 min, respectively (Table 4.2). To investigate whether the B pyridine ring played an
indispensable role in the antiproliferative potency, we replaced the pyridine with phenyl
to produce compound 64. Compound 64, however, was much less active against the tested
cancer cell lines, with an average IC50 value of 60.8 nM. These results suggested that the
pyridine moiety of the B ring played an important role in improving the cytotoxicity.

4.3.2

In vitro microsomal stability

Previously synthesized compounds with ABP template are supposed to be deactivated
metabolically by methyl oxidation, o-demethylation and/or ketone reduction. To improve
the therapeutic indexes of ABPs, we set the goal to block their metabolism labile sites and
design novel ABPs analogs as indicated above. We first measured the metabolic stability
for two demethylated compounds at A ring (4a and 4b). These modifications preserved the
potency, but they did not exhibit improvement in metabolic stability. To bypass the potential metabolic instability caused by the o-demethylation leading to reduced half-life, we designed and synthesized two potent compounds 7 and 10 with an extended methoxyethoxy
at para-position of C ring and linked two adjacent methoxy moieties into a conformationally restricted ring (3-methoxybenzo[4,5]-dioxane), respectively. However, 7 and 10 did
not show improvement in the metabolic stability in human liver microsomes. Introducing
an ethyl at C-ring (13) at the para-position demonstrated improved metabolic stability, but
13 was less potent than its parent compound CH-2-77. Incorporating the metabolically
liable ketone into a metabolically stable ring (D-ring), as exemplified in compound 22,
enhanced the metabolic stability. However, 22 showed reduced antiproliferative activity,
possibly due to the fact that cyclizing the carbonyl moiety could lead to change in compound’s geometry and thus lose its bioactivity. These approaches to block the metabolism
of labile sites were expected to impede the potential phase I metabolic reactions, but they
were not really successful: compounds upon these modifications either lost the cytotoxic
activities and/or maintained unchanged metabolic stability.
To understand the metabolic patterns and major metabolism labile spots of ABPs
analogues in the liver microsomes, we performed additional metabolite identity study
for CH-2-1 and CH-2-77 (Figure 4.2). For compound CH-2-1, three metabolic pathways
were observed when incubated with human liver microsomes. M2 (monohydroxylation)
is a major product. M1 is the metabolite derived from ketone reduction, and it further
hydroxylated to M3. For compound CH-2-77, M4 (monohydroxylation) and M5 (ketone
reduction) are the major metabolites (Figure 4.2). These results were consistent with the
short half-lives (<10 min) of the compounds CH-2-1 and CH-2-77, as ketone is easy to be
reduced and the pyridine B ring is prone to be hydroxylated (nucleophilic attack) due to

Chapter 4. Biological Evaluation of Metabolically Stable 6-Aryl-2-benzoyl-pyridines
as Potential Anticancer Agents

94

Figure 4.2: Proposed metabolites and metabolic pathway of CH-2-1 and
CH-2-77.

the electron-deficiency effect. We then resorted to modify the B ring of the ABP template
in order to adjust the effects of electron push-pull, and thus to improve metabolic stability
while at the same time preserving potency. To test this hypothesis, we first synthesized
and measured compound 28a. Replacement of the pyridine group with imidazole group,
compound 28a showed improved metabolic stability, but it displayed reduced potency.
Strategies to further replace the pyridine B ring with a pyrazine ring or introduce meta-F
in pyridine B ring yielded several compounds (40a and 60c), which preserved the potency
while simultaneously improved metabolic stability about 3-5 fold in human liver microsomes compared to its parent compound CH-2-77. These results confirmed our hypothesis
that the pyridine B ring was subject to modification for improving the metabolic stability.
However, the selection of functional groups in B ring is critically important, and it is worth
further developing ABPs scaffold of tubulin inhibitor for anticancer therapy.

4.3.3

Crystallographic analyses of the 40a and 60c tubulin complexes

To characterize how compounds 40a and 60c bind to the tubulin polymer, we generated
the complexes using the tubulin/RB3-SLD assembly that has previously been shown to
generate excellent crystals (Figure 4.3A) (Nawrotek, Knossow, and B. Gigant, 2011). We
have previously used the T2R-TTL assembly for characterizing CBSIs studies (H. Chen, S.
Deng, et al., 2020; S. Banerjee et al., 2018), but switched to sT2R to facilitate the analyses
and typically obtain higher resolution structures. We first confirmed that colchicine binds
identically in the two assemblies and obtained crystals of the complex that diffracted to 2.5
Å. As shown in Figure 4.3B, the sT2R complex is almost identical to the T2R-TTL complex
that was determined at 2.9 Å (PDB ID: 5XIW). The colchicine occupies its binding pocket
within the β-tubulin at the interface of the α- and β-tubulin subunits opposite the GTP
molecule bound within the α-subunit (Figures 4.3C and C.2A).
We then crystallized and determined the structures of 40a and 60c bound to sT2R at
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Figure 4.3: Crystal structures of tubulin-RB3-SLD complexes with
colchicine, 40a and 60c. (A) The overall crystal structure of the
tubulin-RB3-SLD complex with GTP (red), GDP (magenta), and ligand
(green). (B) Colchicine bound in T2R-TTL (gray, PDB ID: 5XIW) and sT2R
(magenta) complexes. (C-E) sT2R complexes with colchicine (C), 40a (D,
PDB ID: 6XES), and 60c (E, PDB ID: 6XET). (F) Superimposed colchicine
bound (gray tubulin and magenta colchicine) and 60c bound (cyan and
gold tubulin and green 60c) tubulin complexes. Hydrogen bonds with
colchicine and 60c are shown as magenta and green dashed lines,
respectively. (G) Superimposed 40a (blue stick) and 60c (green stick). (H)
superimposed CH-2-77 (orange, PDB ID: 6AGK), 40a and 60c.
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2.3 Å (PDB ID: 6XES) and 2.6 Å (PDB ID: 6XET), respectively. Both compounds bound at
the colchicine site (Figures 4.3D-F and C.2B and C) and in a very similar fashion (Figure
4.3G). The key interactions are as follows: The C ring that contains the three methoxy
groups engages a hydrophobic pocket comprising Cys239, Leu240, Leu246, Ala248, Leu253,
Ala314, Ile316, Ala352 and Ile368. Two methoxy oxygen atoms form hydrogen bonding interactions with the main chain carbonyl oxygen of Gly235 and amide nitrogen of Cys239
via a water molecule at the distal end of this pocket. The A ring at the opposite end of the
molecules also engage a hydrophobic pocket comprising Leu253, Asn256, Met257, Ala314
and Lys350. In addition, Ala180 and Val181 from the α-subunit engage the A ring, and the
hydroxyl substituent forms two hydrogen bond interactions, to the main chain carbonyl
oxygen of Asn347 (β-subunit) and the main chain amide nitrogen of Val181 (α-subunit).
Note that Leu253 and Ala314 are able to engage both A and C rings because 40a and
60c adopt a bent conformation. The central ring B (pyrazine in 40a and fluoropyridine
in 60c) occupy a pocket bounded by Leu246, Lys252, Leu253, Asn256 and Lys350 from
the β-subunit and Asn101, Thr179 and Ala180 from the α-subunit. Finally, the carbonyl
group that links rings B and C forms a hydrogen bond interaction with the main chain
amide nitrogen of Asp249. Compared to the binding mode of CH-2-77 that we previously
characterized (PDB ID: 6AGK, 2.8 Å) (H. Chen, S. Deng, et al., 2020), 40a and 60c bind in
very similar ways. The major difference is that ring C is shifted by ~1.3 Å in 40a and 60c,
which allows the distal water mediated hydrogen bonds to Gly235 and Cys239 that are not
present in the CH-2-77 structure (Figure 4.3H). This shift may be caused by the interactions
of the additional nitrogen in ring B of 40a to Asn101, and the additional fluorine in ring B
of 60c with Leu246, Ala248 and Lys252. Thus, the tight interactions between tubulin and
40a or 60c mediated by water molecule might contribute the enhanced metabolic stability
of 40a and 60c as compared to CH-2-77.

4.3.4

Effects of the most potent compound 60c on taxane-resistant cell lines

Recently, we generated two new drug-selected paclitaxel-resistant cell lines by incubating the parental A375 cells or MDA-MB-231 cells with paclitaxel gradually and continually until the cells were stable in growth media containing 100 nM of paclitaxel. These
paclitaxel-resistant cells (A375/TxR and MDA-MB-231/TxR cells) were confirmed with
overexpression of P-gp by western blot (Figure C.2). The parental A375, MDA-MB-231
and their paclitaxel-resistant daughter lines were then used to evaluate the effect of the
most potent compound 60c on taxane resistance. As shown in Table 4.3, after 72 h of treatment, the A375/TxR and MDA-MB-231/TxR cells were resistant to paclitaxel as expected
with the resistance indices of 70 and 131, respectively. In contrast, 60c maintained the
equivalent potency on A375/TxR or MDA-MB-231/TxR cells with IC50 values in the low
nanomolar range, and the resistance index was 1.04 and 0.36, respectively. Similar results
were also observed with 60c treatment on M14 and its MDR1 overexpressing daughter line
M14/LCC6MDR1, which are both highly resistant to paclitaxel and colchicine. These data

Chapter 4. Biological Evaluation of Metabolically Stable 6-Aryl-2-benzoyl-pyridines
as Potential Anticancer Agents

97

Table 4.3: In vitro cytotoxic effect of selected compound 60c on three
parental or paclitaxel-resistant cell lines.1,2

1
2

n = 4 biological replicate experiments
The RI is calculated by dividing the IC50 value of the resistant cell lines
by the IC50 value of their respective parental cell lines.

demonstrated that 60c was not a substrate of P-gp and thus could overcome paclitaxel resistance, which suggested the potential roles of newly synthesized ABPs in circumventing
P-gp-mediated taxane resistance.

4.3.5

Inhibition of tubulin polymerization in vitro by 60c

Many antimitotic agents bind to microtubules and influence their polymerization and dynamics in multiple ways. We therefore evaluated the tubulin polymerization inhibitory
effects of the new ABPs (Dumontet and Jordan, 2010). The most potent compound, 60c,
was selected to evaluate the tubulin assembly in a cell-free tubulin polymerization assay
with CH-2-77 as the reference control. Colchicine and paclitaxel were employed as positive and negative assay controls, respectively. As shown in Figure 4.4, 10 µM of paclitaxel
treatment led to an increased rate of tubulin polymerization through bypassing the nucleation phase, growing microtubules rapidly in growth phase, and reaching the steady
state phase in a higher OD number at 340 nm as compared to the control group with three
normal phases. However, the presence of 10 µM of colchicine or CH-2-77 lengthened the
nucleation phase, slowed the microtubule growth in growth state phase, and reduced the
final tubulin polymer mass with a significant low OD number at the steady state phase,
thus interfering with tubulin polymerization. 60c proved to be a tubulin depolymerizing agent that strongly inhibited microtubule polymerization in a similar mode to that of
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Figure 4.4: Inhibition of tubulin polymerization by compound 60c at 10
µM. The effect of 60c on in vitro tubulin polymerization was conducted in
the tubulin buffer containing pure porcine brain tubulin (3 mg/mL) and
GTP (1 mM) in the presence of DMSO, colchicine, paclitaxel, CH-2-77, and
60c at the concentration of 10 µM. Colchicine and paclitaxel were used as
known inhibitors that enhance tubulin depolymerization and
polymerization, respectively. The polymerization of tubulin was
monitored at 340 nm for 1 h at 30 sec intervals. The curve represents the
average of two experiments.

CH-2-77 and colchicine.

4.3.6

60c treatment inhibits paclitaxel-resistant melanoma cell colony formation

Based on the in vitro cytotoxicity results of all newly synthesized ABPs against 6 different cancer cell lines and the strong anti-proliferating effect of 60c on a panel of paclitaxelresistant cancer cell lines, 60c was prioritized to carry out further experiments on A375/TxR
cells for mechanistic studies. First, we investigated the effect of 60c on the inhibition of cell
growth and colony formation of A375/TxR cells by performing a clonogenic assay. As
shown in Figure 4.5A, A375/TxR cells treated with 60c (2.5 nM, 5 nM and 10 nM) displayed fewer colonies compared with that of the control, colchicine or paclitaxel groups.
In addition, 5 nM of 60c treatment significantly reduced the percentage of colony formation area by 95% compared with control group, indicating that 60c remarkably inhibited
the proliferation and colony formation of A375/TxR cells in a concentration-dependent
manner (Figure 4.5B). 60c treatment exhibited similar results as CH-2-77 treatment, suggesting that 60c and CH-2-77 possessed comparable anti-colony formation activities.
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Figure 4.5: Colony formation assay displaying A375/TxR cell colonies
after colchicine, paclitaxel, CH-2-77 or 60c treatment. Each seeded single
cell was split into 4 cells, and cells were treated with 2.5 nM, 5 nM or 10 nM
of each drug for 7 days. (A) Representative images of colonies after
staining with crystal violet. (B) All colony formation percentage are
expressed as the percentage of colony area density in triplicate. ****p <
0.0001 versus control cells of each drug group.
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4.3.7

60c treatment induces G2/M phase arrest in A375/TxR cells

Anti-mitotic agents usually affect the progression of the cell cycle and induce cell cycle arrest, thereby influencing cell division and the proliferation of cancer cells. 60c was shown
to have strong anti-proliferating activity against a panel of taxane-sensitive cancer cell
lines and taxane-resistant cancer cell lines, the effect of 60c on cell cycle distribution of
A375/TxR cells was therefore tested using flow cytometry by staining the cells with propidium iodide. Cells were treated with 2.5 nM, 5 nM and 10 nM of 60c in complete growth
medium for 24 h with 10 nM of colchicine, paclitaxel, and CH-2-77 as positive controls. The
distribution of cell cycle phases (G1, S and G2/M) was then compared between the cells
from each group. As expected, colchicine or paclitaxel-treated A375/TxR cells displayed
the normal cell cycle population as present in untreated cells since A375/TxR cells overexpressed P-gp, which would expel colchicine or paclitaxel out of the cells and thus cause no
effect (Figure 4.6A and B). In contrast, treatment of cells with 60c resulted in a pronounced
dose-dependent accumulation of cells in the G2/M phase and concomitant decrease of
cells in G1 and S phases. Cell cycle analysis of A375/TxR cells with 10 nM of 60c treatment showed that major populations of the cells arrested at the G2/M phase (62%), which
was comparable to those treated with 10 nM of CH-2-77 (G2/M phase: 60%), whereas untreated cells only had 12% of cells in the G2/M phase as shown in Figure 4.6. Together,
these results demonstrate that 60c potently induces G2/M phase arrest of taxane-resistant
melanoma cells.

4.3.8

60c treatment causes apoptosis in A375/TxR cells

The cell cycle analyses showed that 60c was able to cause G2/M phase arrest, and to determine whether 60c would eventually induce cell apoptosis, we used Annexin-V-FITC / PI
staining to investigate the effect of 60c on A375/TxR cells. As shown in Figure 4.7A, both
CH-2-77 (10 nM) and 60c (5 nM or 10 nM) induced apoptosis of A375/TxR cells in comparison with the control, colchicine (10 nM) or paclitaxel (10 nM) group. Untreated control
cells had 8.8% of apoptotic cells in necrosis, early apoptosis, and late apoptosis, and 10
nM of colchicine or 10 nM of paclitaxel-treated cells possessed 10.6% and 11.8% of apoptotic cells, respectively (Figure 4.7A and B). However, treatment with 10 nM of CH-2-77 or
10 nM of 60c led to a significant increase in the proportion of apoptotic cells (from 8.8% to
51.1% and 54.3%, respectively), demonstrating the important role of 60c in the induction of
cell apoptosis, and its efficacy was as potent as CH-2-77. Moreover, 60c treatment resulted
in 14.5%, 45.4%, and 54.3% of apoptotic cells at concentrations of 2.5 nM, 5 nM and 10 nM,
respectively, showing that 60c induced apoptosis of A375/TxR cells in a dose-dependent
manner.

4.3.9

Antitumor activity of 60c in A375/TxR xenografts

Considering the potent cytotoxic and apoptotic properties of 60c in vitro, the antitumor
activity was further assessed in an A375/TxR xenograft model. The A375/TxR xenograft
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Figure 4.6: Effect of compound 60c on cell cycle distribution of A375/TxR
cells by flow cytometry. (A) Representative images of A375/TxR cells
treated with the indicated concentrations of 60c for 24 h followed by cell
cycle analysis using propidium iodide staining. Colchicine, paclitaxel, and
CH-2-77 were used as the positive controls. (B) Bar graph shows the
percentage of A375/TxR cells with different treatments in each phase of the
cell cycle.
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Figure 4.7: Cell apoptosis induction after treatment with 60c. (A)
Representative flow cytometry images showing A375/TxR cells treated
with colchicine, paclitaxel, CH-2-77, or 60c at indicated concentrations for
24 h followed by the Annexin-V-FITC and PI staining. (B) Percentage of
apoptotic cells in each group was shown by adding the proportion of cells
in early apoptosis (AV + PI -), later apoptosis (AV + PI +) and necrosis (AV
+ PI -). ****p < 0.0001 significant as compared with control.
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model was established by subcutaneously inoculating A375/TxR cells in the logarithmic
phase into the right flank of the NSG mice. When tumors had grown to approximately
100 mm3 , mice were randomly assigned to 4 groups based on the body weight and tumor
volume. Compound 60c was IP administered at a dose of 10 mg/kg or 20 mg/kg to the
mice 3 times/week for 18 days, respectively, and paclitaxel was intraperitoneally administered at a dose of 10 mg/kg to the mice with the same frequency as the 60c treatment.
From Figure 4.8A and B, it is evident that 60c treatment showed dose-dependently tumor
growth inhibition without weight loss for the entire drug therapy period. At the end of
the study, the tumors were isolated from animals, weighed, and imaged. As shown in
Figure 4.8C, 10 mg/kg and 20 mg/kg 60c treatment groups exhibited 57.6% and 72.9% of
reduction in average tumor volume compared with the vehicle group, respectively, while
paclitaxel treatment increased the tumor volume by about 5.3%. Similarly, the average tumor weights of 10 mg/kg 60c-treated and 20 mg/kg 60c-treated groups were 1.13 g (tumor
growth inhibitory rate: 44.4%) and 0.76 g (tumor growth inhibitory rate: 62.4%), respectively, which were much less than that of the vehicle mice (average tumor weight: 2.0 g) or
10mg/kg paclitaxel-treated mice (average tumor weight: 2.1 g) (Figure 4.8D). The image
of excised tumors from all groups further confirmed the strong antitumor activity of 60c
in suppressing A375/TxR tumor growth (Figure 4.8E). Hence, these results indicate that
60c could inhibit tumor growth effectively. We next analyzed the tumor necrosis in tumor
tissues stained with H&E and found that 60c-treated tumors were highly necrotic. As displayed in Figure 4.8F, a number of necrotic tumor cells were observed in either 10 mg/kg
or 20 mg/kg 60c treatment group, which was consistent with the in vitro findings. While
the tumor cells in vehicle or paclitaxel-treated tumors were all viable. The representative
images of whole tumor section further confirmed that the necrotic area of tumors increased
upon 60c treatment as compared to vehicle or paclitaxel treatment (Figure C.3A).

4.3.10

60c treatment attenuates spontaneous metastasis to major organs without appreciable toxicity

While removing organs from xenograft mice, we detected axillary lymph node metastases
and presence of multiple tumor nodules in lungs or livers from vehicle or paclitaxel-treated
mice, suggesting that A375/TxR cells were highly metastatic. We then evaluated the antimetastasis effect of 60c by performing H&E staining to detect metastasis in lungs and livers. As Figure 4.9A and B show, 60c treatment significantly inhibited the spontaneous
melanoma metastasis to lungs and livers, and 60c therapy suppressed the liver metastasis
following a dose-dependent manner. Although all the mice in the study have the spontaneous lung metastasis, only large lung metastatic nodules and extensive metastatic burden
were observed in the lungs of vehicle and paclitaxel group, and markedly sparse and reduced size of lung nodules were detected in the animals given 60c (Figures 4.9C and C.3B).
In this model, five-sixths vehicle-treated mice developed liver metastases, and five-sixths
of paclitaxel-treated mice formed liver metastases. While only two-sixths 10 mg/kg 60ctreated mice had liver metastases and none of the mice in 20 mg/kg 60c treatment group
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Figure 4.8: 60c suppresses growth of melanoma xenografts in vivo. (A)
Changes in tumor volume of mice in each group were recorded three times
per week during the treatment. Data are shown as mean tumor volume ±
SEM. (B) Relative body weight change was monitored three times per
week and calculated based on the body weight of each mouse at the time of
initiating drug treatment. Dash lines denote weight relative to the starting
point (y-axis = 0) and 20% of weight gain (y-axis = 20). (C-D) At the end of
the experiment, the final tumor volume (C) and tumor weight (D) were
measured and plotted in each group of mice. Each dot indicates the tumor
volume or tumor weight of each tumor. Error bar represents the mean ±
SEM. (E) The representative photograph of excised tumors in each group.
(F) Representative H&E stains of tumor sections. Blue arrows indicate
necrotic tumor cells. Images were acquired at × 20 magnification; scale bar:
50 µm. (n = 6, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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Figure 4.9: 60c inhibits lung and liver spontaneous metastasis in
A375/TxR xenograft model. (A-B) At the study endpoint, all the lung and
liver tissues in the study were collected and stained with H&E. the lung (A)
and liver (B) metastasis were manually quantified by counting the number
of metastatic burden present in the whole tissue section. Data shown are
the number of metastasis foci present in 6 mice from each treatment group.
(C) Representative images showing metastatic nodules from lung (top) or
liver (bottom) in each group. Lung metastases were pointed by blue arrows
and live metastases were circled by blue dotted lines, scale bar: 500 µm.
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was observed to has liver metastases, indicating that compared with the vehicle or paclitaxel group, 60c strikingly reduced the incidence of A375/TxR liver metastasis (Figure
4.9B). In addition, liver metastases with significantly reduced size and number were observed in mice treated with 60c in contrast with those treated with vehicle or paclitaxel, as
exhibited in Figures 4.9C and C.3B. In addition, the systemic toxicity of 60c was evaluated
by histological images of major organs (lung, liver, kidney, heart and spleen) collected in
this model through H&E staining. Since lung and liver tissues have a lot of metastatic nodules, we acquired the representative images by avoiding the metastatic area. H&E stained
tissues sections indicated no apparent pathological changes in the major organs between
groups treated with vehicle, paclitaxel, 10 mg/kg 60c, and 20 mg/kg 60c (Figure 4.10).
In short, these results indicated that 60c was efficacious in suppressing the growth and
metastasis of A375/TxR xenografts with low systemic toxicity in vivo.

4.4

Conclusions

In summary, we have reported the design and synthesis of four series of new ABP derivatives by blocking the methyl oxidation in the A ring, ketone reduction, demethylation in
the C ring, and modifications of the pyridine B ring of the ABP template. SAR of these compounds led to the identification of lead analogue 60c, which showed improved metabolic
stability on human liver microsomes while concomitantly maintained potent antiproliferative activity with IC50 values of 1-3 nM against a panel of human melanoma and breast
cancer cell lines. Here we also described the high-resolution crystal structures of the representative compounds 40a and 60c in complex with tubulin, confirming their direct binding
to the colchicine-binding site in tubulin and providing further insight into their molecular interactions with tubulin. Moreover, 60c was able to induce tubulin depolymerization,
arrest cell cycle in the G2/M-phase, and induce apoptosis. Most interestingly, 60c could
effectively overcome taxane resistance and inhibit the growth and metastasis of A375/TxR
xenografts in vivo, and thus represent a promising new generation of tubulin inhibitor that
merits further investigation.
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Figure 4.10: Representative H&E stained images of several healthy organ
tissue sections (heart, lung, liver, kidney, and spleen). H&E staining was
carried out for monitoring systemic toxicity of 60c in A375/TxR
tumor-bearing mice. scale bar: 50 µm.
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Chapter 5
Antitumor Efficacies of Metabolically Stable
Cyclopenta-pyrimidinyl Dihydroquinoxalinone as
Potent Tubulin Polymerization Inhibitors

5.1

Introduction

Highly dynamic microtubules (MTs) are crucial elements of cellular cytoskeleton and known to have important contributions in cell proliferation, migration and mitosis (Kinsie E
Arnst et al., 2019; Kinsie E. Arnst, Yuxi Wang, et al., 2018; Souvik Banerjee et al., 2016).
Assembly as well as disassembly of MTs depend on the polymerization and depolymerization of tubulin. Thus, disruption of MT dynamics has been a well-established strategy
in anticancer therapy, given MTs are deeply involved in mitosis (Kinsie E Arnst et al.,
2019; Kaur et al., 2014; Haider et al., 2019). Three of the major classes of tubulin inhibitors
that have been extensively used for clinical intervention of cancer are taxanes, vinca alkaloids and epothilones (Kinsie E. Arnst, Yuxi Wang, et al., 2018; Cui et al., 2017; Min
Xiao et al., 2013; Humbert et al., 2019). However, development of MDR, peripheral neuropathy as well as narrow therapeutic index often restrict the desired efficacies of these
drugs in the clinic (Z. Wang et al., 2012; Maria Kavallaris, 2010; Ying Zhang, S.-H. Yang,
and Guo, 2017). Colchicine binds at the interface of the αβ-tubulin dimer (Dumontet and
Jordan, 2010). Colchicine and other small molecules that bind to the colchicine site have
been observed to inhibit the ability of tubulin dimers to polymerize and form functional
microtubule (Kinsie E Arnst et al., 2019; Souvik Banerjee et al., 2016). Thus, CBSIs have
demonstrated substantial cytotoxicity in a number of studies (H. Chen, S. Deng, et al.,
2020; Gangjee, Pavana, et al., 2014; X.-F. Wang et al., 2014; Wu, Q. Wang, and W. Li, 2016).
Although colchicine itself is prone to efflux transporter as well as β3-tubulin mediated
multidrug resistance, small molecule CBSIs have been significantly less vulnerable to these
MDR mechanisms responsible for limited clinical efficacy of current FDA approved tubulin inhibitors (Gangjee, Zhao, et al., 2010). However, clinical applications of small molecule
CBSIs have been constrained by the substantial undesired toxicities against normal cells,
low solubility as well as low oral bioavailability (Souvik Banerjee et al., 2016; Lu, Jianjun Chen, Min Xiao, et al., 2012; Mundra et al., 2012; Dumontet and Jordan, 2010). In
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recent years, there has been extensive research on a new class of small molecule CBSIs,
particularly vascular disrupting agents (VDAs), targeting the colchicine-binding site (Kinsie E. Arnst, Souvik Banerjee, et al., 2019; S. Banerjee et al., 2018; Pérez-Pérez et al., 2016;
W. Gradishar, 2009). VDAs have profound advantages over angiogenesis inhibitors (AIs)
by disrupting established blood vessel networks in the tumor and, thereby, introducing
extensive necrosis as well as apoptosis via vascular collapse (S. Banerjee et al., 2018; Souvik Banerjee et al., 2016; Tozer, Kanthou, and Baguley, 2005). It is noteworthy to mention
that VDAs are known to predominantly block the blood flow in solid tumors, leaving the
blood vessels in normal tissues intact (Siemann, 2011). Currently, a significant number of
VDA agents targeting the colchicine site are in advanced clinical trials for the treatment
of diverse cancer types (Souvik Banerjee et al., 2016; Mason et al., 2011; Ya-Ting, Yan-Na,
and Zhao-Peng, 2015). For instance, a phosphate analogue of combretastatin A-4 (CA4P) is in phase III trials targeting anaplastic thyroid cancer, and in phase II trials from the
treatment of non-small-cell lung cancer (NSCLC) (Souvik Banerjee et al., 2016; Siemann,
Chaplin, and Walicke, 2009). Verubulin (MPC-6827), azixa, was introduced a few years ago
as a highly potent tubulin polymerization inhibitor with strong ability to initiate vascular
disruption by rapid collapse of tumor blood flow and inhibition of tumor growth (YaTing, Yan-Na, and Zhao-Peng, 2015; Mahal et al., 2014; Kasibhatla et al., 2007). Verubulin
has exhibited low nanomolar efficacy against diverse cancers, including melanoma, brain,
prostate, and breast cancers (Mahal et al., 2014; Grossmann et al., 2012; Chamberlain et
al., 2014). Verubulin was advanced to Phase I and Phase II clinical trials, however, was
withdrawn from the clinical trials for potential cardiovascular toxicities (Grossmann et al.,
2012; Chamberlain et al., 2014; Zhu, Kesari, and Recht, 2015; Subbiah, Lenihan, and Tsimberidou, 2011). These successes have resulted in intensive research in VDAs leading to a
number of recent reports on small molecule VDA drug-like candidates with significantly
high antiproliferative activities (S. Banerjee et al., 2018; Cui et al., 2017; D. Bates et al., 2016;
Bueno et al., 2018). Most of the recent colchicine binding VDAs have drawn considerable
attention for their dual mechanism of action as antimitotic as well as vascular disrupting
agents resulting in high expectations for success in cancer chemotherapy (Kinsie E Arnst
et al., 2019; Bueno et al., 2018).
Recently, we have developed heterocyclic-pyridopyrimidine, (Figure, 5.1, 1a) and
hydroquinoxalinone (Figure 5.1, 2a), as highly potent tubulin polymerization inhibitors
with significant vascular disrupting capabilities (S. Banerjee et al., 2018; Kinsie E. Arnst,
Souvik Banerjee, et al., 2019). X-ray co-crystal structures demonstrated that 1a, 2a and their
analogues bind to the colchicine site in tubulin (Figure 5.1). Crystal structures unveil that
the pyrimidine portion of these molecules forms water mediated hydrogen bonds with the
β-Cys239 and β-Val236, making these analogues one of the most potent inhibitors of tubulin polymerization. Additionally, in compound 2 and its derivatives, the hydroquinoxalinone moiety forms a hydrogen bond with the α-Thr179 (Kinsie E. Arnst, Souvik Banerjee,
et al., 2019). Thus, Compound 2a is a stronger inhibitor of microtubule polymerization and
has significantly improved metabolic stability against human (t1/2 = 5.5 hrs), mouse (t1/2
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Figure 5.1: Design and synthesis of novel dihydroquinoxalinone
pyrimidine analogues.

= 1 hr), and rat (t1/2 = 5.07 hrs) liver microsomes. Compound 2a was found to have single
digit nanomolar potency against diverse melanoma, prostate, lung and breast cancer cell
lines. However, compound 2a has poor water solubility making it very difficult to work in
either intraperitoneal or intravenous in vivo experiments. Compound 2a in a MTD study
showed toxicity above 1 mg/kg dose leading to loss of body weight and death of mice. The
toxicity finding was in concert with an earlier report by Xie et al (Cui et al., 2017). Thus,
we wanted to develop new hydroquinoxalinone analogues with significantly improved
water solubility and reduced toxicity to achieve higher therapeutic indexes. Upon examining the X-ray co-crystal structure of compound 2a, we designed a new class of pyrimidine analogues with different A rings, namely a) fused heterocyclic-pyrimidines; b) fused
saturated-cycloalkane-pyridines; and c) ring-open substituted pyridine analogues with
hydroquinoxalinone head groups as shown in Figure 5.1. We hypothesize that switching from the fused pyridopyridine tail group to other fused-heterocyclic-pyridine as well
as fused-saturated-hydrocarbon-pyrimidine tail groups would provide two advantages,
namely a) achieving improved water solubility; and b) attaining reduced toxicity while
retaining key hydrogen bonding interactions, one with T-5 loop of α-tubulin monomer
and the other with H-7 helix of the β-monomer mediated by water. Additionally, fused
hydrocarbon ring in the tail group should make these analogues more capable of forming hydrophobic interactions with the predominately hydrophobic pocket in β-tubulin,
thus causing stronger tubulin binding and improved anticancer efficacy. We synthesized
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twenty-two new analogues of compound 2a, tested them for the in vitro anticancer potency against a panel of melanoma and breast cancer cell lines (Table 5.1), determined their
Table 5.1: Cytotoxic effects of new dihydroquinoxalinonepyrimidine
analogues against various human melanoma and breast cancer cell
lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.

mechanisms of action, assessed biological activities, and demonstrated in vivo efficacy of
the three most potent compounds. We have also developed X-ray co-crystal structures for
the four most potent analogues to confirm their direct bindings to the colchicine-binding
site in tubulin. Our study provides insight into the flexibility and possibility of further
structural optimization of dihydroquinoxalinone scaffold.
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Materials and Methods
Cell culture and reagents

Human melanoma cell lines A375, RPMI-7951, M14, M14 multidrug-resistant daughter
line M14/LCC6MDR1, human breast cancer cell lines MDA-MB-231, MDA-MB-453, MDAMB-468 and human lung cancer cell line A549 were purchased from American Type Culture Collection (ATCC, Manassas, VA). Melanoma cells and breast cancer cells were cultured in DMEM (Corning, Manassas, VA) supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis,
MO). A549 cells were cultured with RPMI 1640 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic mixture. Paclitaxelresistant A375/TxR, MDA-MB-231/TxR and A549/TxR cells were developed by the sequential treatment with paclitaxel and maintained in medium with 100 nM paclitaxel at
37 °C in a humidified atmosphere with 5% CO2 . Taxanes were removed from the media a
week before the actual experiment. For biological studies, dihydroquinoxalinone pyrimidine analogues were prepared in DMSO (ATCC) at a stock concentration of 20 mM and
stored in -20 °C in refrigerator. Prior to experiments, stocks were diluted with the proper
culture medium.

5.2.2

Cytotoxicity assay

Depending on their growth rate, cancer cells were seeded at a concentration of 3500-5000
cells per well in 96-well plate. On next day, the culture medium was replaced with the
fresh medium containing the test compounds at concentrations ranging from 0.1 nM to 3
µM in four replicates. After 72 h of incubation, MTS reagent (Promega, Madison, WI) was
added to the each well in dark and incubated at 37 °C for 1-2 h depending on the cell type.
Absorbance was recorded at 490 nm using a microplate reader (BioTek Instruments Inc.,
Winooski, VT). IC50 values were calculated by GraphPad Prism software (San Diego, CA).

5.2.3

Microsomal stability assay

Liver microsomal incubations (1 mg microsomal protein/mL) with human (Corning Life
Sciences, Oneonta, NY), rat, and mouse microsomes (Sekisui XenoTech, Kansas City, KS)
were assessed for compound 5m and verapamil (1 µg/mL), in the presence of NADPH
(Acros Organics, Fair Lawn, NJ) (1 mM). At predefined times (0, 5, 10, 15, 30, 45 and 60
min), aliquots (50 µL) were removed and the reaction was quenched by addition of 200
µL ice-cold methanol containing internal standard. Samples were briefly vortexed and
centrifuged at 3200×g for 5 min at 4 °C. Supernatants were collected and analyzed by LCMS/MS. In vitro half-life and intrinsic clearance were assessed per standard procedures
(Obach, 2001).
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In vivo pharmacokinetics in rats

All animal studies were performed in adherence to the NIH Principles of Laboratory Animal Care and were only initiated after prior approval by the Institutional Animal Care and
Use Committee of the University of Tennessee Health Science Center. Catheterized male
and female Sprague-Dawley rats (225-250 g; Harlan Bioscience, Indianapolis, IN) were
kept at a 12 h light/ dark cycle with access to food and water ad libitum. Groups of 4 rats
(2 male and 2 female) received either a single IV dose of 2 mg/kg of compound 5m by
injection via a femoral vein catheter, or a single oral dose of 5 mg/kg of compound 5m by
oral gavage. The compound was formulated in PEG300 (40%) and water (60%). After drug
administration, blood samples (200 µL) were collected via a jugular vein catheter at up to
10 predefined time points over 24 h. Plasma was immediately separated by centrifugation
(6,000×g for 10 min at 4 °C) and stored at -70 °C until analysis. For urinary excretion, urine
was cumulatively collected after intravenous administration, the volume recorded, and a
specimen stored at -70 °C until analysis.

5.2.5

Quantification of compound concentrations

For quantification of compound 5m concentrations in plasma and urine, samples were processed by protein precipitation with 4 volumes of methanol and analyzed by LC-MS/MS.
Chromatographic separations were carried out on a Phenomenex C18, 2.6 µm, 100 × 4.6
mm column (Phenomenex, Torrance, CA) using a Nexera XR liquid chromatograph (Shimadzu Corporation, Columbia, MD). The mobile phase consisted of a) 95% water and
5% acetonitrile with 2 mM ammonium formate and 0.1% formic acid, and b) 95% acetonitrile and 5% water with 2 mM ammonium formate and 0.1% formic acid. Compound
5m and internal standard [(2-(1 H-Indol-3-yl)-1 H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)]
methanone were eluted in a gradient at 0.5 mL/ min. The eluate was led directly into
an API 4500 triple quadruple mass spectrometer (Applied Biosystem, Foster City, CA)
equipped with a turbospray ion source, operated in the positive ion mode, at a source
temperature of 500 °C with a capillary voltage of 4500 kV. Nitrogen was used as the source
gas, curtain gas, and collision gas. The characteristic mass transfers monitored were m/z
311.1/296.0 for compound 5m and m/z 378.4/210.0 for the internal standard. Concentrations were calculated by weighted least-square regression (1/x2 ) using calibration standards of 5m ranging from 2.93-3000 ng/mL and quality controls at the concentration of
20, 200, and 2000 ng/mL. The obtained plasma concentration-time profiles were analyzed
by standard noncompartmental PK analysis using the software package WinNonlin 8.0
(Certara, Princeton, NJ).

5.2.6

Tubulin polymerization assay

Tubulin polymerization reaction was initiated by adding 100 µL of tubulin protein from
Bovine brain origin (3 mg/mL, Cytoskeleton, Denver, CO) into 10 µM of test compounds
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in general tubulin buffer (80 mM PIPES, 2.0 mM MgCl2 , 0.5 mM EGTA, and 1 mM GTP) according to the manufacturer’s protocol. The reaction kinetics were recorded in every thirty
seconds for 1 h at 37 °C and a microplate reader equipped with absorbance settings at 340
nm wavelength was used for this purpose. The experiment was performed in duplicates.

5.2.7

Immunofluorescence staining

A375/TxR cells (105 cells) were seeded into six-well plates with glass coverslips in each
well and incubated for overnight. 2 nM of colchicine, paclitaxel, 5m or 5t, or 5v (1 nM and 2
nM) were added into the cells and treated for 24 h. Immunofluorescence staining was performed by incubating α-tubulin antibody (Thermo Scientific, Rockford, IL) for overnight at
4 °C and subsequently Alexa Fluor 647 conjugated goat anti-mouse IgG (Molecular Probes,
Eugene, OR) as secondary antibody at room temperature for 1 h. The coverslips were
washed three times with PBS and mounted in a glass slide with DAPI containing Prolong
Diamond Antifade mounting medium (Invitrogen, Eugene, OR). The photographs were
acquired and processed with a Keyence BZ-X700 microscope (Itasca, IL).

5.2.8

X-ray crystallography

Special reagents
Porcine brain tubulin (Catalog#T-238P) was obtained from Cytoskeleton. Bis-Tris propane,
tyrosine, DTT, MES and AMPPCP were purchased from Sigma. Glycerol and antiprotease
cocktail were obtained from Sangon Biotech. β-Mercaptoethanol was obtained from XiYa
Reagent.
Protein expression and purification
The stathmin-like domain of RB3 (RB3-SLD) gene was cloned by the group of Dr. Benoît
Gigant (Université Paris-Saclay, in France), transformed into E. Coli and overexpressed.
Then the bacteria solution was centrifuged and resuspended with lysis buffer (20 mM
Tris-HCl pH 8.0, 1 mM EGTA, 2 mM DTT with the antiprotease cocktail). The supernatant
was collected by centrifugation and purified by anion-exchange chromatography and gel
filtration chromatography. The peak fractions of target protein were finally concentrated
to 10 mg/mL and stored at -80 °C (Charbaut et al., 2001; Dorléans et al., 2009; Yuxi Wang,
H. Zhang, et al., 2016). The plasmid of TTL was a kind gift from Dr Michel O.Steinmetz
(Paul Scherrer Institut, PSI, Switzerland) ,and it was expressed and purified as described
previously (Andrea E. Prota et al., 2013). In brief, the E. Coli were induced in LB medium
overnight at 25 °C with IPTG. Then the cells were collected and lysed by sonication in
the lysis buffer. The lysate was subsequently clarified by centrifugation, followed by the
clarified supernatants were passed over Ni-NTA affinity chromatography and gel filtration
chromatography to purify. The purified protein was finally concentrated to 20 mg/mL
and stored at -80 °C until use. The purity of RB3 and TTL were examined by SDS-PAGE.
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Porcine brain tubulin (Catalog #T-238P, Cytoskeleton, Inc.) was supplied at 10 mg/mL in
G-PEM (General tubulin buffer: 80 mM PIPES pH6.9, 2mM MgCl2 , 0.5 mM EGTA and 1
mM GTP) as a frozen liquid and saved at -80 °C.
Crystallization and crystal soaking
Crystals were grown by the sitting-drop vapor diffusion method. Detailed steps for crystals of T2R-TTL was described as before (Andrea E. Prota et al., 2013; Yuxi Wang, Yu, et al.,
2017). In short, the protein mixtures containing tubulin (10 mg/mL), TTL (20 mg/mL) and
RB3 (10 mg/mL) at the molar ratio of 2: 1.3: 1.2 (Tubulin: RB3: TTL), incubated on ice supplemented with 1 mM AMPPCP, 5 mM tyrosine and 10 mM DTT, and then concentrated
to 20 mg/mL at 4 °C. 1.0 µL protein was used to mix with 1.0 µL crystallization buffer (6%
PEG4K, 5% glycerol, 0.1 M MES, 30 mM MgCl2 , 30 mM MgCl2 , pH 6.7) in order to help
crystal grow. Initial crystals were observed after two days and then the crystal could reach
to the final size around a length of 200-300 µm within 3-5 days. After this, the compound
of 5j, 5k, 5l and 5m, dissolved in DMSO at 10 mM concentration, soak to the crystals. The
crystals were soaked with 5j, 5k, 5l and 5m (0.1 µL) at 20 °C for 12 h. Then the soaked
crystals were quickly dumped into the cryo-protectant (30 mM MgCl2 , 30 mM MgCl2 , 0.1
M MES, pH6.7 contained 20% glycerol) and flash frozen at 100 K for synchrotron X-ray
data collection.
X-ray data collection and structure determination
The crystals of the T2R-TTL-compound complexes were mounted in nylon loops and flashcooled in a cold nitrogen stream at 100K. The diffraction data were collected on beam-line
BL19U1 at Shanghai Synchrotron Radiation Facility (SSRF), Shanghai, China. The data set
was initially processed by the HKL2000 program package (Otwinowski and Minor, 1997).
The previously published T2R-TTL structure (PDB ID: 4I55) was used to determine the
initial phase as the searching model in molecular replacement procedure. The final model
was manually built by using Coot (Paul Emsley and Cowtan, 2004) and all refinements
were performed with phenix refinement module of Phenix program (P. D. Adams et al.,
2002). The model quality was checked with the PROCHECK program, which shows a
good stereochemistry according to the Ramachandran plot.

5.2.9

Clonogenic assay

In case of clonogenic assay, A375/TxR cells were seeded in 6-well plates at very low concentration (1000 cells/well). When each single cell splitted into 4 cells in each well, cells
were treated with 5m, 5t or 5v at different concentrations (0.5 nM, 1 nM and 2 nM) or media only and incubated for 7 days. Medium was replaced with fresh drug once during the
treatment. Cells were then fixed with cold methanol and stained with 0.5% crystal violet.
Colony area density was quantified using the Keyence Hybrid Cell Count module.
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Wound healing assay

The scratch assay was performed with 5m, 5t or 5v treatment (1 nM, 2 nM and 5 nM)
using IncuCyte S3 live cell imager. Briefly, A375/TxR cells (50000 cells/well) were seeded
in 96-well ImageLock plates (Essen BioScience) and allowed to attach overnight. Then a
WoundMaker™ (Essen BioScience) was used to create uniform scratches in all wells and
cell debris was washed away with grow medium for three times. Growth medium or
medium containing 5m, 5t or 5v was added to each well and the plates were monitored
by IncuCyte every 2 hours for up to 2 days. The representative images and the relative
wound density calculation were processed using the IncuCyte™ Scratch Wound Software
Module.

5.2.11

Cell cycle and cell apoptosis analysis

A375/TxR cell were seeded into the 10-cm dishes (2 × 106 /well) and treated with 5m, 5t or
5v at concentrations of 1 nM, 2 nM and 5 nM for 24 h. Cells were trypsinized, washed and
fixed in ice-cold 70% ethanol overnight. Next, the cells were incubated with 100 µg/mL
RNase A for 1 h followed by the staining of propidium iodide. After 5 min of incubation, the samples were analyzed by Bio-Rad ZE5 instrument in the UTHSC Flow Cytometry and Cell Sorting core. Data was processed by ModFit LT™ software (Verity Software
House, Topsham, ME). For cell apoptosis analysis, after the same treatments as in cell cycle
analysis, 105 cells were collected, washed, resuspended in Annexin-V-FITC binding buffer
(eBioscience, Grand Island, NY) and stained with Annexin-V-FITC (eBioscience) and propidium iodide based on the kit instructions. Then the samples were incubated for 10 mins
in dark and analyzed using Bio-Rad ZE5.

5.2.12 In vivo xenograft model
All animal experiments were performed according to the guidelines from the National Institute of Health (NIH) and the Institutional Animal Care and Use Committee at UTHSC
(Memphis, TN). Equivalent numbers of male and female pathogen-free NSG mice (n = 8
mice per group) at age 6-8 weeks of age were maintained under controlled environmental
conditions with 12: 12 hours light-dark cycle in the animal facility. A375/TxR melanoma
cells were suspended in FBS and phenol red-free medium and diluted with Matrigel solution prior to the inoculation. A total of 2 × 106 A375/TxR cells in 100 µL solution were
inoculated in the right flank of each mouse using an insulin syringe. Mice were anesthetized with 2-4% isoflurane inhalation before tumor cell inoculation. The tumor growth
was carefully monitored, and the tumor volume was calculated as a × b2 × 0.5 using a
caliper, where a and b represent the larger and smaller diameter, respectively. Vehicle or
drug treatment was initiated when the tumor reached to around 100 mm3 . Paclitaxel was
dissolved in ethanol and diluted in a 1: 1: 18 ratio of ethanol: Cremophor EL: PBS solution.
5m was formulated in PEG300 solution and further diluted with isotonic saline (ratio 1: 4).
Both paclitaxel (10 mg/kg) and 5m (2 mg/kg and 4 mg/kg) were administered into mice
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intravenously via a tail vein injection every two times per week (2x/Wk) in a total 3-week
time period. In another separate study, the A375/TxR tumor xenograft model was also established in the NSG mice (50% male and 50% female) by following the above-mentioned
protocol (n = 7-8 mice per group). Compound 5t was dissolved in PEG300 solution using
a water-bath sonication and further diluted with sterile saline (PEG300: saline = 3: 7 ratio). The tumor-bearing mice (average 90-100 mm3 tumor volume) were treated with two
different dosage of compound 5t (2.5 mg/kg and 5 mg/kg) by intravenous injection in a
total 7 doses within 24 days. For the xenograft study of 5v, compound 5v was dissolved
in DMSO using a water-bath sonication and further diluted with PEG300, Tween 80 and
sterile saline (DMSO: PEG300: Tween 80: saline = 2: 20: 5: 73 ratio). Mice were dosed
with vehicle, paclitaxel (4 mg/kg) and 5v (2 mg/kg and 4 mg/kg) by intravenous injection with dose frequency as 2 times/week for 23 days. At the end of the study, mice were
euthanized by an overdose with isoflurane and the tumor samples were obtained from the
mice to analyze tumor size and also various histological factors.

5.2.13

Histological and anti-mitochondria IHC staining

Fixed lung, liver and tumor tissues were paraffin-embedded and cut into 4 µm-thick sections. Histological processing of specimens was carried out by dewaxing, staining with
H&E, rehydrating and sealing to attach to glass slides. Anti-mitochondria IHC staining
to visualize metastasis was performed according to previously published protocols (Shanshan Deng, Krutilina, et al., 2020). Briefly, lung and liver slides were stained with antihuman mitochondria antibody (AbCAM, Cambridge, MA, Cat#ab92824) with 1: 1000 dilution overnight after blocking with 10% of horse serum. The following day, the slides
were incubated with secondary anti-mouse antibody, visualized with DAB agent (SigmaAldrich, Cat#D5637), counterstained in Gill’s hematoxylin and mounted with PermountTM
mounting media. Representative tissue images were captured by Keyence BZ-X700 microscope. Representative whole lung or liver images were digitally scanned by a Pannoramic
FLASH III system (3D Histech). Lung or liver metastatic burden of each mouse was quantified by measuring the percentage of metastasis area in 3-4 representative fields per H&E
staining tissue with Keyence Hybrid Cell Count module.

5.2.14

Statistical analysis

All quantitative data were analyzed using GraphPad Prism 7 (San Diego, CA). One-way
ANOVA followed by the Dunnett’s multiple comparison test was applied to all in vitro
experiments and lung & liver metastasis quantification. Significance levels are defined as
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Results
In vitro growth inhibitory effects of novel dihydroquinoxalinone pyrimidine analogues

We designated compound 2a in four ring systems (ring A in red, ring B in purple, ring
C in green and ring D in pink) as shown in Figure 5.1. We were interested in achieving
additional hydrogen bonding with T5 loop of α-tubulin in addition to the one formed between amide group of 2a and α-Thr179 (PDB ID: 6EG6). Thus, we have synthesized 5a-5d,
given fluorine can serve as a hydrogen bonding acceptor. They were tested for cytotoxicity against three human melanoma and three human breast cancer cell lines as shown
in Table 5.1. The mono-fluoro-methoxy analogues, 5a and 5b, are highly potent with 5b
being the most potent across all six cell lines. However, di-fluoro-methoxy analogues, 5c
and 5d, were found to be less potent, suggesting too many electron withdrawing fluorine
substitutions were detrimental to the activity. We then synthesized a fluoro-substitutedtetrahydroquinoline derivative 5e to explore if the methoxide group was necessary for
the antiproliferative activity. The results indicated 5e to be essentially inactive, suggesting that the methoxy moiety in ring D was crucial for activity. We then designed and
synthesized three C-ring opened poly methoxy-substituted D-ring analogues, 5f, 5g and
5h. Trimethoxy-substituted D-ring analogue, 5f, demonstrated no activity. The dimethoxy
analogue, 5g, demonstrated moderate activity with IC50 values in the range of 100-200 nM
(Table 5.1). The 1-3-dioxol analogue, 5h, showed even weaker antiproliferative activity
(Table 5.1).
These findings suggest that the mono-fluoro-methoxy substituted D-ring has the
ideal electronic and steric configuration for the optimal antiproliferative activity. However, we prepared 6-fluoro-7-methoxy-dihydroquinoxalinone derivative, 5i, and found it
inactive against all six cancer cell lines (Table 5.1). It is noteworthy that unlike 5a, the
fluoro group in 5i is not projected towards the T5 loop of the α-tubulin monomer that
is essential to form hydrogen bonding. These findings suggest that the 7-methoxy-3,4dihydroquinoxalinone head group of compound 2a is the best possibility to attain hydrogen bonding with the α-tubulin monomer. Then, we designed and synthesized new
dihydroquinoxalinone analogues with modified A-ring with different fused heterocycles
or fused saturated hydrocarbon rings. The crystal structures of 1a (PDB ID: 6BR1) and
2a (PDB ID: 6EG6) have demonstrated that the ring A (Figure 5.1) of 1a and 2a does not
involve any interaction other than potential hydrophobic interactions and space filling,
given that the pocket accommodating this ring A is relatively hydrophobic. We reduced
the unsaturation in the ring A of the scaffold and introduced an aliphatic ring with the goal
to improve solubility and metabolic stability of the newly designed molecules. Thus, we
synthesized analogues 5j-5p and tested their cytotoxicities in vitro (Table 5.1). Analogues
5j and 5k demonstrated strong cytotoxicity with low nanomolar IC50 values. All three
6,7-dihydrocyclopentapyrimidine analogues (5l-5n) were found to be very potent with 5l
and 5m IC50 values around in single digit nanomolar range against all six cancer cell lines
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(Table 5.1). Particularly, 5m has IC50 values around 1 nM across all six cell lines and it is
also highly water soluble. However, to our surprise, the six membered tetrahydroquinazoline, 5o, with the enlarged ring lost antiproliferative activity (Table 5.1).
Compound 5p was found to be moderately active as well with IC50 value below in
the range of 19-37 nanomolar. Upon these findings, we wanted to explore whether an A
ring fragmented analog would be active. Thus, we prepared two A ring opened pyrimidine analogues, 5q and 5r. Compound 5r was found to be very potent with IC50 values
ranging from 4 nanomolar to 18 nanomolar (Table 5.1). Surprisingly, compound 5q, with
chloro-substituted B-ring, was found to be inactive (Table 5.1). Hence, our findings suggest that the ring A is flexible and could be modified to attain improved potency as well as
water solubility. We then synthesized the pyridopyridine analogue 5s, given the nitrogen
atom at 1-position of 1a and 2a are involved in water mediated hydrogen bonding with the
β-Cys239 and β-Val236 of tubulin. Compound 5s has diminished potency compared to its
pyrimidine counterpart 2a, with IC50 values ranging from 13 to 24 nM. Finally, upon looking at the crystal structure of 2a (PDB ID: 6EG6), we have found that the chlorine atom,
attached to the B-ring, is located in a pocket between β-H7 and β-T7 loop. The pocket is hydrophobic in nature and has more free space to allow further synthetic modification. Thus,
we designed and synthesized two ethylamine substituted B-ring analogues of 2a, 5t and
5u. We hypothesized that the ethylamine moiety would be able to form hydrogen bonding
with the β-H7 and β-T7 backbone as well as help improve water solubility of those analogues for better efficacy in vivo. Cytotoxic evaluation results showed that 5t was potent in
inhibiting the proliferation of cancer cells with an average IC50 of 1 nM. Based on the structures of two of the most potent compounds, 5m and 5t, we designed and synthesized the
compound 5v (Figure 5.1), which turned out to be the most potent analogue with average
IC50 of 0.6 nM among 3 melanoma and 3 breast cancer cell lines.
Since a major clinical limitation for existing tubulin inhibitors such as taxanes is
their high susceptibility to efflux pumps, we evaluated the potency of three of the most
potent dihydroquinoxalinone analogues, 5m, 5t and 5v, in additional cancer cell lines
(A375/TxR, M14/LCC6MDR1 and MB-231/TxR) that are highly resistant to taxanes (Table
5.2). Paclitaxel, colchicine, and verubulin have been used as the controls for the side by side
comparison. Unlike paclitaxel which significantly lost potency in these cell lines, 5m, 5t,
5v and verubulin retained their potency (Table 5.2). The IC50 values of the compounds 5m,
5t and 5v ranged from 0.3 to 1.4 nanomolar against taxane-resistant melanoma and breast
cells. It is conceivable from the Table 5.2 that the compounds 5m, 5t and 5v are almost as
potent as the verubulin against taxanes resistant cell lines.
A major obstacle in drug discovery is the inadequate in vivo stability of compounds
which leads to the rapid loss of pharmacological activity. Therefore, we wanted to see if
the above modifications which improved the potency of the analogs, would also improve
metabolic stability. We first determined the microsomal metabolic stability of compound
5m in mouse, rat and human liver microsomes (Table 5.3). The results indicated that com-

Chapter 5. Antitumor Efficacies of Metabolically Stable Cyclopenta-pyrimidinyl
Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors

Table 5.2: Cytotoxic effects of 5m, 5t and 5v against resistant melanoma
and breast cancer cell lines.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.

Table 5.3: In vitro metabolic stability of compound 5m in human, rat and
mouse liver microsomes.1,2

1
2

the values in parentheses indicate %CV.
Verapamil was used in this study as an assay control.
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pound 5m had acceptable microsomal stability that was substantially higher in humans
compared to rodents. We subsequently performed an in vivo PK study for compound 5m
in rats after intravenous and oral administration (Table 5.4). While the low cumulative
Table 5.4: Pharmacokinetic parameters of compound 5m after
intravenous and oral administration to Sprague-Dawley rats.1

1

the numbers in parenthesis indicate %CV.

uronary excretion in unchanged form indicated a high degree of metabolic conversion, the
in vivo terminal half-life remained with 14.7 h long, most likely due to the large volume
of distribution. The systemic exposure quantified as area under concentration-time curve
was on a per mg dose basis nearly twice as high as what has been observed for verubulin
in mice (Sirisoma et al., 2009). Oral bioavailability, however, remained limited with 3.2%.

5.3.2

Inhibition of tubulin polymerization

To determine if the new structurally modified compounds are exhibiting potent antiproliferative activities due to their binding to microtubules, we first performed the cell-free
tubulin polymerization assay with three most potent compounds, 5m, 5t and 5v, as well as
the reference compounds, colchicine and paclitaxel. As shown in Figure 5.2A, compounds
5m, 5t and 5v significantly inhibited microtubule polymerization, similar to colchicine
serving as a positive control. The negative control paclitaxel showed the expected accelerated microtubule nucleation and growth, thus, causing polymerization enhancement. In
agreement with the tubulin polymerization assay, compound 5m, 5t and 5v demonstrated
the soluble cytoplasmic tubulin that associated with microtubule fragmentations, resulting
in heavy disruption in microtubule dynamics in interphasic A375/TxR cells (Figure 5.2B),
and the efficacy of 5v to inhibit microtubule depolymerization was the strongest among all
three compounds, which only required 1 nM to function. While cells in the vehicle control
group, during interphase, were observed with regular microtubule network that wrapped
towards the nucleus with uncondensed chromosomes. Colchicine or paclitaxel treated cell
also showed the intact tubulin network with normal filamentous arrangement at the concentration of 2 nM. Compared with the mitotic cells which had normal functioning mitotic
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Figure 5.2: Binding patterns of dihydroquinoxalinone pyrimidine
analogues with tubulin and their localization within the cell. (A) Tubulin
polymerization assay of 5m (10 µM), 5t (10 µM) and 5v (10 µM) using
tubulin protein from Bovine brain origin. Identical concentration of
paclitaxel and colchicine were used in this assay as standard controls. (B) A
comparison between the morphology and α-tubulin distribution of
A375/TxR melanoma cells in interphase (top) and mitosis (bottom) after
treatment with colchicine (2 nM), paclitaxel (2 nM), 5m (2 nM), 5t (2 nM)
and 5v (1 nM and 2 nM) in vitro.
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spindles in control, colchicine or paclitaxel group, 2 nM of 5m-treated cells appeared defects in the assembly of the mitotic spindle with the formation of multipolar spindles and
misaligned chromosomes. Similar results were observed in mitotic cells with 2 nM of 5t
treatment or 1 nM of 5v treatment.

5.3.3

X-ray crystallographic analyses of compounds 5j, 5k, 5l and 5m in complex with tubulin

To further validate the molecular interactions of the designed analogues with the colchicinebinding site, we determined the tubulin crystal structures in complex with 5j, 5k, 5l and
5m. These crystal structures demonstrated that the designed analogues bound to the
colchicine-binding site as expected (Figure 5.3). All four designed analogues possessed
the similar binding orientations as our previously published tubulin inhibitor analogues,
6a (Figure 5.3A and B) and 2a (Figure 5.1), with A and B rings deep into the β-tubulin
pocket and the C and D rings in the interface with α-tubulin (Figure 5.3C-J). Most of the
molecular interactions of the co-crystallized ligands with the tubulin are hydrophobic in
nature, including β-Ala352 from the sheet S9, β-Ala314, β-Ile368 and β-Ile316 from the sheet
S8, β-Leu253 and β-Met257 from the helix H8, β-Leu246 and β-Ala248 from the loop T7, βLeu240, β-Cys239 and β-Val236 from the helix 7, as observed for the compounds 1a and
2a. The NH group, from the amide moiety of C-ring, acts as a hydrogen bond donner
and forms a H-bonding with the backbone carbonyl group of α-Thr179 from the loop T5.
The carbonyl group of amide moiety in C-ring forms an additional water mediated hydrogen bonding with the α-Thr179 and α-Asn101 from the loop T5, as observed in 2a. Two
of the compounds, 5j and 5m, have also retained a water mediated H-bonding between
the N-atom in B-ring as well as β-Cys239 and β-Val236 from the helix 7. However, unlike
compounds 1a and 2a, all the newly determined co-crystallized structures present a new
H-bonding between α-Ser178 from loop T5 and β-Lys350 from the sheet S9. Hence these
findings suggest that the new analogues with hydrophobic A-ring as well as amide C-ring
have stronger interactions with both α- and β-tubulin monomers and, thus, bring them
closer together to a tighter conformation leading to a possibility of H-bonding between
residues from α- and β-monomers. It is noteworthy that the co-crystal structure of 5m
presented two H-bonding between β-Lys350 side chain and the side chain as well as the
carbonyl backbone of α-Ser178 leading to tightest binding of 5m to the colchicine-binding
site compared to other ligands. The strongest binding of 5m to the tubulin stands by the
experimental findings of low single digit nano molar IC50 values (1-5 nM) against different regular and paclitaxel-resistant melanoma, breast as well as lung cancer cell lines. In
mechanistic point of view, it is conceivable that the binding at the α- and β-tubulin interface of the colchicine-binding site keeps the α/β-tubulin dimer from adopting a straight
conformation required for the polymerization to result in functional microtubules for cell
division. The typical characteristics of CBSIs is to effectively block the straight conformation of tubulin and these findings are in concert with CBSIs. Hence, these findings suggest
that the dihydroquinoxalinone analogues with saturated hydrophobic A-rings (5l and 5m)

Chapter 5. Antitumor Efficacies of Metabolically Stable Cyclopenta-pyrimidinyl
Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors

Figure 5.3: X-ray co-crystal structures of tubulin-RB3-SLD-TTL proteins
in complex with 5j, 5k, 5l and 5m. Panels A-J show complexes with 6a
(panel A and B), 5j (panel C and D), 5k (panel E and F), 5l (panel G and H),
and 5m (Panel I and J). Panels K-N show colchicine bound tubulin complex
superimposed with the 5j (Panel K), 5k (panel L), 5l (panel M), and 5m
(panel N). The tubulin α-monomer is shown in gold, and the β-monomer is
shown in green for panels A-J.
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have stronger binding than the previously published 1a as well as 2a resulting in potentially improved antitumor efficacy.

5.3.4

Inhibition of colony formation and migration of taxane-resistant melanoma cells

Based on the results of cytotoxic effects of dihydroquinoxalinone analogues against diverse
regular as well as taxane-resistant cancer cell lines (Tables 5.1 and 5.2), the three most potent analogues, 5m, 5t and 5v, were selected to perform the further in vitro and in vivo experiments to investigate the anticancer mechanisms against A375/TxR cells. Since cancer
cells proliferate through forming colonies, thus, repressing colony formation was regarded
as a key attribute of good anticancer drugs. The clonogenic assay was carried out to investigate if 5m, 5t and 5v had the potency to inhibit colony formation. As displayed in Figure
5.4, the newly synthesized compounds suppressed the colony formation of A375/TxR cells

Figure 5.4: Effects of compounds 5m, 5t and 5v on clonogenic assay.
Representative colony formation images of A375/TxR cells after the
treatment of 5m (A), 5t (B) and 5t (C) with various concentrations for a
week. Colony formation rate is expressed as % of colony area density ±
SEM. *p = 0.0147, ***p = 0.0004, ****p < 0.0001.
in a concentration-dependent manner. Compared with the control group, compounds 5m,
5t and 5v demonstrated the reduction of the number and size of colonies and suppressed
the cell growth for a long exposure time (7 days) even at a very low concentration (1 nM
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for 5m and 5t and 0.5 nM for 5v). Compounds 5m, 5t and 5v completely inhibited the
colony formation at high dose, i.e. 2 nM (Figure 5.4).
As cancer cell migration is very essential in the tumor progression and metastasis, and metastasis is the most common contributing factor leading to the high mortality
rates in cancer patients (Yachida et al., 2010), we analyzed the ability of compounds 5m,
5t and 5v in inhibiting the migration of A375/TxR cells by using wound healing assay. As
shown in Figure 5.5A, after 24 h of wounding the cell monolayer, DMSO-treated control

Figure 5.5: Effects of compounds 5m, 5t and 5v on A375/TxR cell
migration. Scratches were created by the wound maker. Representative
images of wound healing were captured by IncuCyte after 12 h or 24 h
treatment with 5m (A), 5t (B) and 5v (C), and blue lines demonstrates the
wound edges of cell monolayer. Wound closure is shown as the percent of
relative wound density at each time point.
cells filled the wounded area, while the wound in the 2 nM or 5 nM 5m treated cells healed
slowed than that in the control group. The 5 nM of 5m markedly inhibited the migration
of A375/TxR cells even after incubation for 12 h. Similarly, 5t treatment also had strong
capacity to suppress the A375/TxR cell migration, and its potency was equivalent to 5m
(Figure 5.5B). For compound 5v, it was able to remarkedly inhibit the A375/TxR cell migration at the concentration of 2 nM, which was more effective than either 5m or 5t (Figure
5.5C). Collectively, above results indicated that 5m, 5t and 5v were potent to inhibit the
colony formation and migration of cancer cells.
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Compounds 5m, 5t and 5v treatment cause G2/M cell cycle arrest and cell
apoptosis of A375/TxR cells

Considering the pivotal role of the inhibition of microtubule polymerization in disrupting
cell cycle progression and the mitotic spindle defects observed in 5m, 5t and 5v-treated
A375/TxR cells (Figure 5.2B), a flow cytometry-based cell cycle analysis was performed to
evaluate the effects of 5m, 5t and 5v on cell mitosis (Clarke and Allan, 2009). A375/TxR
cells were treated with compound 5m, 5t or 5v at different concentrations (1 nM, 2 nM and
5 nM) for 24 h without serum starvation. As depicted in Figure 5.6A, in comparison with
a normal cell cycle distribution (G1: 48%; S: 33%; G2/M: 19%) in the control cells, 5m, 5t or
5v treatment induced the significant cell cycle arrest at the phase of G2/M concentrationdependently. At the concentration of 2 nM, 5m, 5t and 5v arrested the A375/TxR cells in
G2/M phase with the percentage of 60%, 64% and 73% respectively. The above results
demonstrated that 5m, 5t and 5v could potently induce cell cycle arrest at G2/M phase
against A375/TxR cells and affect the cell mitosis even without serum starvation.
When we analyzed the cell cycle distribution using the ModFit LT™ software, we
observed a significant apoptosis peak in subG1 region (we gated this cell population out
to quantify the percentage of cells in G2/M phase correctively in Figure 5.6A) after 24 h of
treatment with 5m, 5t or 5v. Thus, we performed the Annexin V-FITC/PI staining assay
to verify the effects of 5m, 5t and 5v on cell apoptosis induction in A375/TxR cells using
the same treatment as in cell cycle analysis. The total percentage of apoptotic cells was
namely the sum of the early and late apoptotic cells versus the total number of cells. It can
be observed from Figure 5.6B that the percentage of apoptotic cells after 24 h treatment
was only 9% in the control group, while the apoptotic cells increased to 30%, and 33% and
41%, individually, after the treatment with 2 nM of 5m, 5t or 5v. Additionally, compounds
5v induced the cell apoptosis of A375/TxR in a concentration-dependent manner. Taken
together, compounds 5m, 5t and 5v could significantly cause the apoptosis of tumor cells,
which were consistent with their activities in antiproliferation and cell cycle arrest.

5.3.6

In vivo experiments with compounds 5m, 5t and 5v against A375/TxR
xenograft models

To determine whether the dihydroquinoxalinone pyrimidine analogues had the potential
for the cancer treatment in vivo, compound 5m, 5t and 5v were selected as representative
compounds for treating tumor in A375/TxR xenograft models. A375/TxR melanoma cells
were developed to become resistance against paclitaxel therapy. Thus, this tumor model
might be very useful to study the therapeutic benefits of newer agents over the existing
therapy in where acquired drug resistance is a major problem. We found that 5m treatment strongly inhibited the A375/TxR melanoma tumor growth in a dose-dependent manner (Figure 5.7A). At a dose of 4 mg/kg, 5m significantly suppressed the tumor growth
throughout the study period (p = 0.0452). Treatment with 2 mg/kg of 5m also resulted in
the tumor reduction of 70.5% compared with the control, which was slightly lower than
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Figure 5.6: Compounds 5m, 5t and 5v induce G2/M phase cell cycle arrest
and cell apoptosis in A375/TxR cells. (A) Cell cycle analysis of
compounds 5m, 5t and 5v against A375/TxR cells. A375/TxR cells were
incubated with 1 nM, 2 nM and 5 nM of 5m, 5t or 5v for 24 h without
serum starvation. Quantification of cell cycle distribution was analyzed by
GraphPad based on two independent experiments in triplicate. (B)
Induction of cell apoptosis by compounds 5m, 5t and 5v. A375/TxR cells
were treated with 5m, 5t or 5v for 24 h with the concentration range in A.
The histograms on the right represent the percentage of the sum of the
early and late apoptotic cells of two independent experiments in triplicate.
***p = 0.0001, ****p < 0.0001 vs. control.
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Figure 5.7: Dihydroquinoxalinone pyrimidine analogue 5m inhibits the
tumor growth in A375/TxR xenograft study. 10 mg/kg of paclitaxel
treatment was included as the reference control. 5m was intravenously
administered with two different doses (2 and 4 mg/kg) for every 2 times
per week. Similarly, paclitaxel was administered at a dose of 10 mg/kg (IV)
with the same frequency as 5m. Tumor growth of the injected tumor (A)
and the mice body weight (B) were measured during the therapy. After 21
days of treatment, the tumors were excised, and the final tumor weight
was measured (C) and the image with all tumors was captured (D). The
significant differences between groups were determined by one-way
ANOVA followed by Dunnett’s multiple comparison test. (*p < 0.05, ****p <
0.0001 vs. control). Data = mean ± SD.
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that of 4 mg/kg (88.2% vs. control). As expected, paclitaxel therapy was ineffective and
showed the similar tumor growth trend with vehicle-treated group, suggesting the drug
resistance. Individual mouse body weight was monitored during study. And the results
showed consistent body weight gain without any obvious adverse reactions caused by
the test compound (Figure 5.7B). At the study endpoint, the tumors were collected and
weighed. The tumor weight in mice treated with 2 mg/kg and 4 mg/kg of 5m were decreased 76.7% and 91.8%, respectively, in comparison with that in vehicle group (Figure
5.7C and D). However, comparatively higher dose of paclitaxel (10 mg/kg) showed no
benefits in tumor weight reduction.
The in vivo antitumor efficacy of compound 5t was also assessed in the same A375/TxR melanoma model, where paclitaxel treatment was used as positive control. Since the
IC50 of 5t (1.3 nM) is a little bit higher than 5m (1.1 nM) in A375/TxR cells, we increased
the dose of 5t treatment in mice-bearing A375/TxR tumors to 2.5 mg/kg and 5 mg/kg.
Both 2.5 mg/kg and 5 mg/kg of 5t treatments demonstrated superior antitumor efficacies
in contrast to the control and paclitaxel treatment groups (Figure 5.8A). Compared to the
vehicle-treated group, treatment with 2.5 mg/kg and 5 mg/kg of 5t decreased the final
A375/TxR tumor volume in mice as a ratio of 64.6% and 78.4% (p = 0.0374), respectively.
It was important to note that there was no marked difference in body weight between
different treatment groups compared to control (Figure 5.8B). Furthermore, compound 5t
was dose-dependently reduced the tumor weight of mice (67.4% of decrease in 2.5 mg/kg
and 78.7% decrease in 5 mg/kg treatment group versus vehicle group), and the results
were significant (p< 0.0001) (Figure 5.8C). The picture of all tumors in this study further
confirmed the potency of 5t in vivo (Figure 5.8D). Taken together, compound 5t demonstrated the enhanced antitumor efficacy against paclitaxel-resistant melanoma model without clear side effects.
Since the in vitro antiproliferative activity of 5v was more potent than 5m or 5t, and
5m showed stronger antitumor activity than 5t in A375/TxR xenograft model, we further
evaluated the in vivo efficacy of 5v using the same doses as 5m xenograft model. Inconsistently, the dose of paclitaxel used here was 4 mg/kg, which was similar to the higher dose
of 5v. After 6 times of IV injections, as displayed in Figure 5.9A, treatment with 2 mg/kg
or 4 mg/kg of 5v notably inhibited the tumor growth of A375/TxR xenografts, while 4
mg/kg of paclitaxel treatment had no significant effect in suppressing A375/TxR tumor
growth. There was no body weight loss observed in the treatment groups, indicating the
absence of acute toxicity caused by 2 mg/kg of 5v or 4 mg/kg of 5v treatments (Figure
5.9B). At the end of the experiment, the ex vivo tumor volume and tumor weight measurements demonstrated that 2 mg/kg of 5v inhibited the tumor growth by 62.3% decrease in
tumor volume and 47.4% in tumor weight, and 4 mg/kg of 5v inhibited the tumor growth
by 76.6% decrease in tumor volume and 61.3% in tumor weight (Figures 5.9C and D). The
photographs of excised tumors further confirmed the in vivo potency of 5v in inhibiting the
A375/TxR tumor growth (Figure 5.9E). When collecting the major organs, we detected the
existence of lymph node metastasis in A375/TxR-bearing mice by the side of tumor. Thus,
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Figure 5.8: Dihydroquinoxalinone pyrimidine analogue 5t inhibits the
tumor growth of A375/TxR xenografts in NSG mice. The mice were
treated with intravenous injections with 2.5 mg/kg or 5 mg/kg of 5t for
every 2 times per week. Paclitaxel-treated group (10 mg/kg) was used as
positive control. (A) Tumor growth curve of inoculated A375/TxR
xenografts. (B) Changes of mice body weight. (C) Final tumor weight at
the study endpoint. (D) Representative tumor images in this study. Data
are presented as the mean ± SD. *p < 0.05, ****p < 0.0001 vs. control, as
analyzed by one-way ANOVA followed by Dunnett’s multiple comparison
test.
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Figure 5.9: Compound 5v inhibits the growth of A375/TxR xenografts
following a dose-dependent manner. We used 4 mg/kg of paclitaxel
treatment group as a control in this study. The mice were treated with
intravenous injections with vehicle, 4 mg/kg paclitaxel, 2 mg/kg 5v or 4
mg/kg 5v for every 2 times per week. During the treatment, tumor
volumes (A) and body weights (B) of mice were recorded and plotted
relative to the treatment days. At the study endpoint, excised tumor
volume ± SD (C) and tumor weight ± SD (D) were measured, and the
tumor individual images were taken and shown in (E). Images of
A375/TxR lymph nodes (F) were acquired when terminating the study.
***p < 0.001, ****p < 0.0001 vs. control, as analyzed by one-way ANOVA
followed by Dunnett’s multiple comparison test.
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we collected all the lymph nodes and imaged them (Figure 5.9F). Results showed that 5v
was able to inhibit the lymph node metastasis in a dose-dependent manner, implying the
potential role of 5v in the inhibition of spontaneous melanoma metastasis and 5v deserves
further investigations.

5.3.7

Compounds 5m and 5t treatment induce tumor necrosis in vivo

Due to the strong effects of compounds 5m and 5t on cell apoptosis induction observed
in vitro, we next explored the disruptive effects of 5m and 5t in vivo using tumors in
A375/TxR xenograft models as exhibited in Figures 5.7 and 5.8. After measurement and
imaging, tumors were fixed in 10% buffered formalin, embedded in paraffin and sectioned
for H&E staining. As displayed in Figure 5.10, in vehicle-treated group, the tumor cells

Figure 5.10: Necrosis in A375/TxR tumors caused by 5m or 5t treatment.
Tumors were harvested, fixed, embedded, sectioned and stained with
H&E, slides from 5m xenograft model (up panel) and 5t xenograft model
(bottom panel) were scanned by a Pannoramic FLASH III system and
representative images were captured using CaseViewer.
exhibited a normal shape with a round and intact nucleus, and the tumor cells arranged
tightly and constantly. Paclitaxel-treated tumor cells showed similar cell morphology and
distribution. However, after 5m or 5t treatment, tumor cells arranged loosely and unevenly, and extensive necrotic area with several necrotic cells could be observed clearly in
tumors. And the tumor necrosis area increased in a dose-dependent manner. Altogether,
these results confirmed the potent antitumor ability of 5m and 5t.
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Compounds 5m and 5t treatments inhibit spontaneous lung and liver
metastasis

Malignant melanoma is a dangerous disease with aggressive potential for metastasis, a
process that tumor cells spread from a primary site to visceral organs. One major step
of metastasis is the developments of tumor microenvironments in visceral organs that are
suitable for the survival and growth of tumor cells (Peinado et al., 2017; Qin et al., 2020).
Many studies reported that a spontaneous metastasis xenograft model was widely used to
study this critical step of metastasis, such as the occurrence of pulmonary or brain metastasis cause by melanoma (Wicklein et al., 2018; Gener Lahav et al., 2019; Ben Baruch et al.,
2018). To investigate the effects of compounds 5m and 5t in inhibiting the spontaneous
melanoma metastasis in vivo, we utilized the lung and liver tissues of above A375/TxR
subcutaneous xenograft models in which spontaneous lung metastases would occur. First,
H&E staining of lung tissues of 5m xenograft model was performed. As shown in Figure D.1A, multiple macrometastases (yellow arrows) were observed in the control group,
indicating severe melanoma lung metastasis. While 5m-treated group displayed limited
number of metastases with smaller size, and 5m treatment suppressed the lung metastasis
dose-dependently. Paclitaxel treatment group was used as the positive control. It had no
effect on the lung spontaneous metastasis compared to the vehicle treatment. The quantitative analysis of tumor burden in the lungs further confirmed the inhibiting effect of 5m
on the migration of metastatic tumor cells (Figure 5.11A). Since liver is another major organ for tumor cells to seed on and grow, we also did the H&E staining of liver tissues in
this study. Similarly, the reduction of metastases on the hepatic surface in the 5m treatment
group confirmed the efficacy of 5m in repressing the spontaneous migration of melanoma
(Figures D.1B and 5.11B). Of note, the livers of 4 mg/kg 5m-treated mice were all clean,
suggesting the strong inhibiting effect of 5m on liver metastasis. Significant inhibition of
tumor migration by 5m treatment was further confirmed by the reduced density (brownstained tissues) of anti-human mitochondria immunostains in lung or liver sections, which
were consistent with the results obtained through H&E staining (Figures 5.11C and D and
D.2). Due to the promising data acquired from 5m xenograft model, we also did the H&E
staining for the lung and liver tissues in 5t xenograft model. In accordance with the final tumor weight, relative to the control or paclitaxel group from 5m xenograft model,
the number of lung and liver metastases increased in the control or paclitaxel group from
5t xenograft model, validating the tumor progression difference between two xenograft
models (Figures D.3 and 5.12A and B). H&E staining results exhibited the strong effect of
5t treatment on suppression of lung and liver metastasis following a dose-dependent manner. Moreover, the anti-human mitochondria IHC staining also showed the metastases in
5t-treated mice were sparse and smaller, and when the dose of 5t increased, the number
and size of metastases decreased (Figures 5.12C and D and D.4). Collectively, these data
support the roles of 5m and 5t as potent tubulin-destabilizing agents in the inhibition of
melanoma spontaneous metastases into the lungs and livers of mice.
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Figure 5.11: 5m displays anti-lung and liver spontaneous metastases
effects in A375/TxR subcutaneous xenograft model. The number of lung
(A) or liver (B) metastases were counted in all the mice by averaging the
percentage of metastatic area of 3 to 4 representative H&E images of each
mouse (****p < 0.0001 vs. control). The anti-human mitochondria IHC
staining of lung (C) and liver (D) tissues confirmed the presence of
melanoma metastases in vehicle or paclitaxel-treated mice and the
metastases were reduced with 5m treatment. Images were acquired by
Keyence BZ-X700 microscope. Brown staining indicates the metastases.
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Figure 5.12: In vivo efficacy of 5t in lung or liver spontaneous metastasis.
Scatter plots of mean ± SEM show the quantification of metastases present
in the lung (A) and liver (B) through counting the average of the
percentage of metastatic area in 3 to 4 representative H&E images of each
mouse (*p = 0.016, ****p < 0.0001 vs. control). Immunohistochemical
staining for anti-human specific mitochondria to detect metastases in lung
(C) and liver (D) sections. Images were acquired by Keyence BZ-X700
microscope. Brown staining indicates the metastases.
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Discussion and Conclusion

In summary, we have reported the design, synthesis and potency of new dihydroquinoxalinone pyrimidine analogs. The newly synthesized compounds demonstrated strong anticancer potency in a multitude of cancer types, including melanoma, lung, breast cancer
cell lines. They share trademark characteristics with other potent antimitotic agents such
as inducing G2/M phase cell cycle arrest and promoting apoptosis. We also report highresolution crystal structures for representative compounds 5j, 5k, 5l and 5m, providing
insight into the direct binding to the colchicine site in tubulin as well as demonstrating
their molecular interactions to tubulin proteins. Compounds 5j and 5m have been observed to make a new hydrogen bond with α-Thr179 from α-T5 loop while retaining the
water mediated hydrogen bonding with β-Cys239 and β-Val236 from β-H7 helix, in which
we observed from our previous finding (S. Banerjee et al., 2018). Additionally, all the
newly determined co-crystallized structures present a new H-bonding between α-Ser178
from loop T5 and β-Lys350 from the sheet S9. These X-ray crystallography findings suggest
that the new analogues with hydrophobic A-ring as well as amide C-ring have stronger interactions with both α- and β-tubulin monomers and, thus, bring them closer together to a
tighter conformation leading to a possibility of H-bonding between residues from α- and
β-monomers. Compound 5m, in particular, presented two H-bonding between β-Lys350
side chain and the side chain as well as the carbonyl backbone of α-Ser178 leading to tightest binding to the colchicine-binding site compared to other ligands. Based on the preliminary result, compounds 5m, 5t and 5v demonstrated the most promising efficacy on
cytotoxicity, cell proliferation and migration assay. In addition, compound 5m displayed
promising in vivo PK behavior with good systemic exposure and long terminal half-life,
as well as good water solubility. Thus, we selected compounds 5m, 5t and 5v for evaluation of antitumor efficacy using A375/TxR melanoma xenograft model in mice. All the
compounds 5m (Figure 5.7), 5t (Figure 5.8) and 5v (Figure 5.9) strongly reduced the tumor growth in a dose-dependent manner and also showed significantly enhanced tumor
inhibition compared with the paclitaxel-treated mice. The doses of 4 mg/kg of compound
5m and 5v, and 5 mg/kg of compound 5t displayed the highest tumor reduction among
all groups without any significant loss of body weight in mice. Compounds 5m and 5t
strongly induced tumor necrosis in vivo in a dose-dependent manner with tumor cells arranged loosely and unevenly, and extensive necrotic areas with several necrotic cells were
clearly visible in tumors. Finally, compounds 5m and 5t were observed to significantly
reduce the melanoma spontaneous metastasis into lungs and livers of mice, which were
unlike the paclitaxel treatment group. These studies demonstrate the potential of 5m, 5t
and 5v as potent anticancer agents, provide proof-of-concept for their mechanisms of action, and reveal the structural basis to support the continued development for these lead
compounds as tubulin inhibiting chemotherapeutic agents.

138

Chapter 6
Summary and Future Direction

Triple negative breast cancer accounts for ~15% of all breast cancers in the United States.
TNBC has poorer overall prognosis relative to other molecular subtypes, due to the rapid
development of drug resistance to conventional chemotherapies and the increased risk of
visceral metastasis. A standard treatment regimen for TNBC is a taxane-based chemotherapy, such as paclitaxel, which stabilizes microtubules. However, drug resistance and
hematologic and neurotoxicities often limit taxane clinical efficacy. Thus, there is an urgent
need to develop new effective therapies to overcome drug resistance. Extensive preclinical
studies have suggested that tubulin inhibitors targeting the colchicine-binding site are significantly less vulnerable to transporter-mediated drug resistance. Several of these agents
are entering into clinical trials, indicating the importance of developing new anticancer
agents that bind to the colchicine-binding site for effective cancer chemotherapy.
In Chapter 2, we first evaluated the preclinical efficacy of a novel, potent, and orally
bioavailable tubulin inhibitor, VERU-111, in taxane-sensitive TNBC models. VERU-111
showed potent cytotoxicity against TNBC cell lines, inducing apoptosis and cell-cycle arrest in a concentration-dependent manner. VERU-111 also efficiently inhibited colony formation, cell migration, and invasion. In addition, orally administered VERU-111 suppressed the growth of MDA-MB-231 xenografts in a dose-dependent manner with efficacies similar to paclitaxel, but without acute toxicity. VERU-111 significantly reduced
metastases originating from the mammary fat pad and visceral metastasis in a separate
experimental metastasis model. To better understand the effect of VERU-111 on taxaneresistant TNBC, we developed taxane-resistant TNBC cell sublines, namely MDA-MB231/TxR, MDA-MB-468/TxR, SUM159/TxR, with acquired resistance by exposing paclitaxel continually. MTS assay confirmed that VERU-111 maintained the potency against all
taxane-resistant sublines. We further investigated the underlying mechanism of action of
VERU-111 and found that it inhibited taxane-resistant TNBC cell proliferation by inducing
mitotic arrest and apoptosis via disruption of microtubule stability. Moreover, relative to
paclitaxel, orally administered VERU-111 effectively inhibited the tumor growth in two aggressive taxane-resistant TNBC xenograft models, including a taxane-resistant PDX model.
VERU-111, but not paclitaxel, significantly repressed the growth of preestablished axillary
lymph node metastases and endpoint metastasis in mice bearing HCI-10-Luc2 xenografts,
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suggesting VERU-111 is a promising drug candidate for the treatment of taxane-resistant
TNBC. Taken together, our data demonstrate that VERU-111 is a new generation of oral
tubulin inhibitor that potently inhibits the growth of taxane-sensitive and taxane-resistant
TNBC.
In Chapter 3, we performed the efficacy evaluation of a novel series of pyridine
analogues of VERU-111, also termed 6-aryl-2-benzoyl-pyridines, for cancer therapy. We
tested the antiproliferative activities of over 40 ABP analogues and found compound 4v
was the most potent compound against 3 melanoma and 3 breast cancer cell lines. Tubulin polymerization assay and X-ray crystal studies confirmed that 4v targeted the tubulin
and inhibited tubulin polymerization. We then showed that 4v suppressed the melanoma
tumor growth by using a subcutaneous melanoma xenograft model, and 4v was able to
induce tumor necrosis, disrupt tumor angiogenesis and lead to tumor cell apoptosis in
vivo. Inspired by the potency observed on melanoma, we further evaluated the effect of
4v on TNBC cells. Results showed that 4v could inhibit colony formation, migration and
invasion of TNBC cells, and it induced G2/M arrest and apoptosis of two TNBC cell lines
significantly. We also evaluated the efficacy of 4v in an orthotopic TNBC mouse model in
vivo. As expected, 4v inhibited the growth of TNBC xenografts significantly following a
dose-dependent manner and it was able to inhibit spontaneous TNBC metastasis.
In Chapter 4, based on the structure of 4v, we made a series of modifications focusing on increasing the metabolic stability of ABPs, while at the same time maintaining
or improving their antiproliferative activities because PK studies showed that 4v had low
bioavailability and low metabolic stability. Among all the analogues synthesized, compound 60c was the most active compound with an average IC50 value of 2.4 nM against all
cancer cell lines tested. In addition, its half-life time in human liver microsomes was ~42
min, which was longer than 4v (10 min). We then determined the high-resolution X-ray
crystal structure of 60c in complex with tubulin and confirmed its direct binding at the
colchicine site. Further in vitro studies showed that 60c was effective against P-gp mediated multiple drug resistance and taxane resistance, and it was able to inhibit the colony
formation of taxane-resistant cancer cells, arrest cells in the G2/M phase and induce cell
apoptosis. When assessing its in vivo potency, we used one new taxane-resistant A375/TxR
subcutaneous xenograft model. 60c exhibited a strong inhibitory effect on tumor growth
without obvious toxicity. And it suppressed the lung and liver metastasis originating from
the subcutaneous tumors. Together, our results substantiated that compound 60c was a potent colchicine-binding site tubulin inhibitor with limited systemic toxicity and may serve
as a good drug candidate in cancer treatment.
In Chapter 5, we evaluated the efficacies of hydroquinoxalinone analogues, which
represent another interesting class of anti-tubulin compound targeting colchicine-binding
site. Previous studies have shown that compounds with hydroquinoxalinone structures
had sub-nanomolar potency against a panel of cancer cell lines with significantly improved
metabolic stability, while these compounds were found to have poor water solubility and
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toxicity leading to loss of body weight and death of mice. Thus, we wanted to develop new
hydroquinoxalinone analogues with significantly improved water solubility and reduced
toxicity to achieve higher therapeutic indexes. Upon examining the X-ray co-crystal structures, the chemist synthesized 21 new analogues, which were further tested for the in vitro
antiproliferative potency against a panel of melanoma and breast cancer cell lines. Then
we chose two most potent compounds, 5m and 5t, determined their mechanisms of action
and assessed their antiproliferative activities in vitro. 5m had enhanced metabolic stability
and increased water solubility, for example, 5m can be dissolved in the vehicle consisting of 20% of PEG300 and 80% of saline. We also picked the aggressive taxane-resistant
A375/TxR xenograft model to evaluate the potency of 5m and 5t in vivo. Results showed
that 5m and 5t suppressed the growth and metastasis of A375/TxR xenografts significantly, and they were potent to induce the tumor necrosis in vivo. Based on the structures
of 5m and 5t, we generated another novel compound, 5v, by combining the structures of
5m and 5t together. The average IC50 of 5v is 0.5 nM among a panel of cancer cell lines,
and 5v maintained its potency on a panel of taxane-resistant or VERU-111-resistant cancer
cell lines. In addition, 5v induced tubulin depolymerization, cancer cell colony formation inhibition, cell migration inhibition, cell cycle arrest and apoptosis in taxane-resistant
A375/TxR cells. And in vivo studies showed that 5v was able to inhibit the growth of
A375/TxR xenografts in a dose-dependent manner and lymph node metastasis originating from subcutaneous tumors.
FDA-approved tubulin inhibitors, such as paclitaxel, are effective for the treatment
of sensitive TNBC, but intrinsic or acquired resistance is commonly observed after longterm treatment. And paclitaxel needs to be formulated as an albumin-bound formulation
or with a vehicle containing Cremophor EL due to its poor aqueous solubility. There are
also neurotoxicities associated with paclitaxel use, including persistent peripheral neuropathies, which significantly impact the patient’s quality of life and limit its clinical efficacy. Our preliminary studies have shown that VERU-111 has comparable antitumor
efficacy with paclitaxel and it is orally bioavailable. More importantly, the fact that VERU111 can overcome paclitaxel resistance in vitro and in vivo orally is clinical innovative since
chemoresistance is a major obstacle in the successful treatment of TNBC. Recently, a new
orally available taxane, tesetaxel, was developed aiming for becoming first-line or secondline therapy for TNBC patients (Seidman et al., 2018). Preclinical studies have shown that
tesetaxel has very potent cytotoxicity in vitro and in vivo, good PK profiles and aqueous solubility with limited toxicity (Shionoya et al., 2003). So tesetaxel has moved to clinical trials
quickly and promisingly. However, in phase 3 clinical trial on patients with metastatic
breast cancer, more severe adverse events, such as neutropenia, were observed in patients
taking tesetaxel plus capecitabine as compared to the patients taking capecitabine alone,
showing that tesetaxel was not as safe as reported (O’Shaughnessy et al., 2018). These
events lead to a lawsuit to the company that developed tesetaxel and the investigations of
tesetaxel are temporarily suspended. The preclinical and phase 1b clinical trial of VERU111 showed that VERU-111 was well tolerated in patients without the neurotoxicity and

Chapter 6. Summary and Future Direction

141

neutropenia (Getzenberg et al., 2019), thus, VERU-111 is still a promising CBSI that could
be used as second-line therapy for TNBC patients with the advantage of oral bioavailability.
To further conduct the projects on TNBC, one direction is to understand the mechanisms involved in acquired resistance to each MTA considering the urgent demand to
find new strategies to circumvent TNBC acquired chemoresistance. It’s because although
highly responsive to MTAs such as paclitaxel, many TNBC patients develop acquired
chemoresistance, and acquired paclitaxel resistance remains a challenge in oncology. Although VERU-111 was reported to overcome P-gp-mediated MDR and was able to inhibit
the tumor growth in taxane-resistant TNBC models, a clear explanation of the mechanism is still needing to elaborate the function of VERU-111 in taxane-resistant TNBC so
as to help the future design of new colchicine-binding site agents based on the understanding of VERU-111 in evading chemoresistance of paclitaxel. Another direction for the
TNBC project is to understand the potential resistance mechanism of VERU-111 in TNBC
in advance and come up with specific strategies to overcome the resistance. VERU-111 is
currently in clinical trials for advanced prostate cancer (NCT 03752099), so in case it will
develop acquired chemoresistance in TNBC patients in the future, it is necessary to find
the underlying mechanism of potential VERU-111 resistance. In addition, figuring out the
mechanisms underlying VERU-111 resistance in TNBC will lay a foundation for designing
new colchicine-binding agents based on the structure and function of VERU-111 to avoid
chemoresistance of VERU-111. It is highly recommended to check the cross-resistance between taxanes, VERU-111 and VERU-111 analogs in TNBC since tubulin inhibitors are
widely used in various cancer types, results got from TNBC studies will likely have a significant impact to improve the outcome for many other solid tumor types, such as prostate
cancer, lung cancer and ovarian cancer.
Although CBSIs have several advantages including overcoming MDR and β3-tubulin
overexpression, there are currently no FDA-approved CBSIs available for cancer therapy
mainly due to undesired adverse events, lack of bioavailability or low aqueous solubility.
Therefore, extensive efforts are still needed to find more CBSIs that can avoid MDR or are
non-MDR substrates, and these promising CBSIs should have a wider therapeutic window, excellent pharmacokinetic/pharmacodynamic properties and better efficacies. All
CBSIs that we generated had different chemical structures, but they were potent and were
able to overcome MDR. And all the representative compounds shown in this study could
efficiently suppress the tumor metastasis to the liver, suggesting the potential role of CBSIs in inhibiting the liver metastasis, which deserves further investigations. Among all the
compounds synthesized, compound 5m appeared as one of the most potent CBSIs with
sub-nanomolar antiproliferative activity, good aqueous solubility (formulation as PEG300:
saline = 1: 4 for animal study), promising PK behavior with good systemic exposure (t1/2 =
14.7 h) and acceptable microsomal stability (53.6 min) in humans. In addition, 5m was not
only efficacious in suppressing the growth of primary tumors, but it was also potent in inhibiting the metastasis at a dose of 2 or 4 mg/kg. Thus, 5m deserves further investigations
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on many other solid tumor types, such as prostate cancer, lung cancer and ovarian cancer.
The two limitations of 5m were the toxicity when applying for a higher dose and poor
bioavailability, therefore, it is necessary to develop more orally available 5m analogues
that have reduced toxicity while at the same time maintain the efficacy.
One way to reduce the toxicity of CBSIs, such as compound 5m, is to use hybrid
chemotherapy, such as antibody-drug conjugates, chimeric compounds or nanomedicines,
which could selectively target the cancer cells with limited toxicity to normal tissues. The
hybrid drugs can synergistically improve anticancer activity and avoid the accumulated
toxicity due to the lower concentration of CBSIs used. At the same time, adding watersoluble agents into hybrid drugs could help improve the aqueous solubility of the compounds. Finally, drug combination therapy is widely recognized to be more efficient in
treating cancer. For example, the combination of tubulin inhibitor A1mcMMAF and dual
PI3K/mTOR catalytic site inhibitor was reported to be very effective in treating a variety
of solid tumors with high efficacy and limited toxicity (Shor et al., 2016). Therefore, the
combination use of CBSIs will likely be a promising approach for reducing the systemic
toxicity of CBSIs and represents another critical future direction.
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Figure A.1: VERU-111 inhibits TNBC cell migration and invasion at 16
nM. (A) Representative images of migration assays showing MDA-MB-231
(upper panel) and MDA-MB-468 (lower panel) cells treated with VERU-111
(16 nM) for 24 h and 48 h, respectively, that have migrated through
transwell membrane inserts. (B) Representative images of invasion assays
showing MDA-MB-231 (upper panel) and MDA-MB-468 (lower panel)
cells treated with VERU-111 (16 nM) for 24 h and 48 h, respectively, using
Matrigel-coated transwell membrane inserts. All data are presented as the
grand mean ± SEM of three independent experiments, with p-values
determined relative to the Control group (normalized to 100%), scale bar =
100 µm.
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Figure A.2: Images of the effects of VERU-111, paclitaxel and colchicine
on inhibition of TNBC cell wound healing at a concentration of 16 nM.
Representative images show that VERU-111 inhibits wound closure in
MDA-MB-231 (upper panel) and MDA-MB-468 cells (lower panel).
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Figure A.3: FACS analysis profiles of MDA-MB-231 and MDA-MB-468
TNBC cells following treatment with vehicle (Control), colchicine or
paclitaxel, showing VERU-111 induces G2/M checkpoint arrest and
apoptosis in TNBC cells. (A) Representative cell cycle distribution images
after VERU-111 (10, 20, 50 and 100 nM), colchicine (100 nM) and paclitaxel
(100 nM) treatment. Cells were treated for 24 h and stained with
anti-phospho-histone H3 (Ser10) and propidium iodide. (B) Representative
FACS analysis profiles of apoptotic TNBC cells after 24 h treatment with
VERU-111, colchicine or paclitaxel as detected by Annexin-V-FITC/PI
staining. (C) Representative FACS analysis profiles of apoptotic TNBC cells
after treating with 100 nM VERU-111 for 24, 48 or 72 h, cells were stained
with Annexin-V-FITC and PI.
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Figure A.4: Body weight changes and histopathology of visceral organs
following tail vein injection of MDA-MB-231 cells. VERU-111 exhibits
potent anti-metastasis effects. (A) Percent change in body weight ± SEM
over time relative to starting body weight of mice in the vehicle (blue
circles), paclitaxel (red triangles) or VERU-111-treated (green squares)
cohorts (n = 7 mice/group). Untreated mice that develop lung metastases
typically lose body weight as they approach morbidity. (B) Representative
H&E-stained slides of the metastases present in the lungs, livers, and
kidneys harvested from mice in each cohort; examples of metastatic lesions
are indicated by yellow arrows.
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Figure A.5: P-gp protein levels of HCI-2-Luc2 and HCI-10-Luc2
patient-derived primary cells and representative endpoint ex vivo
bio-imaging data obtained using the taxane-resistant HCI-10-Luc2
patient-derived reporter-labeled xenograft model. (A) P-gp expression in
HCI-2 and HCI-10 cells was determined by western blotting. (B) The
growth inhibitory effect of colchicine, paclitaxel and VERU-111 was
measured in vitro by the IncuCyte S3 live cell imaging system. IC50 values
were calculated based on changes in density as measured by phase
contrast at study endpoint relative to initial plating density. The bar graphs
represent the grand mean ± SEM of the calculated IC50 values from at least
3 independent experiments. (C-E) Images representative of the mean total
photon flux per treatment cohort as determined by ex vivo bio-imaging for
the lungs (C), liver (D) and leg bones (E).
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Table A.1: Comparison of growth inhibition effects of paclitaxel,
VERU-111 and colchicine against treatment-naïve HCI-2-Luc2 and
taxane-resistant HCI-10-Luc2 TNBC patient-derived primary cells as
measured by the MTS assay.1,2

1
2

mean ± SEM.
n = 4 biological replicate experiments.
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Figure B.1: Superimposition of the co-crystallized ligand ABI-231 (grey,
wire, PDB code 6O61) and the docking pose of 3a (orange, ball & stick)
on tubulin. The tubulin heterodimer (green, α-tubulin; cyan, β-tubulin) is
shown as ribbon. Hydrogen bonds observed between 3a and residues or
water are shown as blue dashed lines.

Appendix B. Supplementary Data for Chapter 3

Figure B.2: Concentration-dependent inhibition of 4v on the colony
formation of MDA-MB-231 and MDA-MB-468 cells.
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Figure B.3: 4v induces cell cycle arrest and cell apoptosis in TNBC cells.
(A) Representative cell cycle distribution images of TNBC cells treated
with colchicine, paclitaxel and 4v (2.5 nM, 5 nM and 10 nM) for 24 h. (B)
Representative images showing cell apoptosis in TNBC cells with the same
treatment in (A).
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Figure B.4: Microscopy representative H&E stained lung images in
orthotopic MDA-MB-231 xenograft model. Lung metastases were pointed
out by black arrows.
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Figure C.1: Electron densities of compounds colchicine, 40a, and 60c
within their respective tubulin-RB3-SLD complexes. Compounds
colchicine (A), 40a, (B) and 60c (C) bind two binding sites within each
complex (left and right). The 2Fo-Fc electron density maps are shown as a
blue mesh and contoured at 1σ.
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Table C.1: Data collection and refinement statistics.

a
b

Values in parentheses refer to the highest resolution shell.
Rmerge = Σ|(I-<I>)|/ Σ(I), where I is the observed intensity.
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Figure C.2: Expression of P-gp in parental and paclitaxel-resistant cell
line. Paclitaxel was removed from the media at least a week before
collecting the protein from parental or paclitaxel-resistant A375 or
MDA-MB-231 cells. Levels of β-actin were used as loading control.
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Figure C.3: 60c treatment induces tumor necrosis and anti-metastasis in
vivo. (A) Representative whole tumor sections by H&E staining. Necrosis
areas of tumors were enclosed with blue dotted lines. Images were
acquired at × 0.5 magnification; scale bar: 2000 µm. (B) Representative
H&E-stained slides of the metastases present in the lungs or livers. The
pulmonary metastatic nodules were shown by dark violet staining and the
liver nodules were pointed by blue arrows. scale bar = 2000 µm for lung
sections and scale bar = 5000 µm for liver sections.
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Figure D.1: Histopathological evaluation of tumor nodule in lung and
liver tissues of 5m subcutaneous xenograft model (A) Representative
H&E-stained images of lungs in mice treated with vehicle, 10 mg/kg
paclitaxel, 2 mg/kg 5m and 4 mg/kg 5m for 21 days. (B) Representative
H&E-stained images of livers harvested in the same treatment groups in
(A). Examples of metastases are indicated by yellow arrows.
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Figure D.2: 5m exhibits potent anti-metastasis effects in anti-human
mitochondria IHC staining. Representative images of whole lungs (up)
and livers (bottom) treated with vehicle, 10 mg/kg paclitaxel, 2 mg/kg 5m
and 4 mg/kg 5m for 21 days after staining with anti-human mitochondria
antibody. Brown staining decreased in 5m-treated lungs as compared to
that in vehicle or paclitaxel group. The livers in 5m-treated groups were
clearer than that in vehicle or paclitaxel groups.
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Figure D.3: Histopathological evaluation of melanoma metastasis of
tissues in 5t subcutaneous xenograft model (A) Representative
H&E-stained images of lungs in mice treated with vehicle, 10 mg/kg
paclitaxel, 2.5 mg/kg 5t and 5 mg/kg 5t for 24 days. (B) Representative
H&E-stained images of livers in the same treatment groups in (A).
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Figure D.4: 5t treatment reduces melanoma metastasis in anti-human
mitochondria IHC staining. Representative images of whole lungs (up)
and livers (bottom) treated with vehicle, 10 mg/kg paclitaxel, 2.5 mg/kg 5t
and 5 mg/kg 5t for 24 days after staining with anti-human mitochondria
antibody. Brown staining decreased in 5t-treated lungs or livers as
compared to the vehicle or paclitaxel group.
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